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Abstract	
	
	
This	 thesis	 presents	 a	 body	 of	 original	 research	 describing	 the	 synthesis,	 characterisation	
and	biological	properties	of	novel	arsonium-	and	phosphonium-	alkylthiosulfate	zwitterions	
and	 thioacetate	 salts	 and	 gold	 nanoparticles	 functionalized	 with	
triphenylarsoniumpropylthiolate	ligands.	
	
Chapter	1	presents	a	systematic	literature	review	of	the	preparation	of	functionalized	gold	
nanoparticles,	their	biomedical	properties,	the	biological	applications	of	phosphonium	and	
arsonium	ions	and	phosphonium-functionalized	nanomaterials.	
	
Details	of	the	analytical	methods	employed	to	characterize	all	the	compounds	produced	in	
this	study	are	outlined	in	chapter	2.		
	
Chapter	3	reports	 the	synthesis	of	 the	triphenylarsoniopropylthiosulfate	zwitterion	and	ω-
thioacetylpropyl(triphenyl)arsonium	 bromide	 salt.	 Both	 compounds	 have	 been	
characterized	spectroscopically	and	by	single	crystal	X-ray	diffraction.	The	thiosulfate	group	
of	 the	 triphenylarsoniopropylthiosulfate	 zwitterion	 and	 the	 thioacetate	 group	 of	 the	 ω-
thioacetylpropyl(triphenyl)arsonium	 salt	 undergo	 reductive	 cleavage,	 forming	 the	
corresponding	triphenylarsoniumpropylthiolate	 ions	that	attach	to	the	surface	of	gold	 in	a	
modification	 of	 the	 established	 Brust-Schiffrin	 method	 for	 preparing	 gold	 nanoparticles.	
TEM	studies	show	the	 triphenylarsonium-functionalized	gold	nanoparticles	 to	be	spherical	
with	 diameters	 of	 c.a.	 3nm.	 The	 presence	 of	 the	 triphenylarsonium	 groups	 has	 been	
confirmed	 by	 Raman	 and	 XPS	 spectroscopy	 and	mass	 spectrometry.	 It	 also	 describes	 the	
synthesis,	 characterisation	 and	 biological	 properties	 of	 a	 family	 of	
phosphoniopropylthiosulfate	 zwitterions	 and	ω-thioacetylpropyl(triaryl)phosphonium	 salts	
derived	 from	 tri(4-methoxyphenyl)phosphine,	 tri(2,6-dimethoxyphenyl)phosphine	 and		
tri(2,4,6-trimethoxyphenyl)phosphine.	
	
The	 IC50	 values	 of	 the	 triphenylarsoniopropylthiosulfate	 zwitterion,	 ω-thioacetylpropyl-
(triphenyl)arsonium	bromide	salt,	 triphenylarsonium-functionalized	gold	nanoparticles	and	
family	 of	 phosphoniopropylthiosulfate	 zwitterions	 and	 ω-
thioacetylpropyl(triaryl)phosphonium	 salts	 derived	 from	 tri(4-methoxyphenyl)phosphine,	
tri(2,6-dimethoxyphenyl)phosphine	 and	 	 tri(2,4,6-trimethoxyphenyl)phosphine	 have	 been	
determined	 against	 PC3	 prostate	 cancer	 cells	 using	MTT	 and	 CellTiter-Glo	 assays	 and	 are	
reported	 in	 Chapter	 4.	 The	 uptake	 of	 the	 triphenylarsonium-functionalized	 gold	
nanoparticles	 by	 PC3	 and	 Human	 Fibroblast	 cells	 has	 also	 been	 determined	 by	 ICP-OES	
spectroscopy.	
	
	
Conclusion	and	suggestions	for	future	work	are	presented	in	chapter	5.		
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1.0	Introduction	
	
Arsenic	and	phosphorus	both	sit	in	group	15	of	the	periodic	table.	Both	elements	display	an	
extensive	 and	 varied	 chemistry	 forming	 a	 wide	 range	 of	 compounds.	 Although	 the	
compounds	of	phosphorus	and	arsenic	show	some	similarities,	they	also	display	important	
differences.	 For	 example,	 inorganic	 phosphates	 are	 essential	 for	 the	 existence	 of	 life	
whereas	 inorganic	 arsenic	 oxides	 are	 very	 toxic.	 Organo-phosphorus	 and	 -arsenic	
compounds	have	been	very	thoroughly	investigated	and	find	diverse	application,	especially	
in	synthesis	e.g.	the	Wittig	reaction.	Organophosphorus	compounds	find	use	in	the	field	of	
nanotechnology,	 and	 as	 outlined	 below,	 are	 finding	 application	 in	 biomedical	 science.	
Similarly,	 the	potential	biomedical	application	of	organoarsenic	compounds	 is	a	 topic	 that	
has	received	much	attention	since	the	advent	of	medicinal	chemistry	and	has	been	revisited	
recently.	 This	 chapter	 provides	 a	 background	 to	 the	 work	 presented	 in	 this	 thesis,	
introducing	 the	 broad	 topics	 of	 nanotechnology	 and	 cancer	 before	 focusing	 on	 the	
biomedical	 applications	 of	 phosphonium-	 and	 arsonium-	 compounds	 and	 associated	
functionalized	nanomaterials.	
	
1.1	Nanotechnology	
	
Nanotechnology	 is	 a	 multidisciplinary	 subject	 that	 encompasses	 physics,	 chemistry,	
biotechnology,	engineering	and	medicine.	Nanomaterials	can	be	synthesized	from	a	diverse	
range	 of	 substances	 including	metals,	metal	 oxides,	 semi-conductors,	 polymers,	magnetic	
compounds,	 liposomes,	 carbon	 and	 silica-based	materials.	 The	 field	 of	 nanotechnology	 is	
rapidly	 advancing	and	 is	 constantly	 attracting	 immense	 interest	 from	 researchers	 from	all	
over	 the	 world.	 These	 include	 industries	 such	 as	 electronic,	 textiles,	 cosmetics,	
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pharmaceuticals	 and	 environmental	 remediation	 (Daniel	 and	 Astruc,	 2004).	 Gold	
nanoparticles	 are	 amongst	 the	 most	 widely	 studied	 nanomaterials	 due	 to	 their	 ease	 of	
preparation,	stability,	biocompatibility,	and	perceived	biological	inertness.	
	
1.1.1	Gold	Nanoparticles	
	
The	 past	 twenty-five	 years	 have	witnessed	 an	 explosion	 of	 interest	 in	 gold	 nanoparticles,	
due	to	their	applications	in	drug	delivery,	solar	cells,	diagnostics,	sensors	and	catalysis	(Peer	
et	 al.,	 2007).	 Gold	 nanoparticles	 have	 been	 of	 significant	 interest	 in	 biomedical	 research	
owing	 to	 their	 surface	 functionalizing	 properties	 (Papasani	 et	 al.,	 2012).	 They	 have	 found	
application	particularly	in	disease	diagnosis	and	treatment,	due	to	their	larger	surface	area,	
reactivity	in	living	cells	and	small	size	(Tiwari	et	al.,	2011).	
	
However,	due	to	their	smaller	size,	transport	of	nanoparticles	 into	cells	has	been	an	issue.	
Consequently,	strategies	have	been	focused	in	binding	these	gold	nanoparticles	with	various	
ligands	and	bio-molecules	to	achieve	targeted	delivery	(Papasani	et	al.,	2012).			
	
1.1.1.1	Synthesis	of	Gold	Nanoparticles	
	
A	wide	variety	of	 routes	have	been	developed	 for	 the	synthesis	of	gold	nanoparticles	 (Fig	
1.1).		The	most	common	method	is	the	citrate	reduction	of	gold(III)	chloride	salts	in	water,	
the	 citrate	 forming	 a	 loosely	 bound	 shell	 around	 the	 gold	 core.	 This	 method	 was	 first	
reported	by	Turkevitch	 in	1951	and	leads	to	gold	nanoparticles	of	approximately	20	nm	in	
diameter	 (Turkevitch	et	al.,	 1951).	 The	method	was	 refined	by	Frens,	who	 found	 that	 the	
size	of	the	gold	nanoparticles	could	be	controlled	by	varying	the	ratio	of	gold	salt	and	citrate	
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(Frens,	 1973).	 A	 significant	 breakthrough	 came	 through	 the	 seminal	 work	 of	 Brust	 and	
Schiffrin	who	devised	a	method	for	producing	gold	nanoparticles	with	good	polydispersity,	
which	 are	 very	 easily	 handled	 and	 can	 be	 isolated	 and	 re-dissolved	 in	 common	 organic	
solvents	without	aggregation	or	decomposition	(Chen	PhD	Thesis,	2014).	The	initial	method	
utilized	 an	 aqueous-toluene	 two-phase	 system	with	 dodecanethiol	 as	 the	 capping	 ligand,	
sodium	borohydride	as	 the	 reducing	agent,	 and	 tetraoctylammonium	bromide	as	 a	phase	
transfer	agent.	The	size	of	the	particles	can	be	varied	by	modifying	the	relative	amounts	of	
capping	 ligand	 and	 gold	 salt;	 the	 greater	 the	 amount	 of	 capping	 ligand	 the	 smaller	 the	
average	particle	size.	Varying	the	temperature	of	the	reaction	also	affects	the	particle	size.	
Brust	and	co-workers	refined	the	initial	method	by	developing	a	single-phase	method	that	
obviated	the	need	for	the	phase	transfer	agent,	which	can	be	difficult	to	remove	from	the	
metallic	particles	produced	using	the	two-phase	method	(Brust	et	al.,	1995).	Subsequently,	
many	 workers	 have	 adopted	 the	 Brust–Schiffrin	 method	 and	 have	 prepared	 gold	
nanoparticles	functionalized	with	a	huge	variety	of	thiolate	ligands.	
	
	
	
	
	
	
	
	
	
	
5	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
(a)	Citrate	reduction	(Turkevitch	et	al.,	1951).	
(b)	Brust-schiffrin	two-phase	system	(Brust	et	al.,	1994).	
(c)	Brust-schiffrin	one-phase	system	(Brust	et	al.,	1995).	
Figure	1.1	 Synthesis	of	Gold	Nanoparticles	
	
1.1.1.2	Role	of	the	Capping	Ligand	
	
The	capping	ligand	is	a	crucial	component	in	both	the	synthesis	and	subsequent	use	of	gold	
nanoparticles,	 stabilizing	 the	 particle,	 and	 preventing	 uncontrolled	 growth	 and	
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agglomeration.	The	choice	of	capping	 ligand	 influences	the	size	and	shape	of	the	resulting	
particles.	 The	most	 frequently	 used	 species	 are	 organic	 thiolates	 (RS-,	 where	 R	 =	 alkyl	 or	
aryl),	 usually	 derived	 from	 the	 corresponding	 thiols	 or	 disulfides.	 Other	 common	 ligands	
include	 tertiary	 phosphines	 or	 alkyl	 amines.	 Organic	 thiolates	 have	 been	 widely	 studied	
because	of	the	high	affinity	of	sulphur	for	gold	and	the	stability	of	the	resulting	S–Au	bonds.	
The	nature	of	the	bond	formed	between	the	donor	atom	of	capping	ligand	and	the	surface	
of	the	nanoparticle	has	been	the	subject	of	much	investigation	and	speculation.	However,	a	
significant	 breakthrough	 came	 in	 2007	 with	 the	 reporting	 of	 the	 single	 crystal	 X-ray	
diffraction	 study	 of	 a	 sample	 of	 monodisperse	 gold	 particles	 functionalized	 with	
mercaptobenzoic	acid	(MBA)	(Jadzinsky	et	al.,	2007)	(Fig	1.2).	The	structure	revealed	a	core	
containing	102	gold	atoms	that	is	surrounded	by	44	MBA	ligands.	The	gold	core	comprises	
89	Au	atoms,	49	of	which	are	arranged	in	a	Marks	decahedron	with	two	20-atom	caps.	The	
remaining	13	atoms	form	a	band	around	the	equator	of	the	core.	A	significant	finding	was	
that	the	MBA	ligands	not	only	bind	to	the	gold	through	Au–S	bonds	but	also	 interact	with	
each	other	through	a	series	of	face-to-face	and	face-to-edge	interactions	between	adjacent	
phenyl	rings	and	also	phenyl–sulphur	interactions.	The	inter-ligand	interactions	observed	in	
this	system	may	provide	an	 indication	of	how	capping	 ligands	are	ordered	on	 the	particle	
surface.	
	
Fig	1.2	Mercaptobenzoic	acid	
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In	 addition	 to	 their	 stabilizing	 role,	 the	 capping	 ligands	 can	 be	 used	 to	 functionalize	 the	
particles,	enabling	them	to	be	used	as	sensors,	for	biomolecular	recognition,	or	as	transport	
vectors.	Functionalization	can	be	achieved	by	a	number	of	ways.	The	organic	groups	that	are	
attached	 to	 the	 particle	 during	 the	 initial	 synthesis	 can	 be	 modified	 by	 subjecting	 the	
particle	 to	 further	 chemical	 protocols.	 Alternatively,	 the	 particles	 can	 be	 used	 to	 form	
conjugates	with	biomolecules.	 The	 capping	 ligands	 that	 are	utilized	 in	 the	 synthesis	 stage	
can	be	displaced	by	other	species	that	exhibit	the	required	functionality	or	biocompatibility	
through	ligand	exchange	procedures.		
1.1.1.3	Optical	Properties	of	gold	nanoparticles	
	
Gold	 nanoparticles	 are	widely	 studied	 because	 of	 their	 unique	 properties,	 including	 large	
optical	 ﬁeld	 enhancements	 and	 their	 intense	 color	which	 results	 in	 strong	 scattering	 and	
absorption	of	light.	In	the	presence	of	the	oscillating	electromagnetic	ﬁeld	of	the	light,	the	
free	electrons	of	the	gold	nanoparticle	undergo	a	collective	coherent	oscillation	with	respect	
to	 the	 positive	 metallic	 lattice	 (Link	 and	 El-Sayed,	 1999).	 This	 process	 is	 resonant	 at	 a	
particular	frequency	of	the	light	and	is	also	known	as	Surface	Plasmon	Resonance	(SPR).	The	
SPR	 depends	 on	 the	 particle	 size,	 temperature,	 shape	 and	 the	 surrounding	 of	 the	 gold	
nanoparticles.	 (Jain	 et	 al,	 2008).	 	 The	 distinctive	 feature	 of	 this	 SPR	 band	 is	 its	 position	
around	520nm	and	as	 the	 size	of	 the	gold	nanoparticles	 varies	 it	 shows	a	 sharp	decrease	
with	decreasing	core	size.	The	SPR	band	is	absent	when	the	AuNPs	are	less	than	2nm	and	for	
bulk	 gold.	 The	 SPR	 λmax	was	observed	 at	 517,	 520,	 533	 and	575nm	 for	AuNP	 size	 ranging	
from	9,	15,	48	and	99nm	respectively	(Daniel	and	Astruc,	2004).	
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1.1.1.4	Biomedical	applications	of	AuNPs:	
	
The	field	of	nanotechnology	has	grown	rapidly	and	was	estimated	to	have	a	market	value	of	
around	 $53	 billion	 in	 2014.	 (Akhter	 et	 al,	 2013).	 Functionalization	 of	 these	 gold	
nanoparticles	 facilitates	 targeted	delivery	 to	various	cell	 types,	bio-imaging,	gene	delivery,	
drug	delivery,	and	other	therapeutic	and	diagnosis	applications.	(Tiwari	et	al,	2011).		
Functionalities	that	observe	changes	 in	response	to	enzymatic	activity	or	other	alterations	
can	be	used	as	sensors	to	provide	information	about	a	tumor	or	the	efficiency	of	treatment.	
These	sensors	depend	on	the	ability	of	the	gold	nanoparticles	to	undergo	a	change	in	their	
SPR	 when	 aggregated.	 Many	 methods	 have	 been	 developed	 to	 improve	 the	 biosensor	
activity	 by	modifying	 nanomaterials	 for	 fabrication	 which	 permits	 applications	 of	 various	
signal	transductions	in	biosensors.	Colloidal	gold	nanocrystals	were	synthesized	to	develop	
biosensors	 that	 identify	 special	 DNA	 sequences	 and	 they	were	 able	 to	 detect	 single	 base	
mutation	in	a	homogenous	format.	Electro-catalytic	sensors	to	detect	tumor	cells	were	also	
synthesized,	AuNPs	conjugated	with	DNA	and	using	ethylene	blue	as	an	electroactive	label	
and	 differential	 pulse	 voltammetry	 for	 DNA	 sensing	 (Maxwell	 et	 al,	 2002).	 Many	 other	
examples	 including	 the	 detection	 of	 carcinogenic	 substances	 such	 as	 uocra-toxin	 A,	
Aflatoxin,	naphthalene	(Fig	1.3)	and	the	herbicide	picloram	(Fig	1.4),	were	completed	using	
electrochemical	immunosensors.	(Khan	et	al,	2013).	
																															 	
	 			Fig	1.3	Naphthalene		 	 	 	 Fig	1.4	Picloram	
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1.2	Cancer	
	
Cancer	 is	a	collective	term	for	a	group	of	diseases	characterized	by	 invasive	abnormal	cell	
growth,	and	 is	a	common	terminology	for	describing	a	malignant	tumour	(Hesketh,	2013).		
While	 the	 origin	 of	 the	 word	 cancer	 is	 credited	 to	 the	 Greek	 physician	 Hippocrates	 who	
described	tumours	as	karkinos	and	karkinona,	 it	was	Galen	who	described	the	appearance	
of	a	tumour	as	similar	to	the	legs	of	a	crab,	and	this	resemblance	lead	to	the	name	of	the	
disease-	karkinos	(cancer)	which	means	crab	in	Greek	(Papavramidou	et	al.,2010).	
Cancer	is	a	major	cause	of	death	in	economically	developed	countries;	this	is	predominantly	
driven	 by	 increasing	 average	 life-span,	 in	 addition	 to	 unhealthy	 lifestyle	 choices	 including	
smoking,	lack	of	physical	activity	and	poor	diets.	In	2014,	approximately	14.7	million	cancer	
cases	were	diagnosed	with	7.6	million	deaths	globally.	However,	more	than	half	 the	cases	
and	 deaths	 (56%	 and	 64%	 respectively)	 occurred	 in	 economically	 developing	 countries,	
despite	being	the	second	leading	cause	of	death	in	developing	countries	(Jemal	et	al.,	2011).	
In	 the	 UK	 alone,	 325,000	 people	 were	 diagnosed	 with	 cancer	 in	 2014	 and	 someone	 is	
diagnosed	with	cancer	every	two	minutes	(Cancer	Research	UK).	
	
1.2.1	Causes	of	Cancer	
	
Cancer	 is	perceived	as	a	genetic	disease	 involving	a	 series	of	 irreversible	genetic	 changes,	
encompassing	single	point	mutations,	gene	amplification	and	the	loss	of	large	regions	of	the	
genome	 (Tlsty	 and	 Coussens,	 2006).	 The	 concept	 of	 cancer	 being	 a	 genetic	 disease	 of	
somatic	 cells	 was	 proposed	 in	 1914	 by	 Theodor	 Boveri	 (Knudson,	 2001).	 Alterations	 in	
genetics	may	result	in	the	gene	no	longer	functioning	normally	and	can	acquire	new	cellular	
phenotypes	 that	 are	 beneficial	 to	 the	 cell	 such	 as	 resistance	 to	 cell	 death	which	 are	 also	
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known	as	the	hallmarks	of	cancer	(Hanahan	and	Weinberg,	2011).	The	transition	of	normal	
cell	 into	 malignant	 phenotype	 is	 facilitated	 through	 the	 occurrence	 of	 genetic	 mutation,	
which	can	be	induced	by	a	variety	of	chemical,	physical	and	biological	agents.	
1.2.1.1	Chemical	Carcinogens	
	
Chemical	 carcinogens	 are	 substances	 that	 are	 generally	 genotoxic	 and	 are	 able	 to	 induce	
DNA	 damage	 either	 through	 deletions,	 amplifications,	 single	 point	 mutations	 or	 re-
arrangements.	 To-date	 a	 large	 number	 of	 chemical	 carcinogens	 have	 been	 identified	
(Wogan	et	al.,	2004,	Cohen	and	Arnold,	2011).	However,	not	all	cancer-causing	agents	result	
in	 DNA	 damage;	 phorbol	 (Fig	 1.5)	 esters	 are	 a	 class	 of	 tumour	 promoters	 which	 induce	
cellular	proliferation	but	are	not	mutagenic	themselves	(Goel	et	al.,	2007).	
	
Fig	1.5	Phorbol	
	
The	 role	 of	 cigarette	 smoking	 as	 a	 cause	 of	 cancer	 is	 unquestionable	 and	more	 than	 60	
carcinogens	from	cigarette	smoke	have	been	verified	to	be	carcinogenic	in	either	animals	or	
humans.	(Pfeifer	et	al.,	2002,	Peto	et	al.,	2000).	Among	all	tobacco-specific	carcinogens	the	
nitrosamine	 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone(NNK)	 (Fig	 1.6)	 and	 polycyclic	
aromatic	hydrocarbons	(PAH)	have	shown	to	be	predominately	involved	in	the	induction	of	
lung	cancer	(Hecht,	1999).	
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Fig	1.6	Nitrosamine	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone	
	
1.2.1.2	Viruses	
	
It	has	been	estimated	that	15%	of	all	human	cancers	are	caused	by	viruses,	contributing	to	a	
substantial	 proportion	 of	 the	 cancer	 burden	worldwide	 (Liao,	 2006).	 Retroviruses	 cover	 a	
diverse	class	of	ribonucleic	acid	(RNA)	viruses	which	are	small	viruses	containing	only	RNA	in	
their	genome	and	are	associated	with	an	array	of	immunodeficiency,	neurological	disorders	
and	malignancies	 (D'Souza	and	Summers,	2005).	Human	T	 lymphotrophic	virus	type	1	and	
hepatitis	 C	 virus	 are	 two	 RNA	 viruses	 that	 have	 shown	 to	 contribute	 towards	 the	
development	 of	 cancers	 (Liao,	 2006).	 Retroviruses	 can	 either	 be	 non-transforming	 or	
transforming,	 depending	 on	 the	 absence	 or	 presence	 of	 oncogene	 in	 their	 viral	 genome	
(Uren	et	al.,	2005).	Although	no	human	retroviruses	have	this	ability,	many	viruses	in	other	
species	do	and	these	viruses	produce	an	enzyme	called	reverse	transcriptase,	enabling	the	
host	 cell	 to	make	 a	 replica	 of	 the	 viral	 genome	 and	 integrate	 into	 the	 host	 cell	 genome	
(Weinberg,	2013).	
1.2.1.3	Radiation	
	
Acute	 or	 prolonged	 exposure	 to	 high	 dose	 of	 ionizing	 radiation	 can	 lead	 to	 damaging	
consequences	 in	 humans	 including,	 but	 not	 limited	 to,	 cancer.	 In	 contrast,	 the	 effects	 of	
very	low	levels	of	radiation	remain	unclear	(Brenner	et	al.,	2003).	The	carcinogenic	effect	of	
12	
	
radiation	has	been	well	documented	and	is	undisputed;	radiation	exposure	in	Hiroshima	and	
Nagasaki	 in	 Japan	has	been	associated	with	a	number	of	different	cancers,	predominately	
leukemia.	 Underground	 miners	 exposed	 to	 radon	 sources	 were	 prone	 to	 develop	 lung	
cancer	and	luminous	dial	painters	exposed	from	radium	have	been	linked	with	bone	cancer	
(Gilbert,	2009).	
	
DNA	 damage	 from	 ionizing	 radiation	 can	 occur	 from	 either	 a	 direct	 interaction	 between	
DNA	and	radiation	or	via	the	creation	of	free	radicals,	which	can	result	in	cell	death	or	non-
lethal	 DNA	 modification	 including	 DNA	 cross-linking,	 mutations,	 chromosomal	 loss	 and	
single	and	double	strand	breaks	(Wakeford,	2004,	Cwikel	et	al.,	2010).	It	is	well	known	that	
UV	radiation	(UVR)	present	in	sunlight	is	a	potent	carcinogen	and	chronic	repeated	exposure	
of	UVR	 is	 the	main	cause	of	skin	cancers.	Both	ultraviolet	A	radiation	(UVA)	 (320-400	nm)	
and	ultraviolet	B	 radiation	 (UVB)	 (280-320	nm)	have	 important	biological	 significances	 for	
the	skin;	UVA	has	a	crucial	 role	 in	 the	carcinogenesis	of	 stems	cells	of	 the	skin	while	UVB	
produces	 DNA	 damage	 and	 subsequently	 gene	 mutations,	 oxidative	 stress,	
immunosuppression	and	tumorigenesis	(Narayanan	et	al.,	2010).	UVB-induced	DNA	damage	
by	forms	dimeric	photoproducts	at	"hot	spots"	of	UV-induced	mutations	between	adjacent	
pyrimidine	 bases	 on	 the	 same	 strand;	 pyrimidine-pyrimidone	 (6-4)	 photoproducts	 and	
cyclobutane	 diners	 (CPDs)	 are	 the	 two	 most	 prevalent	 adducts	 formed	 (Ichihashi	 et	 al.,	
2003).	
1.2.2	Cancer	Therapeutics	
	
To	 date	 the	 most	 common	 types	 of	 cancer	 treatment	 include	 surgery,	 radiotherapy	 and	
chemotherapy.	Surgery	is	most	effective	for	the	treatment	of	localized	primary	tumours	and	
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associated	 metastases	 in	 regional	 lymphatics	 (Urruticoechea	 et	 al.,	 2010).	 Radiotherapy	
utilizes	 high	 energy	 radiation	 sources	 to	 cause	 damage	 to	 the	DNA	 of	 cancer	 cells	 hence	
blocking	 their	 cell	 division	 cycle	 and	 is	 an	 effective	 treatment	 for	 early	 cancers	 including	
prostate,	lung,	cervix,	head	and	neck,	lymphomas,	and	skin	cancers,	all	of	which	are	curable	
with	 radiation	 therapy	alone.	Furthermore,	 radiotherapy	 is	commonly	used	 in	conjunction	
with	surgery	and	chemotherapy;	around	50%	of	all	patients	will	receive	radiotherapy	during	
the	course	of	their	illness	contributing	towards	40%	of	curative	treatment	of	cancer	(Baskar	
et	al.,	2012).		
	
The	use	of	chemotherapy	to	treat	cancer	dates	back	to	the	early	20th	century	with	the	use	
of	nitrogen	mustards	and	anti-folate	drugs.	Since	this	time	cancer	drugs	have	become	one	
of	 the	 most	 extensively	 researched	 areas	 and	 have	 evolved	 into	 a	 multi-billion-dollar	
industry	 (Chabner	 and	 Roberts,	 2005,	 Devita	 and	 Chu,	 2008).	 Chemotherapy	 involves	 the	
use	 of	 cytotoxic	 drugs	 that	 disrupt	 the	 cell	 cycle;	 alkylating	 agents	 such	 as	 cisplatin	 and	
cyclophosphamide	form	adducts	with	DNA	bases	primarily	at	the	guanine	sites	and	interfere	
with	 DNA	 replication	 (Emadi	 et	 al.,	 2009,	 Zamble	 and	 Lippard,	 1995).	 Antimetabolites	
including	methotrexate	 (Fig	 1.7)	 and	 5-fluorouracil	 inhibit	 vital	 enzymes	 in	 the	metabolic	
processes,	thus	halting	cell	growth	(Kaye,	1998).	
	
Fig	1.7	Methotrexate	
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Existing	cancer	treatments	possess	several	drawbacks;	surgery	is	limited	to	large	accessible	
tumors,	 radiation	 therapy	 is	 non-specific	 and	 kills	 both	 normal	 and	 abnormal	 cells	 in	 the	
radiated	 pathway,	 chemotherapeutic	 drugs	 have	 a	 narrow	 therapeutic	 index	 and	 are	
carcinogenic,	cause	immuno-suppression,	and	are	highly	expensive.	Consequently,	research	
has	 focused	 on	 the	 development	 of	 new,	 novel	 therapies	 to	 decrease	 drug	 toxicity	 in	
healthy	cells	and	increase	efficacy	and	this	has	led	to	the	development	of	targeted	therapies		
(Arruebo	et	al.,2011).	
	
One	 approach	 is	 to	 use	monoclonal	 antibodies	 to	 target	 receptors	 overexpressed	 on	 the	
surface	of	 cancer	 cells.	 Antibody-based	 therapy	has	 become	established	over	 the	past	 15	
years	and	is	now	often	the	preferred	choice	in	the	treatment	of	hematological	malignancies	
and	 solid	 tumours	 (Scott	 et	 al.,	 2012).	 Over	 the	 years	 several	 fully	 human	 monoclonal	
antibodies	(e.g.	Herceptin)	have	been	approved	by	regulatory	agencies	and	others	are	under	
clinical	 trial	 (Arruebo	 et	 al.,	 2011).	 Alternative	methods	 include	 targeting	 specific	 cellular	
signaling	 pathways	 with	 the	 use	 of	 tyrosine	 kinase	 inhibitors	 (e.g.	 Imatinib)	 (Arora	 and	
Scholar,	2005),	triggering	the	extrinsic	apoptotic	pathway	via	the	use	of	apoptosis-inducing	
ligands	 (e.g.	TRAIL)	 (Mahmood	and	Shukla	2010,	Wang,	2010)	and	 targeting	 the	p53	gene	
therapy	pathway	to	reactivate	the	p53	apoptosis	pathway	(Bykov	and	Wiman,	2003.	The	use	
of	 nanomaterials	 for	 novel	 applications	 in	 the	 field	 of	 oncology	 has	 emerged	 a	 hot	 topic,	
with	many	publications	in	this	area.	
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1.2.3	Cancer	nanotechnology	
	
	At	 present,	 there	 is	 a	 strong	 focus	 on	 the	 applications	 of	 nanotechnology	 in	 cancer	
research;	cancer	nanotechnology	 is	a	comparatively	new	field	of	 interdisciplinary	research	
cutting	 across	 chemistry,	 engineering,	 biology	 and	 medicine,	 and	 is	 anticipated	 to	
revolutionize	 the	 detection,	 diagnosis	 and	 treatment	 of	 cancer	 (Llevot	 and	 Astruc,	 2012,	
Portmey	and	Ozkan,	2006,	Srinivas	et	al.,	2002,	Ferrari,	2005,	Davis	et	al.,	2008).	
	
The	 utilization	 of	 nanomaterials	 for	 imaging	 applications	 has	 been	 widely	 investigated;	
Cellular	 labelling	 using	 quantum	 dots	 (QDs)	 has	 advanced	 the	 most	 and	 has	 provided	 a	
useful	new	class	of	fluorescent	probes	for	in	vivo	biomolecular	and	cellular	imaging,	(Walling	
et	al.,	2009,	Gao	et	al.,	2004,	Li	et	al.,	2009,	Bentolila	et	al.,	2009).	Furthermore,	QDs	have	
been	used	 in	cell	 tracking	 for	 the	study	of	 tumour	metastasis	 (Voura	et	al.,	2004)	and	the	
binding	of	EGF	 to	EGFR	 (Lidke	et	al.,	2004)	magnetic	nanoparticles	has	been	exploited	 for	
magnetic	 resonance	 imaging	 and	 cell	 tracking	 (Arbab	 et	 al.,	 2006,	 Pankhurst	 et	 al.,	 2003,	
Singh,	2001,	McCarthy	and	Weissleder,	2008).	
	
The	application	of	nano-size	devices	for	drug	delivery	has	blossomed	(Wagner	et	al.,	2006,	
Kumar	et	al.,	2013).	A	range	of	nanometric	delivery	vehicles	has	been	proposed,	 including	
polymeric	 micelles,	 dendrimers,	 and	 liposomes,	 QDs,	 carbon	 nanotubes	 and	 inorganic	
nanoparticles,	 especially	 gold	 (Rivera	 Gil	 et	 al.,	 2010,	 Bawarski	 et	 al.,	 2008,	 Elhissi	 et	 al.,	
2012,	Riggio	et	al.,	2011,	Akhter	et	al.,	2012,	Ahmad	et	al.,	2013,	Han	et	al.,	2007).	
	
	 	
16	
	
1.2.3.1	Nanoparticles	as	Drug	Delivery	Carriers	
	
As	mentioned	above,	the	majority	of	current	anti-cancer	agents	are	not	specific	and	lack	the	
ability	 to	 differentiate	 between	 normal	 and	 cancerous	 cells,	 leading	 to	 systemic	 toxicity.	
Furthermore,	because	of	 the	 rapid	elimination	and	widespread	distribution	of	agents	 into	
non-targeted	organs	and	tissues,	a	higher	dosage	 is	 required	which	 is	not	economical	and	
often	result	in	adverse	side	effects	due	to	non-specific	toxicity	(Nie	et	al.,	2007).	The	use	of				
nanomaterials	to	delivery	anti-cancer	drugs	to	tumour	sites	is	a	promising	platform,	and	can	
be	achieved	by	either	passive	or	active	targeting.	
	
1.2.3.2	Passive	Targeting	
	
Passive	targeting	refers	to	the	accumulation	of	a	drug	or	drug	delivery	system	at	a	desired	
site	 due	 to	 physio-chemical	 or	 pharmacological	 factors;	 AuNPs	 take	 advantage	 of	 their	
inherent	 size	 in	 the	 nature	 of	 the	 tumour	microenvironment.	 Tumour	 vasculature	 differs	
dramatically	compared	to	normal	tissue.	Blood	vessel	walls	 in	tumours	are	generally	more	
porous	 and	 leaky	 owing	 to	 the	 formation	 of	 new	 blood	 vessel,	 a	 process	 also	 known	
angiogenesis	 (Carmeliet	 and	 Jain,	 2000,	 Nishida	 et	 al.,	 2006).	 Angiogenic	 blood	 vessels	 in	
tumour	 tissues	 have	 gaps	 as	 large	 as	 600-800	 nm	 between	 adjacent	 endothelial	 cells.	
Furthermore,	 tumours	 have	 a	 dysfunctional	 lymphatic	 drainage	 resulting	 in	 AuNPs	 being	
retained	 longer	 at	 the	 tumour	 site.	 Together	 these	 effects	 induce	 a	 phenomenon	 called		
enhanced	 permeability	 and	 retention	 (EPR)	 effects,	 enabling	 nanoparticles	 to	 extravagate	
through	 these	 large	 gaps	 into	 extravascular	 spaces	 and	 accumulate	 inside	 tumour	 tissues	
(Misra	et	al.,	2010,	Ghosh	et	al.,	2008,	Nie	et	al.,	2007).	
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A	 significant	 increase	 in	 tumour	 drug	 concentration	 can	 be	 achieved	 when	 the	 drug	 is	
delivered	by	a	nanoparticle	in	comparison	to	the	free	drug	form.	However,	passive	targeting	
does	 suffer	 from	 several	 limitations.	 It	 is	 not	 always	 feasible	 to	 target	 all	 cells	 within	 a	
tumour	as	some	drugs	cannot	diffuse	efficiently.	In	addition,	the	random	nature	of	passive	
targeting	makes	 it	difficult	 to	control	the	process	and	can	 lead	to	multiple-drug	resistance	
(Peer	 et	 al.,	 2007).	 Furthermore,	 the	 permeability	 of	 vessels	 may	 not	 be	 identical	
throughout	the	tumour	and	certain	tumours	do	not	exhibit	the	EPR	effect.	Nanocarriers	may	
potentially	suffer	from	non-specific	uptake	and	degradation	in	macrophages	and	therefore	
targeting	is	critical	for	achieving	maximum	drug	efficacy	with	minimal	size	effects	(Ghosh	et	
al.,	2008).	
	
1.2.3.3	Active	Targeting	
The	development	of	nanocarriers	with	the	capability	of	binding	to	specific	cells/tumour	sites	
of	interest	is	an	attractive	proposition,	and	can	be	achieved	by	attaching	targeting	moieties	
onto	the	nanoparticle	scaffold	to	enable	their	selective	uptake	by	specific	interactions	such	
as	 ligand-receptor,	 antibody-antigen	 and	 lectin-carbohydrate	 (Allen,	 2002).	 Lectin-
carbohydrate	binding	is	very	specific	and	delivery	based	on	this	system	has	been	developed	
to	 target	 organs	 as	 a	 whole	 (Yamazaki	 et	 al.,	 2000,	 Kannagi	 et	 al.,	 2004).	 The	 fact	 that	
receptors	or	antigens	are	usually	over-expressed	in	human	cancer	cells	has	been	exploited	
as	receptor-ligand	binding	facilitates	internalization	via	receptor-mediated	endocytosis.	The	
strength	of	NP	interactions	with	antigens	or	membrane	receptors	can	be	controlled	by	the	
property	 of	 the	 ligand	 (e.g.	 affinity)	 and	 by	 changing	 the	 ligand	 density	 (e.g.	 avidity)	
attached	to	the	surface	of	the	particle	(Chou	et	al.,	2011).	
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Surface	 functionalization	 of	 nanoparticles	 plays	 a	 major	 role	 in	 active	 targeting	 enabling	
scientists	 to	 engineer	 specific	 AuNPs	 with	 active	 targeting	 capabilities	 via	 clever	 surface	
modifications.	These	targeting	groups	can	be	broadly	classified	as	proteins	(antibodies	and	
their	fragments),	nucleic	acids	or	other	receptor	ligands	(small	molecules,	peptides,	vitamins	
and	carbohydrates)	(Chou	et	al.,	2011,	Scheinberg	et	al.,	2010).	
	
Folate	 receptors	 are	 overexpressed	 on	 the	 surfaces	 of	many	 tumour	 cells	 and	 have	 been	
explored	as	a	target.	Dixit	and	co-workers	(Dixit	et	al.,	2006)	have	shown	that	10	nm	AuNPs	
conjugated	to	folic	acid	were	selectively	taken-up	by	folate	receptor	positive	KB	cells,	with	
minimal	 uptake	 in	 cells	 that	do	not	overexpress	 the	 folate	 receptor.	 Chen	and	 colleagues	
(Chen	 et	 al.,	 2007)	 have	 demonstrated	 that	 13	 AuNPs	 conjugated	 to	 methotrexate,	 a	
dihydrofolate	reductase	inhibitor	that	destroys	folate	metabolism,	are	rapidly	taken-up	and	
are	more	cytotoxic	compared	to	methotrexate	alone.		
	
1.3	Mitochondria	
	
Mitochondria	are	essential	to	cell	function	because	they	control	critical	cellular	parameters	
including	 energy	 production,	 modulation	 of	 redox	 status,	 generation	 of	 reactive	 oxygen	
species	 and	 maintenance	 of	 calcium	 homeostasis.	 Furthermore,	 they	 are	 involved	 in	 a	
number	 of	 metabolic	 and	 biosynthetic	 pathways	 and	 the	 regulation	 of	 apoptosis	 or	
programmed	cell	death.	Mitochondrial	dysfunction	 is	associated	with	a	number	of	human	
disorders	 such	 as	 diabetes,	 neurodegenerative	 diseases	 (e.g.	 Parkinsons	 and	 Alzheimers),	
ischemia-reperfusion	 injury	 and	 cancer	 (Gupta	 et	 al.,	 2009,	Wallace,	 2005,	Weissig	 et	 al.,	
2004).	 Mitochondrial	 research	 has	 become	 one	 of	 the	 fastest	 growing	 disciplines	 in	
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biomedicine	 and	 current	 research	 activities	 include	 targeting	 the	mitochondrial	 apoptotic	
mechanism	 (D'Souza	 et	 al.,	 2011,	 Fulda,	 2010,	 Wallace,	 2012,	 Wang,	 2001),	 protecting	
mitochondria	 from	 oxidative	 stress	 (Kelso	 et	 al.,	 2002,	 James	 et	 al.,	 2004,	 Coulter	 et	 al.,	
2000,	 Sheu	 et	 sl.,	 2006)	 and	 diseases	 caused	 by	 mutated	 mitochondrial	 DNA	 (mt	 DNA)	
(Pulkes	and	Hanna,	2001,	Tuppen	et	al.,	2010,	D'Souza	and	Weissig,	2004).	
1.3.1	Role	of	Mitochondria	in	Cell	Death	
	
At	 the	 center	 of	 the	 intrinsic	 apoptotic	 pathway	 is	 the	 mitochondrion.	 It	 is	 the	 cell's	
reservoir	of	pro-apoptotic	 factors	which	reside	 in	 the	mitochondrial	 intermembrane	space	
(IMS).	 Following	 an	 apoptotic	 stimulus,	 pores	 are	 formed	 in	 the	 outer	 mitochondrial	
membrane	permeabilisation	(MOMP)	and	this	is	a	crucial	event,	referred	to	as	the	"point	of	
no	 return"	 of	 cell	 death.	 Subsequently	 IMS	 proteins	 are	 released	 into	 the	 cytosol;	 while	
some	of	 these	proteins	are	considered	to	be	"innocent	bystanders"	and	do	not	cause	any	
cellular	response,	cytochrome	c	and	Smac/DIABLO	(Second	mitochondria-derived	activator	
of	caspase/	direct	inhibitor	of	apoptosis-binding	protein	with	low	pl)	promotes	cell	death	via	
the	activation	of	caspases	(Parssons	and	Green,	2010,	Gupta	et	al.,	2009).	
	
Caspases	are	very	 important	 in	the	apoptotic	response	and	to	date	eleven	human	caspase	
proteins	have	been	 identified.	Of	these,	seven	are	thought	to	have	functions	 in	apoptosis,	
including	 the	 initiator	 caspases	 (caspases-3,	 -6	 and	 -7).	 In	 normal	 cells,	 caspases	 exist	 as	
zymogens	 (catalytically	 inactive)	 and	 must	 undergo	 proteolytic	 activity	 to	 become	 active	
(Riedl	and	Shi,	2004).	
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1.3.2	Targeting	Mitochondria	for	Cancer	Therapy	
	
Mitochondria	 have	 emerged	 as	 an	 attractive	 novel	 pharmacological	 target	 for	 cancer	
therapeutics	 (Gupta	 et	 al.,	 2009,	 Frantz	 and	 Wipf,	 2010,	 Modica-Napolitano	 and	 Singh,	
2002,	 Costantini	 et	 al.,	 2000,	 Weissig,	 2003).	 Interestingly	 cancer	 cell	 mitochondria	 are	
structurally	and	functionally	different	in	comparison	to	their	normal	counterparts	(Gogvadze	
et	 al.,	 2008,	 Modica-Napolitano	 and	 Singh,	 2004).	 These	 notable	 differences	 have	 been	
exploited	 as	 potential	 targets	 for	 anti-cancer	 therapy	 by	 using	 agents	 that	 either	 interact	
directly	at	the	site	of	mitochondria	or	target	metabolic	alterations	caused	by	mitochondrial	
dysfunction.	
	
1.3.3	Strategies	for	Mitochondrial	Pharmacology	
	
With	mitochondria	emerging	as	a	novel	pharmacological	targets,	there	has	been	a	growing	
interest	in	delivering	biologically	active	molecules	including	proteins,	enzymes	and	drugs	to	
the	 site	 of	 mitochondria	 for	 therapeutic	 effects	 (Smith	 et	 al.,	 2012,	 Malhi	 and	 Murthy,	
2012).	The	main	strategy	employed	in	mitochondrial	pharmacology	for	site	specific	delivery	
involves	 the	 conjugation	 of	 small	 molecules	 to	 a	 lipophilic	 cation,	 and	 this	 has	 been	
reviewed	 extensively	 elsewhere	 (Murphy,	 1997,	 Murphy	 and	 Smith,	 2007,	 Murphy	 and	
Smith,	 2000,	 Ross	 et	 al.,	 2005).	 Other	 strategies	 include	 mitochondria-targeted	 peptides	
(Yousif	et	al.,	2009,	Yousif	et	al.,	2009,	Jacotot	et	al.,	2006,	Cai	et	al.,	2010)	and	making	use	
of	the	high	affinity	mitochondria-specfic	binding	sites(Smith	et	al.,	2004).	
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1.4	Lipophilic	cations	
	
Lipophilic	 cations	 are	 known	 to	 be	 lipid-soluble,	 despite	 carrying	 a	 positive	 charge.	 These	
cations	 pass	 through	 phospholipid	 bilayers	 of	 cells	 and	 are	 accumulated	 in	 the	
mitochondria.	 The	 activation	 energy	 for	 these	 cations	 is	 much	 lower	 compared	 to	
hydrophilic	cations,	mostly	due	to	the	fact	that	energy	demand	for	the	latter	compounds	is	
much	higher	when	they	pass	through	the	biological	membrane.	The	lipophilic	cations	adsorb	
on	 the	membrane	 surface	 and	 travel	 via	 the	 hydrophobic	 core	 of	 the	membrane	 to	 the	
other	side	before	desorbing	from	the	membrane.	This	passage	helps	the	lipophilic	cations	to	
pass	 through	 the	 phospholipid	 bilayers,	 and	 hence	 these	 cations	 travel	 through	 the	
mitochondrial	inner	membrane	(Le	Gall	et	al.,	2010).	
	
The	 mitochondrial	 transmembrane	 proton-motive	 force	 which	 is	 powered	 by	 oxidative	
phosphorylation	 consists	 of	 a	 chemical	 component	 and	 an	 electrical	 component.	 The	
electrical	component	or	mitochondrial	membrane	potential	is	higher	in	carcinoma	cells	than	
in	normal	epithelial	cells.	Lipophilic	cations	having	a	delocalized	positive	charge	(delocalized	
lipophilic	 cations)	 penetrate	 the	 hydrophobic	 barriers	 of	 the	 plasma	 and	 mitochondrial	
membrane	 and	 accumulate	 in	 mitochondria	 in	 response	 to	 the	 negative	 charge	 inside	
transmembrane	potentials.		
	
Ek=					2.303
%&
'(
)*+10
[./0	/234.56	7688]
[./0	.04.56	7688]
	
Equation	1:	Nernst	potential	equation.	(Ek=	Equilibrium	constant)	
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The	 Nernst	 equation	 (Equation	 1)	 is	 used	 to	 calculate	 the	 potential	 of	 an	 ion	 of	
charge	z	across	 a	 membrane.	 According	 to	 the	 Nernst	 equation,	 a	 difference	 of	 60	 mV	
membrane	potential	between	carcinoma	and	control	epithelial	cells	is	enough	to	produce	a	
10-fold	 greater	 accumulation	 of	 the	 compound	 in	 carcinoma	 mitochondria.	 The	 higher	
plasma	membrane	 potential	 observed	 in	 some	 carcinoma	 cells	 vs.	 control	 epithelial	 cells,	
thus	 further	 contributes	 to	 increased	 DLC	 accumulation	 in	 carcinoma	 mitochondria	
(Josephine	S	2001).	
	 	
Lipophilic	cations	are	widely	used	as	molecular	probes	for	studying	mitochondrial	function	
and	have	demonstrated	applications	 in	antineoplastic,	antioxidant,	antimicrobial	 transport	
into	mitochondria	(Le	Gall	et	al.,	2010).	The	increased	mitochondrial	membrane	potential	in	
carcinoma	 cells	 which	 leads	 to	 selective	 accumulation	 of	 DLCs	 and	 consequent	
mitochondrial	 toxicity	 suggests	a	 rationale	 for	 the	 selective	 chemotherapy	of	 cancer	 cells.	
Rhodamine123	was	the	first	DLC	to	demonstrate	anticancer	activity	(Josephine	et	al,	2001).	
In	 a	 study,	 1-Ethyl-2-[[3-ethyl-5-(3-methyl-2(3H)-benzothiazolylidene)-4-oxo-2	
thiazolidinylidene]methyl]-pyridinium	 chloride,	 (MKT-077)	 (Fig	 1.8)	 was	 shown	 to	
significantly	 inhibit	 the	 growth	of	 a	 variety	 of	 keratin-positive	 human	 cancer	 cell	 lines,	 as	
measured	 by	 clonogenic	 assays	 and	 growth	 inhibition	 of	 cultured	 cells	 (Josephine	 et	 al,	
2001).	 The	 same	 compound	 demonstrated	 significant	 in-vivo	 anti-tumor	 activity	 in	 nude	
mice	 implanted	 with	 human	 melanoma	 LOX,	 human	 renal	 carcinoma	 A498,	 and	 human	
prostate	 remaining	 viable	 nandrolone	 deconate	 (DECA)	 treated	 versus	 untreated	 control	
carcinoma	DU-145,	 all	 of	which	 are	 highly	 refractory	 to	 a	 variety	 of	 traditional	 therapies.	
MKT-077	was	the	first	DLC	to	be	approved	by	the	US	Food	and	Drug	Administration	(FDA)	
for	clinical	trials	for	the	treatment	of	carcinoma	(Le	Gall	et	al.,	2010).	However,	trials	were	
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discontinued	 in	phase	 II,	 since	efficacy	 in	 tumour	cell	 killing	was	not	demonstrated	at	 the	
particular	approved	dosage	and	drug	regimen	(Josephine	et	al,	2001).		
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Figure	1.8:	1-Ethyl-2-[[3-ethyl-5-(3-methyl-2(3H)-benzothiazolylidene)-4-oxo-2-
thiazolidinylidene]	methyl]-pyridinium	chloride	(MKT-077).	
	
1.4.1	Lipophilic	Phosphonium	Cations	
	
Organophosphonium	cations	are	species	with	the	formula	R4P
+,	i.e	they	contain	four	organic	
groups	 bound	 to	 a	 central	 phosphorus	 atom.	 Phosphonium	 compounds	 have	 been	
extensively	 studied	 because	 of	 their	 use	 in	 the	 Wittig	 reaction	 (Joseph	 et	 al.,	 2009).	
However,	organophosphonium	compounds	are	also	of	interest	because	of	their	applications	
in	 biomedical	 science;	 the	 compounds	 act	 as	 delocalised	 lipophilic	 cations	 (DLC)	 and	 are	
readily	taken-up	by	cells.	The	ability	of	the	tetraphenylphosphonium	ion	(Ph4P
+)	to	act	as	a	
DLC	was	discovered	by	Liberman	in	1969,	who	was	investigating	the	membrane	potential	of	
cells.		
	
In	1969,	studies	by	Liberman	had	significant	influence	regarding	understanding	the	passage	
of	compounds	through	mitochondrial	membranes	aided	by	membrane	potentials	(Liberman	
et	 al.,	 1969).	 Delocalized	 lipophilic	 compounds	 (DLCs)	 such	 as	 tetraphenylphosphonium	
(TPP)	 chloride	 and	 triphenylmethylphosphonium	 (TPMP)	 iodide	 are	 known	 to	 accumulate	
selectively	in	cancer	cells	(Joseph	et	al.,	2009).	The	salts	display	remarkable	tumor	selectivity	
24	
	
as	they	are	able	to	easily	traverse	the	lipophilic	mitochondrial	membrane	of	a	tumor	cell	as	
its	membrane	potential	is	ca.	60	mV	higher	than	that	of	a	healthy	cell	(Ross	et	al.,	2005)	
	
As	 noted	 above,	mitochondrial	 dysfunction	 is	 associated	with	 a	 number	 of	 disorders	 and	
there	is	increasing	awareness	of	the	importance	of	targeting	drugs	to	this	organelle.	(Malhi	
and	Murthy	2012).	Lipophilic	cations,	especially	phosphonium	species,	have	been	found	to	
be	extremely	valuable	for	mitochondria-targeted	therapeutics	and	diagnostics.	Recent	work	
has	 demonstrated	 the	 potential	 of	 combining	 phosphonium	 moieties	 with	
nanotechnological	 approaches	 to	 traffic	 pharmaceutical	 and	 diagnostic	moieties	 into	 cells	
(Malhi	and	Murthy	2012).			
	
1.4.2	Mitochondrial	Accumulation	of	Lipophilic	Phosphonium	Cations	
	
Lipophilic	 phosphonium	 cations	 such	 as	 tetraphenylphosphonium	 and	
methyltriphenylphosphonium	are	attracted	to	the	negative	energy	potentials	of	cellular	and	
sub-cellular	membranes.	Despite	their	net	positive	charge,	LPCs	have	the	unusual	properties	
of	 being	 relatively	 lipid-soluble,	 enabling	 their	 passage	 through	 the	 lipid	 bilayers	 and	
accumulate	specifically	 inside	the	mitochondrial	matrix,	(Weissig,	2005,	Yousif	et	al.,	2009,	
Murphy,	1997,	Porteous	et	al.,	2010,	Ross	et	al.,	2008).	
	
The	 uptake	 of	 LPCs	 into	 mitochondria	 is	 primarily	 governed	 by	 the	 large	 membrane	
potential	across	the	mitochondrial	 inner	membrane	of	up	to	150-160	mV	(negative	 inside)	
(Fig	1.9).	The	plasma	membrane	potential	(usually	30-60	mV,	negative	inside)	also	drives	the	
uptake	of	cations	into	the	cell	where	they	further	accumulate	inside	the	mitochondria,	with	
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the	majority	of	the	intracellular	cation	(90	-	95%)	localizing	in	the	mitochondria	(Burns	and	
Murphy,	1997).	
	
Figure	1.9:	 	The	proposed	uptake	of	the	phosphonium	cation	by	mitochondria	through	
the	mitochondrial	membrane	potential.	
	
	
Given	the	observation	that	lipophilic	cations	are	taken-up	by	the	mitochondria	in	cells	it	was	
natural	to	consider	linking	molecules	of	interest	to	a	lipophilic	cation	for	targeted	delivery	to	
mitochondria	 in	vivo	 (Murphy,	1997,	Smith	et	al.,	2003,	Weissig,	2005	Le	Gall.	et	al	2010).	
The	 synthesis	 of	 alkyltriphenylyphosphonium	 cations	 from	 the	 reaction	 of	
triphenylphosphine	with	 an	 appropriate	 precursor	 (Smith	 et	 al.,	 2004,	 Kelso	 et	 al.,	 2001,	
Smith	et	al.,	1999)	or	by	conjugation	of	a	pre-formed	alkyltriphenylphosphonium	cation	to	a	
molecule	 is	 relatively	 simple	 (Murphy	 et	 al.,	 2003,	 James	 et	 al.,	 2003).	 This	 property	 has	
been	exploited	to	direct	a	broad	range	of	potential	probes	or	therapeutic	agents	to	the	site	
of	mitochondria	and	some	of	these	are	outlined	below.	
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1.4.2.1	Phosphonium-conjugated	Antioxidants	
	
Conjugating	 lipophilic	 cations	 such	 as	 triphenylphosphonium	 to	 an	 antioxidant	 is	 an	
approach	in	designing	drugs	for	selectively	targeting	mitochondria.	A	number	of	antioxidant	
compounds	could	be	targeted	to	the	mitochondria	conjugating	the	triphenyl	phosphonium	
moiety,	 such	as	ubiquinone,	 tocopherol,	 lipoic	acid,	 spin	 traps	and	the	peroxidise	mimetic	
Ebselen.	The	most	widely	used	and	best	known	from	this	class	is	ubiquinol	known	as	MitoQ	
(Fig	1.10).	These	compounds	are	taken	up	rapidly	by	mitochondria	driven	by	the	membrane	
potential,	 importantly	 all	 the	 accumulated	 vitamin	 E	 compound	MitoQ	 is	 adsorbed	 in	 the	
matrix	 surface	 of	 the	 inner	 membrane.	 MitoQ	 satisfies	 the	 entire	 requirement	 within	
isolated	mitochondria	for	antioxidant	targeting	mitochondria	(Smith	et	al.,	2004).	
	
	
Figure	1.10:	Molecular	structure	of	the	triphenyl	phosphonium-vitamin	E	compound	
(MitoQ).	
 
The	most	essential	feature	that	mitochondria	targeting	antioxidants,	such	as	MitoQ,	 is	not	
to	get	extensively	accumulated	in	the	mitochondria	and	help	in	keeping	the	integrity	of	the	
membrane	 intact;	 thus	 it	 helps	 in	 preventing	 disruption	 of	 the	 respiration	 cycle	 and	 ATP	
synthesis.	The	antioxidants	attached	to	TPP	pass	from	cell	to	isolated	mitochondria	and	get	
accumulated	 at	 5-10	 fold	 by	 the	 plasma	 membrane	 potential.	 Experiments	 show	 that	
binding	 this	 antioxidant	with	 TPP	 cations	 results	 in	 total	mitochondrial	 uptake	within	 the	
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cells,	which	 clearly	 indicates	 that	 almost	 all	 accumulated	 lipophilic	 cations	 are	 present	 in	
mitochondria	(Murphy	et	al,	2003).	More	recent	work	has	focused	on	targeting	antioxidants	
to	 mitochondria	 in	 vivo,	 based	 on	 the	 observation	 that	 TPP	 cations	 easily	 pass	 through	
phospholipid	 bilayers	 from	 the	 gut	 to	 the	 bloodstream	 and	 from	 bloodstream	 to	 various	
tissues	 in	 body.	 Experiments	 clearly	 showed	 that	 once	 these	 compounds	 enter	 the	
bloodstream	alkylTPP	compounds	distribute	into	organs.	These	alkyltriphenylphosphonium	
compounds	can	be	administered	orally	with	good	bioavailability	and	they	are	rapidly	cleared	
from	the	plasma	accumulating	in	mitochondria	within	tissues.	(Murphy,	2008).		
	
1.4.2.2	Mitochondria	Targeted	Photodynamic	therapy	
	
Photodynamic	 therapy	 (PDT)	 is	 a	 novel	 treatment	modality	 for	 several	 types	 of	 cancer;	 it	
involves	 photoreactions	 mediated	 by	 three	 key	 elements:	 photo	 sensitizers,	 light	 and	
oxygen	to	generate	Reactive-Oxygen-Species	(ROS)	such	as	singlet	oxygen,	superoxide	anion	
radical	 and	hydroxyl	 radicals.	 PDT	benefits	 from	 the	 cytotoxic	 effects	 generated	 from	 the	
ROS	to	induce	apoptosis	or	necrosis	in	cytotoxic	effects	generated	from	the	ROS	to	induce	
apoptosis	or	necrosis	 in	cancerous	cells	 (Lei	et	al.,	2010).	The	photo	sensitizer	displayed	a	
time-dependent	 cytotoxicity	 effect	 in	 ovarian	 carcinoma	 cells	 (SKOV-3),	 the	 conjugated	
(Mce6)	exhibiting	greater	cytotoxicity	(Cuchelkar	et	al.,	2008).	
	
Meso-tetraphenylporphyrin	derivatives	incorporating	a	TPP	ion	terminated	alkoxy	group	at	
either	para-or	meta-position	of	one	meso-phenyl	group	have	been	shown	to	be	photoxic	in	
human	breast	cancer	(MCF-7)	(Lei	et	al.,	2010).	More	recently,	a	core-modified	porphyrin-
mono-triphenylphosphonium	cation	 (CMP-tPP)	has	 shown	 improvement	 in	 cellular	uptake	
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and	photodynamic	activity	compared	to	 the	mono-hydroxy	core-modified	porphyrin	alone	
(Rajaputra	et	al.,	2013).	
	
1.4.2.3	Mitochondria	Targeted	Radiotracers	for	Tumour	imaging	
	
Conventional	cationic	radiotracers	such	as	99mTc-Tetrofosmin	and	99mTc-Sestamibi	have	been	
used	for	the	diagnosis	of	cancer	by	Single-photon	emission	computed	tomography	(SPECT)	
and	 the	monitoring	of	 the	multidrug	 resistance	 transport	 functions	 in	 tumors	of	 different	
origin.	However,	 they	suffer	 from	 low	tumor	selectivity	and	 insufficient	 tumor	 localization	
which	limits	their	diagnostic	and	prognostic	values	in	a	clinical	setting	(Zhou	and	Liu,	2011).		
Nearly	30	years	ago,	 radiolabeled	quaternary	phosphonium	cations	were	 first	 investigated	
as	 perfusion	 radiotracers	 for	 myocardial	 perfusion	 imaging	 (Srivastava	 et	 al.,	 1985),	 and	
since	 then	 several	 groups	 have	 proposed	 the	 use	 of	 radiolabeled	 triphenylphosphonium	
cations	as	PET	radiotracers	which	include	18F	labelled	probes	and	64Cu	labelled	phosphonium	
cations	 including	 64Cu-labelled	 2-(diphenylphosphoryl)-ethyldiphenylphosphonium	 cations	
(Yang	 et	 al.,	 2008,	 Liu	 et	 al.,	 2009,	 Yang	 et	 al.,	 2007).	 	 Copper-64	 labelled	 phosphonium	
cations	have	been	developed	as	a	new	class	of	PET	radiotracers	with	high	tumour	selectivity	
and	uptake	(Wang	et	al.,	2007,	Zhou	and	Liu,	2011).	
1.5	Phosphonium-mediated	Pharmaceutical	Nanotechnology	
	
Pharmaceutical	nanotechnology	is	a	term	that	has	been	coined	to	describe	the	biomedical	
and	 pharmaceutical	 applications	 of	 nanomaterials.	 As	 described	 above	 (section	 1.4.2.1),	
organophosphonium	 compounds	 are	 readily	 taken-up	 by	 cells	 and	 accumulated	 in	
mitochondria	 and	 recent	 years	 have	 seen	 phosphonium	 moieties	 being	 combined	 with	
nanomaterials,	including	liposomes,	macromolecules	and	nanoparticles.	
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1.5.1	Liposomes	
	
Liposomes	 are	 hollow	 vesicle-like	 species	 made	 from	 lipids	 that	 can	 be	 used	 for	 drug	
delivery.	Weislg	and	co-workers	prepared	liposomes	from	DOPC	(1,2-dioleoyl-sn-glycero-3-
phosphocholine)	and	cholesterol	 and	 stearyltriphenylphosphonium	bromide	 (Boddapati	 et	
al.,	 2010);	 the	 triphenylphosphonium	 salt	 intercalates	 the	 lipid	 bilayer	 (Fig	 1.11).	 	 They	
demonstrated	that	liposome	surface-modified	phosphonium	cation	can	be	used	to	transport	
drugs	 to	 subcellular	 organelles	 without	 the	 need	 for	 chemical	 modification	 of	 the	 drug	
molecules.	
	
Figure	1.11	Liposomal	drug	delivery	system	surface	modified	with	triphenylphosphonium	
moieties.	
Liposomes	modified	with	 stearyltriphenylphosphoniumcations	 have	 been	 loaded	with	 the	
anticancer	 drug	 Paclitaxel	 (Solomon	 et	 al.,	 2013).	 They	 showed	 improved	 mitochondrial	
colocalization	 and	 cytotoxicity	 in	 a	 paclitaxel-resistant	 cell	 line.	 The	 improvement	 in	
cytotoxicity	was	attributed	to	the	increased	accumulation	of	paclitaxel	in	mitochondria	and	
to	 the	 specific	 toxicity	 of	 stearyltriphenylphosphonium	 compounds	 towards	 the	 resistant	
cell	 line.	 Mechanistic	 studies	 revealed	 that	 the	 cytotoxicity	 of	 the	 stearyl	
30	
	
triphenylphosphonium	 ion	 was	 associated	 with	 a	 decrease	 in	 mitochondrial	 membrane	
potential	and	other	hallmarks	related	to	caspase-independent	cell	death.		
1.5.2	Macromolecules	
	
Phosphonium	 compounds	 been	 incorporated	 into	 polymeric	 species,	 including	 polymers	
(Monge	et	al.,	2011),	hydrogels	and	dendrimers,	in	order	to	improve	their	biocompatibility.	
Tetrakis(hydroxymethyl)phosphonium	 chloride	 (THPC)	 has	 been	used	 as	 a	 gelling	 gent	 for	
the	production	of	protein	hydrogels,	which	proved	useful	materials	 for	cell	encapsulation.	
Dendrimers	 are	 repetitively	 hyper-branched	macromolecules	 that	 have	 found	widespread	
interest	 for	 pharmaceutical	 drug	 delivery.	 Torchilin	 and	 coworkers	 conjugated	
triphenylphosphonium	 groups	 to	 the	 surface	 of	 generations	 5	 of	 poly(amidoamine)	
(PAMAM)	dendrimers(G(5)-D)	(Fig	1.12).	These	dendrimers	were	fluorescently	labelled	with	
fluorescein	 isothiocyanate	 (FITC)	 to	 quantify	 cell	 association	 by	 flow	 cytometry	 and	 for	
visualization	under	confocal	laser	scanning	microscopy	to	assess	the	mitochondrial	targeting	
in	 vitro.	 The	 triphenylphosphonium-conjugated	 dendrimer	 (G(5)-D-Ac-TPP)	 was	 efficiently	
taken	up	by	the	cells	and	demonstrated	good	mitochondrial	targeting.	 In	vitro	cytotoxicity	
experiments	carried	out	on	normal	mouse	fibroblast	cells	(NIH-3T3)	had	greater	cell	viability	
in	 the	 presence	 of	 the	 G(5)-D-Ac-TPP	 compared	 to	 the	 parent	 unmodified	 G(5)-D	
dendrimers.	
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Figure.	1.12	Triphenylphosphonium-functionalized	Dendrimers	
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Wang	et	al.,	have	also	prepared	generation	5(G5)	PAMAM	dendrimers	functionalized	with	
triphenylphosphonium	groups	(Fig	1.12),	albeit	using	a	different	methodology	to	Torchilin,	
which	utilizes	alkyl	 amide	 triphenylphosphonium	derivatives,	 and	 investigated	 their	ability	
to	 act	 as	 gene	 vectors.	 Their	 triphenylphosphonium-conjugated	 dendrimers	 effectively	
targeted	mitochondria	and	showed	efficient	transfection	efficacy	on	HeLa	(a	human	cervical	
carcinoma	 cell	 line),	 and	 COS-7	 (an	 African	 green	monkey	 kidney	 fibroblast-like	 cell	 line),	
with	low	cytotoxicity	on	the	transfected	cells.	
	
Biodegradable	macromolecular	 nanoparticles	 composed	of	 block	 co-polymers	 of	 poly(D,L-
lactic-co-glycolic	acid)-block	(PLGA)	and	poly(ethyleneglycol)	(PEG)	have	been	prepared	and	
conjugated	 with	 triphenylphosphonium	 groups	 (Figure	 1.13)	 (Marrache	 et	 al.,	 2012).	
Different	size	particles	were	synthesised,	with	different	levels	of	surface	functionalization	of	
phosphonium	 groups.	 It	 was	 found	 that	 the	 nanoparticles	 were	 able	 to	 cross	 the	
mitochondrial	 membrane	 and	 it	 was	 postulated	 that	 the	 materials	 could	 be	 used	 as	
nanocarriers	for	various	mitochondrial	dysfunction-related	disorders,	 including	Alzheimer’s	
disease,	obesity,	and	cancer.	
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Figure.	1.13	poly(D,L-lactic-co-glycolic	acid)-block	(PLGA-b)-poly(ethyleneglycol)	(PEG)-
triphenylphosphonium	(TPP)	polymer	(PLGA-b-PEG-TPP)	
	
Teng	and	coworkers	prepared	Poly-L-lysine	(PLL)	nanoparticles	by	a	one-step	precipitation-
encapsulation	method	 assisted	 by	 positively	 charged	 poly-L-lysine	 (PLL).	 The	 effect	 of	 the	
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molecular	 weight	 of	 PLL	 on	 the	 formation	 of	 the	 particles	 was	 studied	 in	 terms	 of	
morphology,	size	and	zeta	potential,	and	medium-sized	PLL	proved	to	be	the	optimum	one	
(Wang	 et	 al.,	 2013).	 Triphenylphosphonium	 groups	 were	 conjugated	 to	 the	 PLL-NPs	 (Fig	
1.14),	and	exhibited	a	low	cytotoxic	effect	and	efficient	cellular	uptake.	The	authors	suggest	
that	 the	materials	 are	 promising	mitochondria-targeted	 nanocarriers	 for	 imaging	 or	 anti-
cancer	 therapies.	 The	 same	 group	 then	 developed	 their	methodology	 to	 encapsulate	 the	
dioxygen	probe	Pt(II)-meso-tetra(pentafluorophenyl)porphine	embedded	 in	 a	hydrophobic	
polystyrene	core,	with	triphenylphosphonium-conjugated	PLL	(Wang	et	al.,	2014).	They	then	
used	these	core-shell	nanoparticles	to	determine	the	oxygen	consumption	rates	of	HepG2	
and	LO2	cells	under	respiratory	conditions.	
	
N
H
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Figure.	1.14:	Triphenylphosphonium-conjugated	Poly-L-Lysine	nanoparticles	
	
1.5.3	Metal	nanoparticles	
	
As	noted	 in	section	1.1.1,	gold	nanoparticles	 (AuNPs)	have	attracted	considerable	 interest	
for	their	potential	biomedical	applications.	The	first	published	report	of	the	preparation	of	
AuNPs	functionalized	with	phosphonium	compounds	was	by	Bricklebank	and	coworkers	 in	
2008.	 They	 devised	 a	 synthetic	methodology,	 illustrated	 in	 figure	 1.15,	 that	 was	 used	 to	
prepare	 a	 family	 of	 phosphonioalkylthiosulfate	 zwitterions	 and	
ϖ-thioacetylalkylphosphonium	salts	(Chen	et	al.,	2017),	that	act	as	'masked	thiolate'	ligands	
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in	which	the	thiolate	is	‘protected’	as	a	thiosulfate	or	thioacetate	group,	respectively.	These	
compounds	 have	 greater	 stability	 and	 are	 easier	 to	 handle	 than	 the	 corresponding	 thiol	
ligands.	Cytotoxicity	studies	show	that	these	compounds	have	low	cytotoxicity	towards	cells	
(Chen	PhD	Thesis,	2014).	
	
The	phosphonioalkylthiosulfate	zwitterions	and	ϖ-thioacetylalkylphosphonium	salts	can	be	
used	 to	 prepare	 AuNPs	 protected	 by	 triorganophosphonioalkylthiosulfate	 groups	 using	 a	
modification	of	the	well-known	Brust-Schiffrin	method	(Brust	et	al.,	1995).	Under	reductive	
conditions	 cleavage	 of	 the	 sulfur–sulfur	 or	 sulfur–carbon	 bonds	 in	 the	 thiosulfate	 and	
thioacetate	 species,	 respectively,	 generate	 thiolate	 anions	 in	 situ	 which	 bond	 with	 the	
surface	 of	 the	 growing	 nanoparticles	 leading	 to	 water-soluble,	 cationic,	 phosphonium-
functionalized	AuNPs.	The	nanoparticles	prepared	using	this	method	are	small,	ca.	3.5	-	4.0	
nm	diameter.		
	
Br OHnR3P + R3P OHn
Br R3P Brn
Br
R3P SSO3n R3P Sn
O
Br
Δ HBr
Na2S2O3
H2O/EtOH
KSC(O)CH3
H2O/EtOH
	
Figure	1.15:	Scheme	showing	synthetic	pathway	for	phosphonium	zwitterions	and	salts	
	
Subsequent	research	completed	by	Yu-Su	Chen	at	Sheffield	Hallam	University	showed	that	
the	 triphenylphosphonium-functionalized	gold	nanoparticles	are	 taken-up	by	PC3	prostate	
cancer	cells	and	are	located	in	the	mitochondria	(Chen	PhD	Thesis,	2014).	Yang	et.al.,	have	
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taken	the	methodology	devised	by	the	Bricklebank	group	and	used	it	to	functionalize	much	
larger	 gold	 nanoparticles	 (ca.	 50	 nm	 diameter)	 (Yang	 et	 al.,	 2015).	 The	 phosphonium-
functionalized	 AuNPs	were	 shown	 to	 accumulate	 in	 the	mitochondria	 of	MCF10A	 human	
breast	 cancer	 and	 MBD-MB-231	 human	 mammary	 epithelial	 cell	 lines	 and	 enhance	 the	
formation	 of	 reactive	 oxygen	 species	 in	 5-aminolevulinic-acid-assisted	 photodynamic	
therapy.	 This	 resulted	 in	 a	 higher	 rate	 of	 destruction	 of	 the	 breast	 cancer	 cells	 and	
demonstrated	the	value	of	phosphonium-functionalized	AuNPs	in	cancer	therapeutics.		
	
Mesoporous	materials,	often	containing	silica	or	alumina,	have	pores	in	the	size	range	2	-	50	
nm.	They	are	of	interest	through	their	potential	applications	in	drug	delivery	and	as	sensors.	
Mesoporous	silica	nanoparticles	(MCM-41),	loaded	with	the	antineoplastic	drug	topotecan,	
have	 been	 conjugated	 with	 triphenylphosphonium	 groups	 and	 the	 antibiotic	 peptide	
(KLAKLAK)2	 (Fig	 1.16)	 (Luo	 et	 al.,	 2014).	 It	 was	 found	 that	 the	 cationic	 charge	 promoted	
cellular	take-up	via	endocytosis	and	that	the	pharmacological	agents	are	released	from	the	
nanoparticle	 and	 induce	 damage	 to	 the	 tumour	 mitochondria.	 Triphenylphosphonium	
derivatives	 of	 magnetic	 mesoporous	 silica	 nanoparticles	 (Fe3O4@mSiO2)	 conjugated	 with	
fluorescent	carbon	quantum	dots	have	been	reported	(Zhang	et	al.,	2015).	The	compounds	
were	found	to	localize	 in	the	mitochondria	and	showed	very	low	cytotoxicity	 in	a	range	of	
cell	lines.		
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Figure	1.16	Structure	of	Triphneylphosphonium-functionalized	mesoporous	silica	
nanoparticles	(MCM-41)	(Luo	et	al.,	2014).	
	
	
Figure	1.17	Structure	of	Triphneylphosphonium-functionalized	core-shed	nanoparticles	with	
a	CdSe	or	ZnS	core	and	a	biocompatible	γ-Fe2O3	shell	(Chakraborthy	et	al.,	2015).	
	
	
Figure	1.18	Structure	of	Water	soluble	triphenylphosphonium-functionalized	Zro2	
nanoparticles	(Tahir	et	al.,	2015).	
Core-shell	nanoparticles	comprising	a	CdSe	or	ZnS	core	and	a	γ-Fe2O3	 (Fig	1.17)	 shell	with	
diameters	 in	 the	 range	 30	 -	 40	 nm	 have	 been	 prepared	 and	 decorated	 with	
triphenylphosphonium	 groups	 (Chakraborthy	 et	 al.,	 2015).	 The	materials	 are	 predicted	 to	
act	 as	 subcellular	 nanoprobes	 for	 imaging	 applications.	 Zirconium	dioxide	 (Fig	 1.18)	 5	 nm	
particles	 bearing	 phosphonium	 groups	 have	 been	 prepared	 (Tahir	 et	 al.,	 2015).	 The	
compounds	are	dispersible	in	water	and	are	photostable	making	them	potentially	valuable	
photoluminescent	 materials.	 Molybdenum	 trioxide	 nanoparticles	 functionalized	 with	
triphenylphosphonium	 groups	 have	 been	 investigated	 as	 a	 potential	 therapy	 for	 sulfite	
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oxidase	deficiency	(Ragg	et	al.,	2014).	The	functionalized	MoO3	nanoparticles	were	shown	to	
cross	the	cellular	membrane	and	accumulate	at	the	mitochondria.	They	are	highly	soluble	in	
water	 and	 have	 a	 low	 toxicity	 profile	 while	 increasing	 the	 SuOx	 activity	 in	 chemically	
induced	SuOx	knockdown	cells.		
	
1.6	Arsonium	Cations	
	
Arsenic	 has	 attracted	 the	 attention	 of	 scientists	 for	 centuries	 and	 its	 compounds	 have	 a	
variety	of	applications	ranging	from	electronic	and	semiconductor	materials	(Mudhoo	et	al.,	
2011)	 to	organic	 reagents,	 arsonium	ylides	 finding	utility	 in	 the	Wittig	 reaction	 (He	et	 al.,	
2005).	 Historically,	 arsenic	 compounds	 have	 been	 widely	 investigated	 for	 their	 medicinal	
properties	 although	 interest	 declined	 as	 greater	 understanding	 of	 their	 toxicity	 became	
apparent	(Chen	et	al.,	2011	and	Swindell	et	al.,	2013).	Generally	inorganic	As(III)	and	As(V)	
species	 are	 highly	 toxic,	 whereas	 organic	 arsenic	 compounds	 are	 significantly	 less	 toxic	
(Mudhoo	et	al.,	2011	and	Jomova	et	al.,	2011).	More	recently	there	has	been	a	resurgence	
of	 interest	 in	 the	medicinal	properties	of	arsenic	 compounds,	 including	 the	use	of	arsenic	
trioxide	 and	 organic	 arsenic	 derivatives	 as	 treatments	 for	 leukemia	 and	 other	 cancers	
(Mudhoo	et	al.,	2011,	Chen	et	al.,	2011	and	Swindell	et	al.,	2013),	the	characterization	of	an	
arsenic	 trioxide	 analogue	of	 cisplatin	 (Miodragovic	 et	 al.,	 2013),	 and	 the	observation	 that	
72As	and	74As	radiopharmaceuticals	could	be	useful	 in	positron	emission	tomography	(PET)	
(Mudhoo	et	al.,	2011).		
	
The	chemistry	of	arsenic	is	broadly	similar	to	that	of	phosphorus,	and	organic	phosphonium	
salts	 are	 known	 to	 act	 as	 lipophilic	 cations	 that	 are	 preferentially	 accumulated	 in	 the	
37	
	
mitochondria	of	cells	(Hoyle	et	al.,	2011).	Similarly,	arsonium	cations	are	also	lipophilic	and	
tetraphenylarsonium	 cations	 have	 been	 used	 to	 investigate	 the	 membrane	 potential	 of	
cells.	
	
In	 devising	 strategies	 to	 target	 mitochondria,	 Cle´ment	 and	 Floch	 et	 al.	 substituted	
ammonium	cations	of	phosphonolipids	with	phosphonium	or	arsonium	groups	(1)	(Picquet	
et	 al.,	 2005,	 Le	 Gall	 et	 al.,	 2010,	 Berchel	 et	 al.,	 2012).	 Similar	 work	 to	 this	 was	 done	
previously	 by	 Stekar	 et	 al.,	 who	 replaced	 the	 ammonium	 group	 of	 edelfosine	 and	
miltefosine	 with	 phosphonium	 and	 arsonium	 groups.	 The	 phosphonium	 and	 arsonium	
derivatives	were	found	to	have	significantly	lower	toxicity	while	maintaining	the	antitumor	
activity.	The	reduced	toxicity	of	the	edelfosine	and	miltefosine	analogues	was	attributed	to	
the	 increased	atomic	radii	of	As	and	P	compared	to	N,	which	resulted	 in	 the	 formation	of	
larger	cationic	 complexes	with	 reduced	charge	densities.	Gene	 transfer	 studies	conducted	
by	 Cle´ment	 and	 Floch	 et	 al.	 have	 shown	 that	 phosphonolipids	 with	 arsonium	 and	
phosphonium	cations	exhibit	significantly	lower	cytotoxicity	than	the	ammonium	analogues.	
In	addition,	in	vivo	gene	transfer	studies	using	lipophosphoramidates	showed	up	to	a	3600-
fold	 increase	 in	 gene	 transfer	 efficiency	 for	 the	 phosphonium	 and	 arsonium	 derivatives	
(Mintzer	MA,	Simanek	EE,	2009).	Other	examples	of	the	mitochondria-targeting	potential	of	
triphenylarsonium	ions	include	64Cu-labelled	complexes	of	1,4,7,10-tetraazacyclododecane-
4,7,10-triacetic	acid-conjugated	triphenylarsonium	cations	which	have	been	found	to	act	as	
tumour-selective	PET	imaging	agents	(Wang	et	al.,	2007).	
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1.7	Aims	of	this	Thesis.	
	
1. To	 investigate	 the	 synthesis	 and	 characterization	 of	 the	 triphenylarsonio	
propylthiosulfate	 zwitterion	 and	 the	 triphenylarsoniopropyl	 thioacetate	 salt,	 from	
triphenylarsine	and	dibromopropane.	
	
2. Investigate	the	attachment	of	the	triphenylarsoniopropylthiolate	anion	derived	from	
the	zwitterion	or	thioacetate	salt	onto	the	surface	of	gold	nanoparticles.	
	
3. Investigate	 the	mechanism	of	uptake	of	 gold	nanoparticles	by	 cells	 and	determine	
whether	 it	 is	 through	 endocytosis	 or	 passive	 penetration.	 Toxicity	 studies	 of	 gold	
nanoparticles	 are	 of	 importance,	 consequently	 the	 cell	 biology	 of	 the	
triphenylarsonio	 propylthiosulfate	 zwitterion,	 triphenylarsoniopropyl	 thioacetate	
salt	 and	 triphenylarsonium-capped	 gold	 nanoparticles	 will	 be	 studied	 on	 prostate	
cancer	(PC3)	cells	by	using	MTT	and	CellTiter-Glo	assays.		
	
4. Previous	 research	 in	 the	 Bricklebank	 group	 on	 the	 biological	 chemistry	 of	
phosphonium	compounds	has	focused	on	triphenylphosphonium	derivatives.	Studies	
have	 revealed	 that	 these	 compounds	 can	 have	 limited	 solubility	 in	 cell	 culture.	
Therefore	 it	 was	 decided	 to	 investigate	 the	 synthesis	 of	 phosphonium	 thiosulfate	
derivatives	of	tris(2,4,6-trimethoxyphenyl)phosphine	and	related	compounds	to	see	
if	the	methoxy	groups	improved	the	solubility	of	the	compounds	in	water.	
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Chapter	2	
Experimental	methods	 	
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This	 chapter	 introduces	 the	 analytical	 methods	 used	 to	 characterize	 the	 compounds	
synthesized	during	this	project.		
	
2.1	Melting	point	
	
Determination	of	the	melting	point	of	compounds	was	carried	out	using	an	electro	thermal	
melting	 point	 apparatus,	 with	 a	 temperature	 gradient	 from	 room	 temperature	
(Temperature	 ramp:	 0.5°C)	 using	 a	 Techne	Stuart	 Digital	 Melting	 Point	 Apparatus	 (Fisher	
scientific,	Sheffield	Hallam	University,	UK)	
2.2	Elemental	analysis	
Elemental	 analysis	 (Carbon,	 Sulphur	 and	 Hydrogen)	 were	 carried	 out	 by	 MEDAC	 Ltd	
(Chobham,	Surrey,	UK).	
2.3	Thin	layer	Chromatography	
Analytical	thin	layer	chromatography	(TLC)	was	performed	on	Merck	silica	gel	60F254	plates	
using	70:30	DCM:MeOH	as	the	mobile	phase.	All	samples	were	dissolved	in	DCM.	
2.4	Nuclear	Magnetic	Resonance	
Deuterated	 solvents	 were	 used	 to	 dissolve	 samples	 (10-15mg	 mL-1)	 for	 1H,	 31P	 and	 13C	
nuclear	magnetic	resonance	spectra.	The	spectra	were	obtained	using	a	Bruker	AVANCE	III	
(400MHz)	 NMR	 spectrometer	 (Bruker,	 Coventry,	 West	 Midlands,	 UK).	 Spectra	 were	
interpreted	 by	 comparison	with	 published	 data	 and	 reference	material	 (Duss	 and	 Roger.,	
1998,	Rensen	and	Keeler.,	2006).	
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2.5	Ultraviolet-visible	absorption	spectroscopy	
	
Ultraviolet	visible	(UV-Vis)	absorption	spectra	of	aqueous	colloidal	solutions	were	recorded	
at	room	temperature	on	a	Jenway	6715	UV/Vis	spectrophotometer	(Bibby	Scientific	Limited,	
Stone,	 Staffordshire,	 UK)	 with	 UV-quartz	 cuvettes	 (1m	 optical	 path).	 Assignments	 were	
made	based	on	published	data	(Daniel	and	Astruc.,	2004).	
	
2.6	Fourier	Transform	Infrared	spectroscopy	
Fourier	 transform	 infrared	 (FTIR)	 spectra	 were	 recorded	 on	 a	 PerkinElmer	 spectrum	 100	
FTIR	spectrometer	(PerkinElmer,	Waltham,	Massachusetts,	USA).	The	data	was	interpreted	
using	interpretation	tables	(Gunzler	and	Gremlich,	2002,	Larkin,	2011).		
	
2.7	Electrospray	Ionization	Mass	Spectrometry	
Samples	were	dissolved	in	EtOH:	DIH2O	(50:50)	to	a	concentration	of	approximately	1mg/mL	
for	molecular	ion	determination.	Electrospray	mass	spectra	were	recorded	using	a	Thermo	
Finnigan	 MAT	 LCQ	 classic	 electrospray	 ionisation	 mass	 spectrometer	 (ESI-MS)	 (Thermo	
Scientific,	 Sanjose,	 California,	 USA)	 in	 a	 positive	 ion	 mode.	 Samples	 were	 introduced	 by	
direct	infusion	using	the	syringe	pump	on	the	instrument	at	a	flow	rate	of	5	µL/min	with	an	
acquisition	time	of	one	minute.		
2.8	X-Ray	Crystallography	
Single	crystals	of	selected	compounds	were	grown	by	slow	diffusion	of	diethyl	ether	into	a	
solution	 of	 the	 compounds	 dissolved	 in	 DCM.	 Crystalline	 Samples	 isolated	 were	 then	
submitted	 for	 analysis	 to	 the	 UK	 National	 Crystallography	 Service	 at	 the	 University	 of	
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Southampton	 (School	 of	 Chemistry,	Highfield,	 Southampton,	UK).	 The	 full	 crystallographic	
reports	for	all	crystal	studies	are	included	in	Appendix	1.	
2.9	Transmission	Electron	Microscopy	
Transmission	 electron	 micrographs	 of	 AuNPs	 were	 conducted	 on	 a	 Jeol	 2000	 FX	
transmission	 electron	 microscope	 (TEM)	 (ETC,	 Brunel	 University,	 Middlesex,	 UK),	 set	 at	
100kV.	Freeze	dried	AuNPs	samples	were	re-suspended	 in	ethanol,	and	placed	on	a	Holey	
coated	copper	gold	grid,	and	the	grids	were	left	dry	in	air	at	room	temperature.	Particle	size	
distribution	was	obtained	over	1000	AuNPs	using	Abel	imaging	software.	TEM	was	also	done	
at	 Sheffield	 Hallam	 University	 using	 Philips	 CM20	 TEM	 (200kV,	 LaB6	 filament)	 using	 the	
same	protocol	as	above.	
	
2.10	X-ray	Photoelectron	Spectroscopy	
	
The	 sample	was	 deposited	 onto	 the	 carbon	 tape	 on	 the	 sample	 bar	 as	 a	 slurry,	 and	 the	
sample	was	left	under	vacuum	in	the	instrument’s	load	lock	for	approximately	48	hours	to	
dry	out.	The	sample	was	analyzed	by	X-ray	Photoelectron	Spectroscopy	using	a	Kratos	Alpha	
DLD	 instrument	 (ETC,	 Brunel	 University,	 Middlesex,	 UK).	 Monochromated	 aluminium	
radiation	was	used	to	collect	a	survey	scan	between	1200	to	0	eV	at	0.5	eV	resolution,	and	
then	 quantified	 using	 calibrated	 relative	 sensitivity	 factors	 to	 give	 the	 elemental	
compositions.	In	addition,	high-resolution	scans	were	collected	over	the	C1s,	O	1s,	S	2p,	Au	
4f	 and	As	 3d	peaks	 at	 0.05	eV	 resolution	 and	20	eV	pass	 energy.	 The	 scans	obtained	are	
after	 curve	 fitting.	 The	 binding	 energies	 have	 all	 been	 adjusted	 such	 that	 the	 C-C/C-H	
component	of	the	C	1s	peak	in	the	wide	survey	spectrum	falls	at	285.0	eV	(Sheffield	Surface	
Analysis	Centre,	University	of	Sheffield,	Sheffield,	South	Yorkshire,	UK).	This	is	to	adjust	for	
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charging	effects	not	sufficiently	compensated	for	by	the	charge	neutralization	used	during	
data	collection.		
	
2.11	Cell	Culture	
Human	prostate	cancer	cells	(PC3)	and	Human	Fibroblast	cells	were	maintained	in	complete	
media	(cDMEM)	which	contains	Dulbecco’s	modified	Eagle	medium	with	GlutaMAX,	4.5	g/L	
D-glucose	 and	 sodium	 pyruvate	 (Invitrogen	 Life	 Technologies,	 Paisley,	 Renfrewshire,	 UK)	
containing	10%	heat-inactivated	 fetal	bovine	serum	(Biosera,	East	Sussex,	Sussex,	UK)	and	
1%	penicillin-streptomycin	(Invitrogen	Life	Technologies,	Paisley,	Renfrewshire,	UK)	at	37°C	
in	5%	CO2	and	95%	air.	Cells	were	sub-cultured	every	4	days	and	periodically	screened	for	
mycoplasma.	
	
2.12	Cytotoxicity	assay	
Cytotoxicity	was	 assessed	 using	 CellTiter-Glo	 luminescent	 cell	 viability	 assay	 kit	 (Promega	
Corporation,	 Southampton,	 Hamshire,	 UK).	 Cell	 viability	 was	 measured	 according	 to	 the	
manufacturer’s	 instructions.	 In	brief	plates	were	equilibrated	at	 room	 temperature	 for	30	
minutes,	100µL	of	assay	reagent	was	added	to	each	well,	placed	on	an	orbital	shaker	for	2	
minutes	 and	 read	 on	 a	Wallac	 Victor2	 1420	multilabel	 counter	 (PerkinElmer,	 Cambridge,	
Cambridgeshire,	UK).		
Data	obtained	are	expressed	a	percentage	of	live	cells	normalised	to	control.	The	average,	
standard	 deviation	 and	 IC50	 values	 were	 plotted	 and	 calculated	 using	 GraphPad	 Prism	
(GraphPad	software,	La	Jolia,	California,	USA).	
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2.13	ICP-OES		
The	Au	 analysis	was	 carried	 out	 by	 digestion	 of	 the	 sample	 in	 8ml	 of	 aqua	 regia	 and	 the	
solution	made	 up	 to	 100ml.	 This	 solution	was	 then	 analyzed	 by	 ICP-OES.	 The	 instrument	
used	for	this	was	a	Varian	Vista	MPX	ICP-OES	at	MEDAC	(Chobham,	Surrey,	UK).	
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Chapter	3	
A)	The	synthesis	and	characterisation	of	
triphenylarsonium-	functionalized	gold	
nanoparticles	and	their	precursor	ligands	
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3.1	Introduction	
As	 outlined	 in	 chapter	 1,	 triphenylphosphonium	 salts	 act	 as	 lipophilic	 cations	 and	 are	
preferentially	 accumulated	 in	 the	 mitochondria	 of	 cells,	 making	 them	 an	 attractive	
proposition	 for	 integration	 with	 nanomaterials	 for	 applications	 in	 pharmaceutical-
nanotechnology	 (Hoyle	 et	 al.,	 2008).	 Arsonium	 cations	 are	 also	 lipophilic	 and	 have	 been	
investigated	as	 intra-cellular	transport	vectors.	For	example,	copper-64	labelled	complexes	
of	 1,4,7,10-tetraazacyclododecane-4,7,10-triacetic	 acid-conjugated	 triphenylarsonium	
cations	have	been	found	to	act	as	tumour-selective	PET	imaging	agents	(Wang	et	al.,	2007)	
and	 lipophosphoramidate	derivatives	containing	arsonium	head-groups	have	been	studied	
as	gene	delivery	systems	(Berchel	et	al.,	2012).		
	
Previous	 work	 in	 the	 Bricklebank	 group	 has	 focused	 on	 the	 preparation	 and	 biological	
properties	 of	 triphenylphosphonioalkylthiosulfate	 zwitterions	 and	 ω-thioacetylalkyl-
(triphenyl)phosphonium	salts,	 and	 the	use	of	 these	 compounds	 to	prepare	phosphonium-
functionalized	 gold	 nanoparticles	 which	 are	 accumulated	 by	 cells	 and	 localized	 in	 the	
mitochondria	 (Ju-Nam	 et	 al.,	 2012,	 Ju-Nam	 et	 al.,	 2006,	 Ju-Nam	 et	 al.,	 2008,	 Chen	 PhD	
Thesis,	2014).	Given	the	success	of	using	arsonium	cations	as	intra-cellular	transport	vectors	
it	was	decided	to	broaden	the	scope	of	our	phosphonium-chemistry	research	to	encompass	
triphenylarsonium	and	methoxyphenylphosphonium	compounds.		
	
In	this	chapter	(3A)	the	synthesis	and	characterization	of	triphenylarsoniopropylthiosulfate	
zwitterion,	 ω-thioacetylpropyl(triphenyl)arsonium	 bromide	 salt,	 	 (3B)	 (methoxy-phenyl)	
phosphoniopropylthiosulfate	 zwitterions	 and	 ω-thioacetylpropyl	 (methoxyphenyl)	 phosphonium	
71	
	
salts	are	described,	together	with	 investigations	 into	the	preparation	of	gold	nanoparticles	
functionalized	with	triphenylarsonium	groups.	
3.2	Material	and	methods	
3.2.1	Chemicals	
All	 chemicals	 were	 used	 as	 received;	 triphenylarsine,	 1,3	 dibromopropane,	 potassium	
thioacetate,	 sodium	 thiosulfate,	 Potassium	 bromide,	 gold(III)	 chloride	 trihydrate,	
hydrobromic	 acid,	magnesium	 sulfate,	 deuterated	 dichloromethane	 and	 chloroform	were	
purchased	from	Sigma-Aldrich	(Gillingham,	Dorset,	UK).	
	
3.2.2	Synthesis	of	Triphenylalkyl	arsonium	compounds	
3-bromopropyl	 (triphenyl)arsonium	 bromide	 (1)	 was	 prepared	 from	 1,3-dibromopropane	
(3ml)	and	triphenylarsine	(1g)	following	the	method	of	Moorhoff	(Moorhoff,	1998)	as	shown	
in	 figure	 3.1.	 The	 triphenylarsoniopropylthiosulfate	 zwitterion	 (2)	 and	 ω-
thioacetylpropyl(triphenyl)arsonium	 bromide	 salt	 (3)	 were	 obtained	 by	 adapting	 the	
methods	described	by	Ju-Nam	and	colleagues	(Ju-Nam	et	al.,	2012,	Ju-Nam	et	al.,	2006).	
	
	The	 triphenylarsoniopropylthiosulfate	 zwitterion	 (2)	 were	 synthesized	 by	 refluxing	 3-
bromopropyl(triphenyl)arsonium	bromide	 (1.0g,	 2.15	 x	 10-3	mol)	with	Na2S2O3	 in	 aqueous	
EtOH	 (0.8g,	 3.23	 X	 10-3	 mol)	 to	 obtain	 the	 product.	 The	 completion	 of	 the	 reaction	 was	
checked	 by	 TLC	 using	 70:30	 DCM:MeOH	 as	 the	 mobile	 phase.	 After	 the	 reaction	 was	
completed,	 20ml	 KBr	 solution,	 10%w/v	 was	 added	 prior	 to	 isolating	 the	 bromide	 salt.	
Solvent	extraction	with	DCM	(3	x	10	ml)	was	done	to	obtain	the	product	which	was	finally	
purified	by	trituration	with	diethyl	ether,	followed	by	characterization	by	elemental	analysis	
FT-IR,	ESI-MS	and	NMR.	
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The	ω-thioacetylpropyl(triphenyl)arsonium	bromide	salt	 (3)	were	synthesized	by	stirring	3-
bromopropyl(triphenyl)arsonium	 bromide	 under	 nitrogen	 with	 potassium	 thioacetate	 in	
aqueous	EtOH	(0.37g,	3.23	x	10-3	mol).	The	completion	of	the	reaction	was	checked	by	TLC	
using	70:30	DCM:MeOH	as	the	mobile	phase.	After	the	reaction	was	completed,	20ml	KBr	
solution,	 10%w/v	 was	 added	 prior	 to	 isolating	 the	 bromide	 salt.	 Solvent	 extraction	 with	
DCM	 (3	x	10	ml)	was	done	 to	obtain	 the	product	which	was	 finally	purified	by	 trituration	
with	 diethyl	 ether,	 followed	 by	 characterization	 by	 elemental	 analysis	 FT-IR,	 ESI-MS	 and	
NMR.	
	
	
	
Figure	3.1	Synthesis	schemes	of	Arsonium	ligands.	
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3.3	Characterization	of	Arsonium	ligands.	
All	arsonium	compounds	were	characterized	by	elemental	analysis	and	by	1H	and	13C	NMR,	
mass	 spectrometry	 and	 by	 FT-IR	 and	 FT-Raman	 spectroscopy	 and	 the	 data	 are	 reported	
below	 in	 section	 3.3.1	 and	 3.3.2.	 Compounds	 2	 and	 3	 were	 also	 characterized	 by	 single	
crystal	 X-ray	 crystallography	 and	 X-ray	 photoelectron	 spectroscopy.	 The	 results	 of	 these	
analyses	are	discussed	in	detail	in	sections	3.3.4	and	3.4.2.2	respectively.	
	
3.3.1	Triphenylarsoniopropyl	thiosulfate	zwitterion	(2):	
Colourless	 crystals,	mp.	196°C.	 Elemental	Analysis:	 found:	C,	 54.46%;	H,	 4.40%;	 S	13.94%.		
C21H21AsO3S2	requires:	C,	54.78%;	H,	4.56%;	S	13.91%.	
1H	NMR: δ 2.3	(2H,	m),	3.2	(2H,	t),	3.6	
(2H,	m),	7.6–7.9	(15H,	m)	ppm.	IR	υmax/cm
-1=2912	(CH),	1483,	1438,	1209	(SO),	1082,	1010	
(SO),	744,	688,	623,	523,	466.		ESI-MS:	460.89	[M]+,	461.97	[M+H+],	482.90	[M+Na+].	
3.3.2	ω-Thioacetylpropyl(triphenyl)arsonium	bromide	(3):	
Colourless	 crystals,	 mp.	 234	 -	 238oC.	 Elemental	 Analysis:	 found:	 C,	 54.97%;	 H,	 4.81%;	 S	
6.42%.		C22H24AsBrOS	requires:	C,	54.87%;	H,	4.77%;	S	6.36%.	
1H	NMR: δ 1.6	(3H, s),	2.1 (2H,	
m),	3.2	(2H,	t),	3.8	(2H,	m),	7.6–7.9	(15H,	m)	ppm.	IR	υmax/cm
-1=2911	(CH),	1483,	1436	(SO),	
1082,	1022	(SO),	742,	687,	623,	466.	ESI-MS:	423.13	[M]+,	424.13	[M+H+].		
	
3.3.3	 Single	 Crystal	 X-ray	 crystallography	 Studies	 of	 the	
Triphenylarsoniopropyl	thiosulfate	zwitterion	(2).	
The	structure	of	2	was	investigated	by	x-ray	crystallography.	Single	crystals	were	grown	by	
slow	diffusion	of	diethyl	ether	 into	a	DCM	solution	of	2,	which	yielded	colourless	needles.	
The	crystals	were	sent	for	full	structure	analysis	at	the	EPSRC	X-ray	Crystallography	service	
at	the	University	of	Southampton.		
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The	molecular	structure	of	2	 is	 shown	 in	Figure	3.2,	 selected	bond	 lengths	and	angles	are	
listed	in	Table	3.1.	Crystal	data	and	structure	refinement	details	are	presented	in	appendix	
1.	
	
Figure	3.2	An	Ortep	representation	of	the	molecular	structure	of	2.	Thermal	ellipsoids	are	
drawn	at	50%	probability	level.	
	
	
Table	3.1	Selected	bond	lengths	[Å]	and	angles	[°]	in	2.	
C1−As1	 1.923(5)	 O1−S2	 1.452(4)	
C3−S1	 1.817(5)	 O2−S2	 1.443(4)	
C4−As1	 1.910(5)	 O3−S2	 1.446(4)	
C10−As1	 1.916(4)	 S1−S2	 2.1081(18)	
C16−As1	 1.904(5)	 	 	
	 	 	 	
C3−S1−S2	 99.84(17)	 O2−S2−S1	 105.78(16)	
O2−S2−O3	 114.6(2)	 O3−S2−S1	 101.28(17)	
O2−S2−O1	 113.7(2)	 O1−S2−S1	 107.13(16)	
O3−S2−O1	 113.0(2)	 	 	
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The	 structures	 of	 several	 organic	 thiosulfate	 zwitterions	 have	 been	 described.	 The	
Bricklebank	 group	 has	 previously	 reported	 the	 structure	 of	
triphenylphosphoniopropylthiosulfate	 zwitterion	 (4),	 together	 with	 those	 of	 the	
tributylphosphoniopropylthiosulfate	 and	 (4-fluorophenyl)phosphoniopropylthiosulfate	
zwitterions	 (Ju-Nam	et	al.,	2012,	 Ju-Nam	et	al.,	2006).	The	only	other	 crystallographically-
characterized	thiosulfate	zwitterion	 is	an	ammonium	derivative,	S-	 [4-	 (trimethylammonio)	
phenyl]	thiosulfate	(5)	(Chen	et	al.,	2004).	
	
	
Figure	3.3	S-	[4-	(trimethylammonio)	phenyl]	thiosulfate	(5)	
Compound	2	displays	the	expected	tetrahedral	geometry	around	the	arsenic	atoms	with	a	
mean	C–As–C	bond	angle	of	109.5(2)	°.	The	S–O	bonds	in	the	thiosulfate	group	are	similar	
with	 a	 mean	 length	 of	 1.447(4)	 Å,	 indicative	 of	 multiple	 bond	 character,	 and	 that	 the	
negative	 charge	 is	 delocalised	 over	 the	 entire	 sulfate	 group.	 The	 mean	 O–S–O	 angle	
[113.8(2)°]	is	consistent	with	those	in	other	thiosulfate	ions	(Ju-Nam	et	al.,	2012,	Ju-Nam	et	
al.,	2006,	Chen	et	al.,	2004).	The	S–S	bond	length	[2.1081(18)	Å],	is	slightly	shorter	than	that	
of	 the	 corresponding	 phosphonium	 compound	 4	 [2.1117(9)	 Å]	 (Ju-Nam	 et	 al.,	 2012),	 but	
longer	than	the	S–S	bond	in	ionic	thiosulfate	ions	such	as	Me2HN(CH2S2O3)2
-Na+	(Ju-Nam	et	
al.,	2006).	However,	all	are	longer	than	the	established	length	of	a	single	S-S	bond	[2.05Å]		
(Huheey	 et	 al.,	 1972).	 The	 ammonium	 thiosulfate	 zwitterion	5	has	 an	 S-S	 bond	 length	 of	
2.1137(7)	Å,	 similar	 to	 those	of	2	 and	4,	but	appreciably	 shorter	 than	 the	S-S	bond	 in	 the	
monoanion	of	thiosulfuric	acid,	HSSO3
-	[2.155	Å]	(K.	Miaskiewicz	and	R.	Steudel,	1992).	The	
lengthening	 of	 the	 S-O	 and	 S-S	 bonds	 in	 the	 organic	 zwitterions	 is	 consistent	 with	 the	
SSO3Me3N
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delocalization	of	the	negative	charge	across	the	entire	thiosulfate	group.	Furthermore,	the	
longer	 and	 weaker	 S-S	 bond	 of	 the	 triphenyl-arsonium	 and	 -phosphonium	 zwitterions	
expedites	 the	dissociation	of	 the	 thiosulfate	group	with	 the	concomitant	 formation	of	 the	
corresponding	thiolate	ion	which	is	a	key	step	in	the	application	of	these	compounds	in	the	
synthesis	of	metal	nanoparticles.		
Within	 the	 crystal	 lattice	 the	 triphenylarsonium	 thiosulfate	 zwitterions	pack	 fairly	 loosely,	
held	 together	 by	 hydrogen-bonding	 interactions	 between	 the	 sulfate	 oxygen's	 and	 the	
phenyl	hydrogens,	but	 there	 is	no	close	 interaction	between	the	arsonium	centre	and	the	
thiosulfate	moieties.		
	
3.3.4	 Single	 Crystal	 X-ray	 crystallography	 Studies	 of	 the	 Thioacetylpropyl	
(triphenyl)	arsonium	bromide	(3)	
The	 structure	of	 arsonium	 salt	3	was	 investigated	by	 x-ray	 crystallography.	 Single	 crystals	
were	grown	by	slow	diffusion	of	diethyl	ether	 into	a	DCM	solution	of	3	which	yielded	the	
compound	 as	 colourless	 needles.	 The	 crystals	 were	 sent	 for	 full	 structure	 analysis	 at	 the	
EPSRC	X-ray	Crystallography	service	at	the	University	of	Southampton.		
	
The	molecular	structure	of	3	 is	 shown	 in	Figure	3.4,	 selected	bond	 lengths	and	angles	are	
listed	in	Table	3.2.	Crystal	data	and	structure	refinement	details	are	presented	in	appendix	
1.	
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Figure	3.4	An	Ortep	representation	of	the	molecular	structure	of	3.	Thermal	ellipsoids	are	
drawn	at	50%	probability	level.	
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Table	3.2	Selected	bond	lengths	[Å]	and	angles	[°]	in	3.	
C1−As1	 1.927(2)	 C6−As1	 1.909(2)	
C3−S1	 1.806(3)	 C12−As1	 1.912(2)	
C4−O1	 1.204(3)	 C18−As1	 1.914(3)	
C4−S1	 1.777(3)	 	 	
	 	 	 	
C2−C1−As1	 114.06(18)	 C17−C12−As1	 119.1(2)	
As1−C1−H1A	 108.7	 C13−C12−As1	 119.9(2)	
As1−C1−H1B	 108.7	 C19−C18−As1	 119.36(19)	
C2−C3−S1	 113.17(19)	 C23−C18−As1	 119.84(19)	
S1−C3−H3A	 108.9	 C6−As1−C12	 108.90(10)	
S1−C3−H3B	 108.9	 C6−As1−C18	 109.88(10)	
O1−C4−C5	 124.0(3)	 C12−As1−C18	 108.21(11)	
O1−C4−S1	 123.0(2)	 C6−As1−C1	 107.02(11)	
C5−C4−S1	 113.0(2)	 C12−As1−C1	 109.52(11)	
C11−C6−As1	 120.18(19)	 C18−As1−C1	 113.24(10)	
C7−C6−As1	 118.98(18)	 C4−S1−C3	 102.23(14)	
 
Arsonium	salt	3	displays	the	expected	tetrahedral	geometry	around	the	arsenic	atom	with	a	
mean	C-As-C	bond	angle	of	109.46(11)o	which	is	very	similar	to	the	mean	C-As-C	bond	angle	
in	2		[109.5(2)o]. The	thioacetate	moiety	displays	the	expected	angular	geometry	around	the	
sulphur	 atom	 and	 the	 mean	 O–C–S	 angle	 [123.0(2)°]	 is	 consistent	 with	 those	 in	 other	
thioacetate	 ions	 (Ju-Nam	 et	 al.,	 2012).	 The	 C-S	 and	 C-O	 bond	 lengths	 of	 the	 thioacetate	
group	in	3	are	similar	to	the	expected	distances	for	C-S	single	and	C=O	bonds,	ca.1.8	Å	and	
1.2	 Å	 respectively,	 and	 are	 similar	 to	 the	 comparable	 bonds	 in	 ω-thioacetylpropyl(tri-4-
fluorophenyl)phosphonium	 bromide	 (Ju-Nam	 et	 al.,	 2012),	 and	
dimethylmonothiocarbonate,	 CH3OC(S)CH3,	 which	 has	 C-S	 bond	 lengths	 of	 1.791(2)Å,	
1.759(1)	Å	and	a	C=O	bond	length	of	1.195(2)	Å	(Erben	et	al.,	2006).	
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3.4	Synthesis	and	characterization	of	Triphenylarsonium	functionalized	gold	
nanoparticles.	
	
Phosphonioalkylthiosulfate	 zwitterions	 (Ju-Nam	 et	 al.,	 2012,	 Ju-Nam	 et	 al.,	 2006),	 and	
phosphonioalkylthioacetate	 salts	 (Ju-Nam	 et	 al.,	 2008)	 are	 known	 to	 act	 as	 ‘masked	
thiolates’	and,	under	reductive	conditions,	cleavage	of	the	thiosulfate	S-S	or	thioacetate	S-C	
bonds	takes	place	generating	phosphonioalkylthiolate	zwitterions	that	can	coordinate	to	the	
surface	of	gold	particles.	The	Bricklebank	group	have	exploited	 this	chemistry	 to	generate	
water	 soluble	 cationic	 gold	 nanoparticles	 functionalized	with	 alkylthiolate	 ligands	 bearing	
phosphonium	 head-groups,	 and	 hence	 it	 was	 of	 interest	 to	 investigate	 if	 the	 analogous	
arsonium	 thiosulfate	 zwitterion	 (2)	 and	 thioacetate	 salt	 (3)	 would	 undergo	 the	 same	
reaction.	Recent	work	has	reported	rare	examples	of	the	coordination	chemistry	of	tertiary	
arsine	ligands	bearing	pendant	thiolate	groups	towards	Ni(II),	Pt(II)	and	Pd(II)	(Hildebrand	et	
al.,	2013).	However,	to	the	best	of	our	knowledge,	there	are	no	reports	of	the	coordination	
chemistry	of	triorganoarsonium	thiolate	species	or	of	the	use	of	tertiary	arsines	or	arsonium	
compounds	 as	 capping	 ligands	 in	 the	 formation	 of	 functionalized	 nanoparticles,	 although	
nanoscale	 liposomes	or	 nanobins,	 composed	of	 lipids	 and	metal	 salts,	 have	been	used	 to	
encapsulate	 and	 stabilize	 arsenic	 trioxide	 in	 order	 to	 extend	 the	 clinical	 utility	 of	 this	
compound	(Swindell	et	al.,	2013).	
	
	
3.4.1	The	Synthesis	of	Triphenylarsonium-	functionalized	gold	nanoparticles.	
	
The	synthesis	is	based	on	methods	developed	previously	by	the	Bricklebank	group	(Ju-Nam	
et	al.,	2012,	Ju-Nam	et	al.,	2006,	Ju-Nam	et	al.,	2008)	as	shown	in	Figure	3.5.	A	solution	of	
the	 arsonium	 ligand	 (2	 or	 3)	 (0.25mmol)	 was	 prepared	 in	 dichloromethane.	 Solid	
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tetrachloroauric	acid	was	added	 to	 form	a	homogenous	 solution.	The	mixture	was	 stirred	
for	5-6	hours	until	the	gold	salt	had	completely	dissolved.	After	the	complete	dissolution	of	
the	gold	salt,	the	reduction	was	carried	out	by	the	addition	an	aqueous	solution	of	sodium	
borohydride,	drop-wise	with	vigorous	stirring.		
	
The	 first	 confirmation	 that	 the	 AuNPs	 had	 been	 successfully	 prepared	 was	 the	 visual	
observation	of	the	color	change	of	the	solution	during	the	synthesis;	when	HAuCl4	(0.25mg)	
was	added	to	the	solution	of	the	corresponding	protecting	ligands	2	and	3	 in	DCM	(10mL),	
the	stirring	organic	solution	turned	yellow.	The	drop	by	drop	addition	of	NaBH4	
	(10mL)	induced	a	color	change	from	yellow	to	a	characteristic	purple	color	which	indicated	
that	 reduction	 had	 taken	 place	 (Daniel	 and	Astruc	 review,	 2004).	When	 the	 reaction	was	
stopped	after	24	hours,	the	DCM	layer	was	colorless	and	the	aqueous	phase	was	purple	in	
color	with	no	evidence	of	aggregation,	indicating	that	functionalized	AuNPs	were	present	in	
the	aqueous	phase.	The	aqueous	phase	was	subjected	to	three	DCM	extractions	in	order	to	
remove	the	excess	organic	matter	present.	A	series	of	experiments	have	been	completed,	as	
outlined	 in	 Table	 3.3,	 varying	 the	 ratio	 of	 HAuCl4	 and	 arsonium	 ligand	 with	 the	 aim	 of	
investigating	the	effect	on	the	size	and	polydispersity	of	the	resulting	AuNPs.		
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Figure	3.5	Reaction	scheme	for	synthesis	of	Triphenylarsonium-functionalized	AuNP	
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Table	3.3	Varying	ratio	of	Gold	and	Arsonium	ligand.	
Sample*	
Capping	
Ligand	
Ratio	of	gold	salt	and	
capping	ligand	
	 Notes	and	observations	
	 	 [AuCl4]
-
	 Ligand	 	
A-Au-Z0.1	 2	 1	 0.1	 No	nanoparticles	formed	
A-Au-Z0.5	 2	 1	 0.5	 	
A-Au-Z1	 2	 1	 1	 	
A-Au-Z1.5	 2	 1	 1.5	 	
A-Au-Z2	 2	 1	 2	 	
A-Au-T2	 3	 1	 2	 	
*NOTE		
In	 order	 to	 differentiate	 the	 samples	 an	 experimental	 notation	 has	 been	 developed	 as	
follows:	
• The	initial	A	or	P	represents	TriphenylArsonium	or	triphenylPhosphonium	head	group	
• The	Au	represents	a	gold	nanoparticle	
• Z	or	T	indicates	whether	the	precursor	ligand	was	a	thiosulfate	Zwitterion	or	Thioacetate	
salt	
• The	 numbers	 indicate	 the	 gold:	 ligand	 ratio	 in	 the	 reaction	mixture,	 e.g.	2	 indicates	 a	
[AuCl4]
-:ligand	ration	of	1:2	
	
Therefore,	A-Au-Z0.5	would	be	a	gold	nanoparticle,	capped	with	triphenylarsonium	ligand,	
prepared	using	the	triphenylpropylthiosulfate	zwitterion	with	gold:	ligand	ratio	of	1:0.5.	
	
The	 mechanism	 by	 which	 the	 triphenylarsonium-functionalized	 AuNPs	 are	 formed	 is	 not	
certain.	 Studies	 into	 the	 formation	 of	monolayers	 on	 gold	 surfaces	 from	 alkylthiosulfates	
show	hydrolysis	by	trace	amounts	of	water	present	in	the	solvent	to	be	crucial	(Fealy	et	al.,	
2011,	 Pillai	 and	 Freund,	 2011).	 The	 nanoparticles	 reported	 here	were	 prepared	 in	 a	 two-
phase	 water/dichloromethane	 mixture,	 i.e.	 more	 than	 a	 trace	 of	 water!	 However	 the	
possibility	that	the	growing	gold	nanoparticles	and/or	the	reducing	agent	are	involved	in	the	
cleavage	 of	 the	 thiosulfate	 S–S	 or	 thioacetate	 S–C	 bonds	 cannot	 be	 excluded.	 Previous	
studies	on	the	analogous	phosphonium	zwitterions	and	salts	indicate	that	the	cleavage	step	
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is	slower	for	the	thioacetate	ligands	than	for	the	thiosulfate	zwitterions	and	so	this	results	in	
slower	monolayer	formation	and	consequently	a	broader	particle	size	distribution.	
	
3.4.2	 Characterization	 of	 Triphenylarsonium-Functionalized	 Gold	
Nanoparticles	
The	 triphenylarsonium-functionalized	 AuNPs	 have	 been	 characterized	 using	 a	 range	 of	
techniques	 including	 UV-visible,	 IR	 and	 Raman	 spectroscopy,	 X-ray	 photoelectron	
spectroscopy	(XPS)	and	Transmission	Electron	Microscopy	(TEM),	as	discussed	below.	
	
3.4.2.1	Spectroscopic	Characterization	of	Triphenylarsonium-capped	AuNPs	
To	study	 the	optical	properties	of	nanoparticles	UV-Vis	absorption	 spectroscopy	has	been	
widely	 used,	 the	 UV-visible	 absorption	 band	 of	 gold	 nanoparticles	 being	 governed	 by	 a	
number	of	factors	such	as	the	shape	and	size	of	the	metal	nanoparticles.	The	evidence	that	
the	AuNPs	were	 successfully	 synthesized	was	 supported	by	 the	broad	adsorption	band	 in	
the	 visible	 region	 centered	 at	 ~520nm	 (Figure	 3.6).	 This	 indicated	 that	 the	 AuNPs	 were	
between	 2-10nm	 in	 diameter,	 according	 to	 the	 data	 for	 other	 thiolate-capped	 gold	
nanoparticles	reported	previously	(Daniel	and	Astruc	review,	2004).	
	
The	position	of	the	λmax	of	the	absorption	band	is	not	significantly	affected	by	the	ratio	of	
gold	and	capping	ligand,	except	for	experiment	A-Au-Z0.1,	indicating	that	the	particle	size	of	
the	AuNPs	were	 very	 similar;	 this	was	 later	 confirmed	by	 TEM.	 The	 reaction	with	 a	 gold:	
ligand	molar	 ratio	 of	 1:0.1	 (A-Au-Z0.1)	 had	 insufficient	 ligand	 to	 be	 able	 to	 stabilize	 the	
growing	 nanoparticles	 and	 hence	 no	 absorption	 band	 was	 observed	 in	 the	 UV-visible	
spectrum.		
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Figure	3.6	UV-vis	spectra	of	triphenylarsonium-functionalized	AuNPs:		(a)	A-Au-Z0.1,		
(b)	A-Au-Z1.5,	(c)	A-Au-Z0.5,	(d)	A-Au-Z2,	(e)	A-Au-Z1.	
	
ESI-MS	 data	 also	 provided	 useful	 information	 regarding	 the	 chemical	 composition	 of	 the	
surface	ligands	on	the	AuNPs.	 	The	ESI-MS	spectra	of	A-Au-Z1,	A-Au-Z1.5,	and	A-Au-Z2,	A-
Au-T2	 all	 contained	 a	 peak	 due	 to	 the	 triphenylarsoniopropylthiolate	 ion	
(Ph3AsCH2CH2CH2S)
+,	with	 no	 evidence	 of	 the	 parent	 thiosulfate	 zwitterion	 or	 thioacetate	
cation.	 This	 indicated	 that	 the	 S-S	bond	of	 the	 thiosulfate	 group	 in	2	 and	 the	 thioacetate	
group	in	3	has	been	successfully	cleaved.	The	spectra	also	included	a	fragment	peak	at	m/z	
306	due	to	the	Ph3As	moiety.	
	
Raman	 spectroscopy	 has	 previously	 been	 used	 to	 characterize	 thiolate-protected	 gold	
clusters	and	nanoparticles	(Varnholt	et	al.,	2014	and	Holze	and	Wu.,	2014).	The	spectra	are	
dependent	on	the	size	of	the	particles	and	the	nature	and	steric	bulk	of	the	ligand	with	Au-S	
(a)	
(b)	
(c)	
(d)	
(e)	
	
85	
	
modes	 typically	 occurring	 in	 the	 region	 250	 -	 325cm-1.	 	 The	 Raman	 spectra	 of	
triphenylarsoniumpropylthiolate-capped	AuNPs	were	recorded	in	the	region	4000	-	150cm-1.	
The	 spectra	 are	 illustrated	 in	 Figures	 3.7	 –	 3.10.	 All	 of	 the	 nanoparticle	 samples	 showed	
significant	 fluorescence	 which	 diminished	 the	 quality	 of	 the	 data.	 Nonetheless,	 some	
deductions	 can	 be	made.	 The	 spectra	 of	 all	 samples,	 contained	 peaks	 at	 1600,	 1021	 and	
999cm-1	 that	 can	 be	 attributed	 to	 C-H	 ring	 bending	 modes	 (Varnholt	 et	 al.,	 2014).	
Furthermore,	the	compounds	all	show	a	band	in	the	region	259	-	271	cm-1	(Table	3.4)	that	
can	 be	 attributed	 to	 an	 Au-S	 vibrational	 mode	 (B	 Varnholt).	 These	 results	 confirm	 the	
presence	of	the	triphenylarsoniumpropylthiolate	groups	on	the	surface	of	the	AuNPs.	
	
Table	3.4	Position	of	Au-S	band	in	Raman	Spectra	of	triphenylarsoniumpropylthiolate-
capped	AuNPs	
	
Sample	 Au-S	/	cm-1	
	
C-H	/	cm
-1
	
	
A-Au-Z0.5	 266	 999.9	 	
A-Au-Z1	 271	 1000.1	 	
A-Au-Z1.5	 259	 1000.3	 	
A-Au-Z2	 259	 998.9	 	
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Figure	3.7	Raman	spectrum	of	A-Au-Z0.5	in	region	4000-500cm-1,	(Inset)	expansion	of	
region	400-200cm-1.	
	
	
	
	
	
	
	
	
	
Figure	3.8	Raman	spectrum	of	A-Au-Z1	in	region	4000-500cm-1,	(Inset)	expansion	of	region	
400-200cm-1.	
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Figure	3.9	Raman	spectrum	of	A-Au-Z1.5	in	region	4000-500cm-1,	(Inset)	expansion	of	
region	400-200cm-1.	
	
	
	
	
	
	
	
	
Figure	3.10	Raman	spectrum	of	A-Au-Z2	in	region	4000-500cm-1,	(Inset)	expansion	of	region	
400-200cm-1.	
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3.4.2.2	X-Ray	Photoelectron	Spectroscopy	(XPS)	
XPS	 is	a	powerful	 tool	 for	understanding	 the	 surface	analysis	of	numerous	 self-assembled	
monolayer	 systems	 and	monolayer-protected	metal	 clusters.	 For	 these	 experiments,	 XPS	
have	 been	 used	 to	 understand	 the	 nature	 of	 the	 Au-S	 linkages.	 XPS	 can	 also	 be	 used	 to	
determine	the	atomic	composition	and	surface	studies	for	the	nanoparticles	having	surface	
layers	(2-10nm	depth)	such	as	for	the	arsonium	functionalized	AuNPs	(Baer	and	Engelhead,	
2010).	
	
Table	3.5	Summary	of	gold,	sulphur	and	arsenic	XPS	binding	energies	for	
triphenylarsonium-functionalized	AuNPs.	
	 	 	 XPS	Binding	Energies	(eV)	
Sample	
Au:As	
Ligand	
ratio	
Conditions	
Au	 S	 As	
4f	7/2	 4f	5/2	 2p	3/2	 3d	5/2	
A-Au-Z2	 1:2	 As	prepared	AuNPs	 84.14	 87.80	 162.25		 169.52	 44.74	
A-Au-Z2w	 1:2	 Sample	washed	with	
aqueous	KBr	before	
analysis	
84.43	 88.08	 162.15		 	 44.97	
A-Au-Z1w	 1:1	 Sample	washed	with	
aqueous	KBr	before	
analysis	
84.34	 87.99	 162.33	 	 44.90	
A-Au-T2	
	
1:2	 As	prepared	AuNPs	 84.00	 87.66	 163.83	 	 45.01	
2	
	
-	 	 -	 -	 163.34		 169.05	 44.84	
3	 -	 	 -	 -	 164.00	 	 45.05	
	
The	data	are	summarised	in	Table	3.5.	Wide	scan	spectra	of	the	AuNPs	(Figure	3.11)	were	
very	 similar,	 showing	 signals	 due	 to	 gold,	 sulphur,	 arsenic,	 carbon,	 sodium,	 oxygen	 and	
chlorine.	 The	 high	 resolution	 Au(4f)	 spectra	 of	 all	 four	 samples	 contain	 a	 doublet	 for	 Au	
(4f7/2)	 and	 Au	 (4f5/2)	 with	 binding	 energies	 of	 c.a.	 84.0	 and	 87.5	 eV,	 respectively	 (Figure	
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3.12).	These	values	are	very	similar	to	those	reported	for	the	analogous	AuNPs	capped	with	
triphenylphosphoniumpropylthiolate	 ions.	 For	 example,	 phosphonium-AuNPs	 prepared	
from	 the	 triphenylphosphoniopropylthiosulfate	 zwitterion	 	 (P-Au-Z2)	 displayed	 Au	 4f7/2	
binding	 energies	 of	 84.0	 eV	 and	 	 87.5	 eV,	 and	 the	 phosphonium-AuNPs	 derived	 from	
ω-thioacetylpropyl(triphenyl)phosphonium	 bromide	 (P-Au-Z2)	 displayed	 Au	 4f7/2	 binding	
energies	of	84.1	eV	and		87.8	eV	(Ju-Nam	et	al.,	2012).	Furthermore,	the	data	reported	here	
are	similar	to	that	reported	by	Brust	(83.8	eV	and	87.5	eV)	(Brust	et	al.,	1994)	Yee	(84.2	eV	
and	87.85	eV)	(Yee	et	al.,	2003)	for	AuNPs	capped	with	dodecanethiol.	
	
The	binding	energy	of	Au	4f7/2	from	Au(0)	in	a	metallic	gold	film	is	84	eV,	whereas	the	Au(I)	
in	a	gold	thiolate	has	a	binding	energy	of	86	eV	and	AuNPs	that	are	reported	to	contain	a	
fraction	of	their	surface	atoms	in	the	Au(I)	oxidation	state	show	Au	4f7/2	peak	with	a	binding	
energy	of	84.9	eV	(McNeillie	et	al.,	1980).	Therefore	the	Au	(4f7/2)	observed	at	84.0	eV	in	the	
triphenylarsonium-AuNPs	strongly	suggests	that	the	bulk	of	the	gold	atoms	are	in	the	Au(0)	
oxidation	state.	
	
Figure	3.13	shows	the	high	resolution	S(2p)	XPS	spectrum	of	a	 freshly	prepared	sample	of	
AuNP	 (A-Au-Z2)	 generated	 using	 the	 triphenylarsoniopropylthiosulfate	 zwitterion	 2.	 This	
material	displayed	two	peaks	with	binding	energies	of	163.80	eV	and	169.52	eV.	The	peak	at	
163.80	eV	is	typical	of	a	thiolate-sulphur	bound	to	gold,	which	occurs	in	the	range	(162.0	to	
162.9	 eV)	 (Bourg	 et	 al.,	 2000,	 Bain	 et	 al.,	 1989).	 The	 XPS	 spectrum	 of	 the	 analogous	
phosphonium-functionalized	AuNPs	 (P-Au-Z2)	 show	a	thiolate-sulphur	peak	with	a	binding	
energy	 of	 162.9	 eV	 (Ju-Nam	 et	 al.,	 2012).	 The	 peak	 at	 169.52	 eV	 is	 characteristic	 of	 an	
oxidised	 sulphur	 species,	 such	as	 a	 sulphonate	or	 sulphite	 (Ju-Nam	et	 al.,	 2012).	 Previous	
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studies	 of	 phosphonium-functionalized	 AuNPs	 showed	 that	 freshly	 prepared	 AuNPs	
contained	only	a	single	sulphur	peak	in	the	XPS	spectrum,	whereas	samples	that	were	over	
six	months	old	showed	two	peaks,	like	that	of	A-Au-Z2	reported	here,	with	the	second	peak	
being	 due	 to	 the	 presence	 of	 oxidised	 sulphur.	 Given	 that	 the	 samples	 of	 arsonium-
functionalized	AuNPs	analyzed	here	were	freshly	prepared,	it	seemed	quite	remarkable	that	
the	sample	had	oxidised	so	quickly.	However,	the	synthetic	procedure	used	to	prepare	the	
nanoparticles	 involves	cleavage	of	 the	S-S	bond	 in	 the	 thiosulfate	zwitterion,	generating	a	
thiolate	anion	(which	coordinates	to	the	growing	gold	nanoparticle),	and	a	sulphite	anion.	
Therefore,	 another	 possibility	was	 that	 the	 peak	 at	 169.52	 eV	 is	 due	 to	 residual	 sulphite	
species	 or	 the	 presence	 of	 unreacted	 zwitterion.	 To	 test	 this	 hypothesis	 a	 sample	 of	 the	
AuNPs	were	prepared	and	washed	three	times	with	a	dilute	aqueous	KBr	10%	w/v	solution	
before	 analysis	 by	 XPS.	 The	 spectrum	 of	 this	 sample	 (A-Au-Z2w),	 showed	 only	 a	 single	
sulphur	peak	with	a	binding	energy	of	163.8	eV,	indicating	that	the	peak	at	169.52	eV	was	
due	to	residual	SO3
-	ions.	Furthermore,	the	wide	angle	scan	of	(A-Au-Z2W)	also	showed	the	
presence	of	bromine	from	the	bromide	 ions,	with	a	 lower	amount	of	sulphur	and	oxygen,	
compared	to	the	original	unwashed	sample	(A-Au-Z2).	A	sample	of	AuNPs	prepared	using	a	
1:1	 ratio	of	gold	 salt	and	zwitterion	2	was	prepared	and	washed	with	KBr	 solution	 (A-Au-
Z1w),	 before	 analysis	 by	 XPS.	 The	 XPS	 spectrum	 of	 this	 material	 contained	 only	 a	 single	
S(2p3/2)	signal	with	a	binding	energy	of	163.40	eV.	
	
The	 XPS	 spectrum	 of	 a	 sample	 of	 AuNPs	 prepared	 from	
ω-thioacetylpropyl(triphenyl)arsonium	 bromide	 salt	 3	 (A-Au-T2)	 showed	 only	 a	 single	
S(2p3/2)		peak	with	a	binding	energy	of	163.50	eV	and	no	evidence	for	a	peak	at	ca.	169	eV	
due	to	oxidised	sulphur,	providing	 further	evidence	that	 the	peak	at	169.52	eV	 in	 the	XPS	
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spectrum	 of	 A-Au-Z2	 is	 due	 to	 residual	 sulphite.	 The	 XPS	 spectrum	 of	 a	 sample	 of	
phosphonium-AuNPs	prepared	from	ω-thioacetylpropyl(triphenyl)phosphonium	bromide	(P-
Au-T2)	also	showed	just	a	single	S(2p3/2)		peak	with	a	binding	energy	of	162.10	eV.
10(Ju-Nam	
et	al.,	2012)	Gold	nanoparticles	capped	with	n-tetradecanethioacetate	also	have	a	S(2p3/2)	
peak	of	162.19	eV	(Zhang	et	al.,	2009).	
	
The	XPS	spectrum	of	the	parent	arsonium	zwitterion	2	displays	two	S(2p)	signals	at	163.34	
and	167.76	eV	(Fig.	3.15),	arising	from	the	non-equivalent	sulphurs	bound	to	carbon	and	to	
oxygen,	 respectively.	 This	 result	 confirms	 the	 cleavage	 of	 the	 sulfur-sulfur	 bond	 in	 the	
zwitterions	 during	 the	 synthesis	 with	 the	 concomitant	 expulsion	 of	 SO3
-	 (or	 some	 other	
sulfur	 species	 derived	 from	 it),	 at	 the	 ligand/Au	 interface.	 The	 spectrum	of	 the	 precursor	
arsonium	thioacetate	ligand	3	contains	a	single	S(2p3/2)	peak	with	a	binding	energy	of	161.1	
eV,	corresponding	to	a	thiolate	sulfur.	
	
The	 high-resolution	 XPS	 spectrum	 of	 the	 arsenic	 component	 of	 the	 functionalized	
nanoparticles	 is	 shown	 in	 Figure	 3.16.	 	 All	 of	 the	 nanoparticle	 samples,	 together	 with	
precursor	 ligands	 2	 and	 3,	 show	 a	 peak	 with	 a	 binding	 energy	 ca	 45	 eV	 that	 can	 be	
attributed	to	the	As	(3d5/2)	electron	in	an	arsenic(V)	compound.	Although	XPS	data	has	been	
reported	 for	 many	 inorganic	 arsenic	 compounds,	 especially	 oxides	 and	 sulphides	 and	
semiconductor	 materials	 such	 as	 GaAs,	 there	 is	 a	 paucity	 of	 data	 on	 organic	 arsenic	
derivatives.	 The	 data	 for	 inorganic	 species	 shows	 that	 As(V)	 generally	 has	 a	 peak	 with	 a	
binding	energy	in	the	region	of	44	-	45	eV	and	that	under	X-rays	this	can	degrade	forming	
As(III)	 species	 with	 a	 binding	 energy	 of	 43	 -	 44	 eV.	 For	 organic	 derivatives	 the	 four-
coordinate,	As(V)	species	tetraphenylarsonium	cation	[Ph4As]
+	has	a	As	(3d)	binding	energy	
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of	44.8	eV	 (Stec	et	al.,	 1972),	whereas	 the	 three-coordinate	As(III)	 species	 triphenylarsine	
(Ph3As)	has	a	As	(3d)	binding	energy	of	42.7	eV	(Bain	et	al.,	1989).	
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(c)	 (d)	
Figure	3.11	Wide	angle	XPS	spectra	of	triphenylarsonium-AuNPs	(a)	A-Au-Z2	(b)	A-Au-Z2w	(c)	A-Au-Z1w	(d)	A-Au-T2	
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(c)	 (d)	
Figure	3.12	High	resolution	Au	XPS	spectra	of	triphenylarsonium-AuNPs	(a)	A-Au-Z2	(b)	A-Au-Z2w	(c)	A-Au-Z1w	(d)	A-Au-T2	
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(c)	 (d)	
Figure	3.13	High	resolution	S	(2p	3/2)	XPS	spectra	of	triphenylarsonium-AuNPs	(a)	A-Au-Z2	(b)	A-Au-Z2w	(c)	A-Au-Z1w	(d)	A-Au-T2	
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(c)	 (d)	
Figure	3.14	High	resolution	As	(3d)	XPS	spectra	of	triphenylarsonium-AuNPs		(a)	A-Au-Z2	(b)	A-Au-Z2w	(c)	A-Au-Z1w	(d)	A-Au-T2
CasaXP S
As 3d/20
Name
As 3d
Pos.
44.74
FWHM
3.031
L.Sh.
GL(30)
Area
827.70
%Area
100.00
56 52 48 44 40 36
Binding Energy (eV)
CasaXP S
As 3d/15
Name
As 3d
As 3d
Pos.
44.97
42.73
FWHM
1.559
1.559
L.Sh.
GL(30)
GL(30)
Area
1118.75
142.71
%Area
88.66
11.34
52 48 44 40 36
Binding Energy (eV)
CasaXP S (Thi s st ring can be edit ed in CasaXPS.DEF/P rintFootNote.txt)
As 3d/73
Name
As 3d
As 3d
Pos.
44.90
43.02
FWHM
1.58
1.58
L.Sh.
GL(30)
GL(30)
Area
2.49
1.03
%Area
70.70
29.30
/2
10
15
20
25
C
P
S
 x
 1
0
1
51 48 45 42 39
Binding Energy (eV)
CasaXP S
As 3d/23
Name
As 3d
As 3d
Pos.
45.01
43.10
FWHM
1.745
1.745
L.Sh.
GL(30)
GL(30)
Area
604.46
239.40
%Area
71.59
28.41
52 48 44 40 36
Binding Energy (eV)
	97	
	
	
(a)	
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Figure	3.15	High	resolution	S	XPS	spectra	of	ligands	(a)	2	and	(b)	3	
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Figure	3.16	High	resolution	As	(3d)	XPS	spectra	of	triphenylarsonium-AuNPs	(a)	2	and	(b)	3	
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3.4.2.3	Transmission	Electron	Microscopy	(TEM)	
TEM	is	routinely	used	for	the	characterization	of	nanoparticles,	which	provides	an	image	of	
the	 gold	 core	 and	 size	 information	 (Daniel	 and	 Astruc	 review,	 2004).	 The	 size	 and	
morphology	 of	 AuNPs	 functionalized	 with	 different	 molar	 ratios	 of	 ligand	 2	 have	 been	
determined	by	TEM.	The	micrographs	were	recorded	by	Prof	Alan	Reynolds	and	Dr	Jesus	
Ojeda	at	the	Experimental	Techniques	Centre,	Brunel	University	or	by	Paul	Allender	at	the	
Materials	 and	 Engineering	 Research	 Institute	 at	 Sheffield	 Hallam	 University.	 The	 images	
were	generated	by	putting	a	solution	of	the	AuNPs	dispersed	in	water	drop-by-drop	onto	a	
carbon-copper	grid.	 	To	remove	the	excess	water	on	the	grid,	a	piece	of	 tissue	was	used	
and	the	samples	were	left	overnight	so	any	remaining	solvent	could	evaporate.	1000	mesh	
copper	 grid	was	 used	 for	 the	 experiment	 and	 the	 TEM	 data	were	 obtained	 using	 a	 low	
voltage	 (kV)	 so	 as	 to	 prevent	 the	 decomposition	 of	 the	 organic	 matter,	 around	 1000	
nanoparticles	were	measured	to	calculate	the	mean	of	the	particle	size.	The	TEM	images	
are	shown	in	Figure	3.17	and	the	results	summarised	in	Table	3.6.			
	
Table	3.6	Average	particle	size	of	Triphenylarsonium-functionalized	AuNPs.	Mean	particle	
size	was	calculated	from	1000	nanoparticles.	
Sample	 Au:As	Ligand	ratio	
Mean	Particle	
size	(nm)	
Standard	
deviation	
A-Au-Z0.5	 1	:	 0.5	 3.63	 1.03	
A-Au-Z1	 1	:	 1	 2.86	 1.35	
A-Au-Z1.5	 1	:	 1.5	 3.84	 0.89	
A-Au-Z2	 1	:	 2	 2.7	 1.02	
A-Au-Z2w	 1	:	 2	 1.15	 1.46	
A-Au-T2	 1	:	 2	 1.28	 1.20	
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(a)	
	 	
(b)	
	 	
(c)	
	 	
(d)	
	 	
Figure	3.17	TEM	micrographs	and	the	core	size	histogram	of	arsonium-functionalized	
AuNPs	(a)	A-Au-Z0.5,	(b)	A-Au-Z1,	(c)	A-Au-Z1.5	and	(d)	A-Au-Z2.	
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The	 TEM	 images	 revealed	 the	 particles	 to	 have	 spherical	 shape.	 The	 particle	 size	 and	
polydispersity	 were	 similar,	 irrespective	 of	 the	 amount	 of	 starting	 ligand	 present.	
Furthermore,	 the	 particle	 size	 is	 very	 similar	 to	 that	 of	 the	 analogous	
triphenylphosphonium-functionalized	 AuNPs	 (P-Au-Z2),	 which	 have	 a	 mean	 diameter	 of	
3nm	±	1.2nm	(Ju-Nam	et	al.,	2012).	The	TEM	micrograph	of	the	washed	sample	A-Au-T2w	
(Figure	3.18)	shows	that	the	washing	process	has	minimal	effect	on	the	size	or	shape	of	the	
gold	nanoparticles.		
	
The	 morphology	 of	 the	 AuNPs	 derived	 from	 ω-thioacetylpropyl(triphenyl)arsonium	
bromide	 salt	 3,	A-Au-T2	 (Figure	 3.19)	 has	 also	 been	 studied	 showing	 that	 the	 particles	
derived	 from	 this	 ligand	are	 slightly	 larger,	 and	have	a	broader	particle	 size	distribution,	
compared	 to	 the	 nanoparticles	 synthesised	 from	 zwitterion	 2.	 This	 observation	 is	 in	
agreement	with	previous	work	on	triphenylphosphonium-functionalized	gold	nanoparticles	
which	 showed	 that	 those	 prepared	 from	ω-thioacetylpropyl(triphenyl)arsonium	 bromide	
salt	are	larger,	and	have	a	broader	particle	size	distribution,	than	those	obtained	from	the		
triphenylphosphoniumpropylthiosulfate	 zwitterion.	 These	 differences	 in	 size	 and	 particle	
size	distribution	can	be	explained	on	the	basis	of	 the	differing	passivation	kinetics	of	 the	
two	types	of	ligand.	(Lohse	et	al.,	2010,	Fealy	et	al.,	2011,	Pillai	and	Freund.,	2011,	Singh	et	
al.,	2010,	Zhang	et	al.,	2009).	The	first	stage	of	the	synthesis	should	be	adsorption	of	the	
ligand	on	the	surface	of	the	growing	particles	and	the	thioacetate	might	be	expected	to	be	
a	 more	 weakly	 binding	 ligand	 than	 the	 thiosulfate.	 Secondly,	 transformation	 of	 the	
thiosulfate	or	thioacetate	to	the	thiolate	occurs.	The	mechanism	of	this	step	in	our	system	
is	unclear.	Studies	into	the	formation	of	monolayers	on	gold	surfaces	from	alkylthiosulfates	
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show	hydrolysis	by	trace	amounts	of	water	present	 in	the	solvent	to	be	crucial.	 (Fealy	et	
al.,	 2011,	 Pillai	 and	 Freund.,	 2011).	 The	 triphenylarsonium-AuNPs	 reported	 here	 were	
prepared	 in	 a	 two-phase	 water/dichloromethane	 mixture,	 i.e.	 with	 an	 excess	 of	 water.	
However,	the	possibility	that	the	growing	gold	nanoparticles	and/or	the	reducing	agent	are	
involved	 in	 the	 cleavage	 of	 the	 thiosulfate	 S–S	 or	 thioacetate	 S–C	 bonds	 cannot	 be	
excluded.	It	would	appear	that	the	cleavage	step	is	slower	for	the	thioacetate	than	for	the	
thiosulfate	and	so	results	 in	slower	monolayer	 formation	and	hence	a	 larger	size	particle	
and	a	broader	particle	size	distribution.	
	
It	was	noteworthy	that	the	ESI-MS	spectrum	of	A-AuT2	showed	no	evidence	of	the	parent	
thioacetate	 salt	 3,	 whereas	 that	 of	 the	 related	 P-AuT2	 did	 indicate	 the	 presence	 of	
unreacted	ω-thioacetylalkyl(triphenyl)	phosphoniopropyl	 ions	(Chen	PhD	thesis,	2014	and	
Ju-Nam	et	al.,	2012).	
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Figure	3.18	TEM	micrograph	and	the	core	size	histogram	of	the	washed	arsonium-
functionalized	AuNP	sample	A-Au-Z2w.	
	
	
	 	
Figure	3.19	TEM	micrograph	and	the	core	size	histogram	of	the	arsonium-functionalized	
AuNP	A-Au-T2,	derived	from	ω-thioacetylpropyl(triphenyl)	arsonium	bromide	salt	3	
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3.5	Conclusion		
	
The	 results	 presented	 in	 this	 chapter	 confirmed	 the	 hypothesis	 that	
triphenylarsoniopropylthiosulfate	 (2)	 and	ω-thioacetylpropyl(triphenyl)arsonium	 bromide	
salt	 (3)	 can	 be	 used	 to	 prepare	 cationic,	 triphenylarsonium-functionalized	 gold	
nanoparticles.	 The	 precursor	 arsonium	 compounds	 2	 and	 3	 have	 been	 characterized	
thoroughly	 using	 a	 range	 of	 spectroscopic	 techniques	 and	 by	 single-crystal	 X-ray	
crystallography.	
The	triphenylarsonium-functionalized	gold	nanoparticles	have	been	characterized	by	TEM	
and	XPS,	and	have	been	found	to	possess	an	average	core	size	of	2.7-3.84	nm.	
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3B)	The	synthesis,	characterisation	and	
biological	properties	of	the	(methoxy-
phenyl)	phosphoniopropylthiosulfate	
zwitterions	and	ω-thioacetylpropyl	
(methoxyphenyl)	phosphonium	salts.	
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3.6	Methoxyphenyl	phosphonium	substituents	
	
Previous	 work	 has	 shown	 that	 alkylthiosulfate	 zwitterion	 and	 alkylthioacetate	 salt	
derivatives	of	 triphenylphosphine,	and	other	 trialkyl-	and	triaryl-phosphines,	can	be	used	
as	precursors	for	the	formation	of	triphenylphosphonium-functionalized	gold	nanoparticles	
(Ju-nam	et	al.,	2006;	Ju-nam	et	al.,	2012;	Yang	et	al.,	2015;	Ju-nam	et	al.,	2007;	Ju-nam	et	
al.,	2015).	Although	the	triphenylphosphonium-functionalized	nanoparticles	are	soluble	in	
water	 and	 biological	media,	 and	 are	 taken-up	 by	 cells	 (Ju-nam	 et	 al.,	 2012),	 the	 parent	
triphenylphosphoniumalkylthiosulfate	 zwitterions	 are	 insoluble	 in	 aqueous	 media	 (Chen	
PhD	 thesis,	 2014)	 This	 observation	 has	 prompted	 us	 to	 investigate	 alternative	
triarylphosphonium	 groups	 in	 an	 attempt	 to	 improve	 the	 aqueous	 solubility	 of	 the	
zwitterions.	
	
Previous	work	by	Liu	and	coworkers	(Kim	et	al.,	2008)	showed	that	tri-(4-methoxyphenyl)	-	
and	tris	(2,	4,	6-trimethoxyphenyl)	phosphonium	compounds	can	be	used	to	functionalize	
macrocyclic	derivatives	1	and	2,	that	are	soluble	in	biological	media	and	which	are	readily	
taken	up	by	cells.	Their	results	showed	that	both	the	4-methoxy-	and	the	2,4,6-trimethoxy-	
compounds	 are	 more	 effective	 at	 mitochondria-targeting	 than	 the	 analogous	
triphenylphosphine	 compound.	 Furthermore,	 compound	 1	 is	 more	 effective	 at	
mitochondria-targeting	than	the	2,4,6-trimethoxy	species	2.		
Another	 biological	 application	 of	 tris(2,4,6-trimethoxyphenyl)phosphonium	 compounds	
such	as	the	S-pentafluorophenylacetate	(3)	(Huang	et	al.,	1997,	Barry	et	al.,	2003,	Huang	et	
al.,	1999,	Sadagopan	et	al.,	2000,	Shen	et	al.,	2000)	and	alkylcarboxylates	(4)	 (Leavens	et	
al.,	2002)	is	to	derivatise	a	range	of	compounds	including	small	molecules,	such	as	amines	
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and	 carboxylic	 acids,	 alcohols,	 aldehydes	 and	 ketones,	 and	 large	 biomolecules	 such	 as	
proteins	and	peptides,	to	enhance	their	detection	by	mass	spectrometry.	
	 	
1 2 
 
  
3 4 
 
Tris	(2,	4,	6-trimethoxyphenyl)	phosphine	is	a	very	unusual	tertiary	aryl	phosphine	(Wada	
et	al.,	1984).	The	presence	of	the	methoxy	groups	increases	the	basicity	of	the	phosphine	
and	 also	 increases	 the	 steric	 bulk	 of	 the	 compound	 (Dunbar	 et	 al.,	 1994).	 Tris(2,6-
dimethoxyphenyl)phosphine	has	a	lower	basicity,	but	similar	steric	properties	to	tris(2,4,6-
trimethoxyphenyl)-phosphine,	 whereas	 tris(4-methoxyphenyl)phosphine	 has	 a	 lower	
basicity	and	lower	steric	bulk	than	tris(2,4,6-trimethoxyphenyl)phosphine.	The	aim	of	this	
chapter	 is	 to	 investigate	 the	 synthesis	 and	 biological	 properties	 of	 a	 series	 of	
alkylthiosulfate	 zwitterion	 and	 alkylthioacetate	 salt	 derivatives	 of	 methoxy-phenyl	
phosphines.	
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3.7	Material	and	methods	
3.7.1	Chemicals	
All	 chemicals	 were	 used	 as	 received;	 tris(2,4,6-trimethoxyphenyl)phosphine	 and	 tris(2,4	
dimethoxyphenyl)phosphine	 and	 tris(4-methoxyphosphine)	 were	 purchased	 from	 Sigma	
Aldrich,	UK	and	used	without	any	further	treatment.		1,	3-	Dibromopropane	was	purchased	
from	Acros	Organics,	UK.	Potassium	thioacetate	(KSCOCH3),	sodium	thiosulfate	(Na2S2O3),	
Potassium	bromide	(KBr),	gold(III)	chloride	trihydrate,	hydrobromic	acid	(HBr),	magnesium	
sulfate	 (MgSO4),	 deuterated	 dichloromethane,	 chloroform	 and	 ICP	 Au	 standard	 were	
purchased	from	Sigma-Aldrich	(Gillingham,	Dorset,	UK).		
3.7.2	Methods	
3.7.2.1	Cytotoxicity	assay	
	
Cytotoxicity	was	assessed	using	a	CellTiter-Glo	luminescent	cell	viability	assay	kit	(Promega	
Corporation,	Southampton,	Hamshire,	UK).		
PC3	cells	were	seeded	in	opaque-walled	96	well	plates	at	a	density	of	10,000	cells/well	and	
allowed	 to	 adhere	 overnight.	 Cells	 were	 subsequently	 treated	 with	 the	 corresponding	
phosphonium	 ligand	 (0-1000µm)	 for	 24,	 48,	 72	 hours.	 After	 each	 incubation	 period,	 cell	
viability	was	measured	according	to	the	manufacturer’s	 instructions.	 In	brief,	plates	were	
equilibrated	at	room	temperature	for	30	mins,	100µL	of	assay	reagent	was	added	to	each	
well,	 placed	 on	 an	 orbital	 shaker	 for	 2mins,	 left	 to	 stand	 at	 room	 temperature	 for	 10	
minutes	and	 read	on	a	Wallac	Victor2	1420	multilabel	 counter	 (PerkinElmer,	Cambridge,	
Cambridgeshire,	UK).	
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Cytotoxicity	 studies	 were	 also	 done	 to	 assess	 IC50	 using	 3-(4,5-dimethyltiazol-2-yl)-2,5-	
diphenyltetrazolium	bromide	 (MTT)	 assay.	 Cells	were	 seeded	 in	 a	 96	well	 plate	with	 the	
corresponding	ligand	(0-1000µm)	for	24,	48,	72	hours.	An	MTT	mixture	was	added	to	each	
well	to	give	a	final	concentration	of	0.3mg/mL	MTT.	Cells	were	incubated	with	MTT	for	3-4	
hours	at	37	oC.	The	supernatant	liquid	was	then	removed	and	DMSO	was	added	to	read	the	
absorbance	at	570nm.		
All	plates	contain	control	wells	and	all	measurements	were	performed	 in	quadruplicates,	
three	 independent	 experiments	 were	 conducted	 (n=12).	 Data	 are	 expressed	 as	 a	
percentage	 of	 live	 cells	 normalized	 to	 control,	 the	 average,	 standard	 deviation	 and	 IC50	
values	 were	 plotted	 and	 calculated	 using	 GraphPad	 Prism	 (GraphPad	 software,	 La	 Jolla,	
California,	USA).	
	
3.8	Results	and	Discussion	
	
The	 established	method	 for	 preparing	 triarylphosphonioalkyl	 thiosulfate	 zwitterions,	 and	
the	associated	phosphonioalkyl	thioacetate	salts	is	to	reflux	the	parent	tertiary	phosphine	
with	 a	 bromoalcohol,	 such	 as	 bromopropanol,	 as	 shown	 in	 scheme	 1.	 The	 resulting	 (3-
hydroxypropyl)	triarylphosphonium	bromide	salt	is	then	refluxed	with	hydrobromic	acid	to	
generate	 a	 (3-bromopropyl)	 triarylphosphonium	bromide	 that	 can	be	 converted	 into	 the	
alkylthiosulfate	zwitterion	or	the	thioacetate	salt.	Unfortunately,	this	synthetic	route	is	not	
possible	for	methoxyphenyl-phosphines	because	the	hydrobromic	acid	used	in	the	second	
step	preferentially	attacks	 the	ether	substituents.	Consequently,	an	alternative	 route	has	
been	developed,	shown	in	scheme	1.	This	involves	treating	the	methoxyphenyl	phosphine	
with	an	excess	of	α,ω-dibromoalkane,	such	as	1,3-dibromopropane.	This	 leads	directly	to	
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the	(3-bromopropyl)	methoxyphenylphosphonium	bromide	that	can	be	converted	into	the	
alkylthiosulfate	 zwitterion	or	 the	 thioacetate	 salt	 by	 refluxing	with	 sodium	 thiosulfate	or	
potassium	thioacetate	respectively.	The	reaction	leads	to	good	yields	of	the	phosphonium	
compounds	 although	 care	 has	 to	 be	 exercised	 in	 the	 initial	 step	 to	 avoid	 the	
methoxyphenyl	phosphine	reacting	with	both	ends	of	the	α,ω-dibromoalkane.	This	is	done	
by	 using	 a	 significant	 excess	 of	 the	 dibromoalkane	 and	 adding	 the	
methoxyphenylphosphine	in	small	amounts	over	an	extended	period	of	time.		
	
Scheme	1. Synthetic	procedures	employed	in	this	study.	
R3P
Br OH
Br
Br
R3P OH Br
R3P Br Br
HBrX
R3P S Br
O
R3P SSO3
Na2S2O3
H2O/EtOH
KSC(O)CH3
H2O/EtOH
OMe
MeO
OMe
OMe
OMe
MeOR =
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The	structures	of	the	compounds	prepared	in	this	study,	their	names	and	numbering,	are	
shown	 below.	 Regarding	 the	 length	 of	 the	 alkyl	 chain	 in	 the	 phosphonioalkylthiosulfate	
zwitterions,	 and ω-thioacetylalkylphosphonium	salts,	 previous	 studies	have	 shown	 that	 a	
propyl	chain	is	the	ideal	length.	Longer	alkyl	chains	tend	to	produce	compounds	that	form	
as	waxy	solids	or	oils	that	are	difficult	to	handle.	Shorter	alkyl	chains	would	be	less	useful	
for	forming	functionalized	nanoparticles.	Therefore,	 in	this	study	we	have	focused	on	the	
propyl	derivatives.	
  
  5 
tris(2,4,6-trimethoxyphenyl)-	
phosphoniopropylthiosulfate	
8 
ω-thioacetylpropyltris(2,4,6-
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3.9	 Synthesis	and	Spectroscopic	Characterisation	of	5	-10	
	
All	six	compounds	were	prepared	in	a	similar	manner,	as	exemplified	by	the	preparation	of	
compounds	5	and	8.	
Tris(2,4,6-trimethoxyphenyl)phosphine	(1.0g,	1.878	x	10-4	mol),	dissolved	in	acetonitrile	(20	
mL),	 was	 added	 dropwise	 to	 a	 1,3-dibromopropane	 (5	 mL,	 1.245	 x	 10-2	 mol)	 under	 a	
nitrogen	 atmosphere.	 The	 mixture	 was	 refluxed	 overnight.	 The	 product,	 3-
bromopropyl[tris(2,4,6-trimethoxyphenyl)]phosphonium	bromide	was	 isolated	by	 diluting	
the	 reaction	 mixture	 with	 deionised	 water	 (20mL)	 followed	 	 by	 liquid-liquid	 extraction	
using	dichloromethane	 (3	 x	 10	ml).	 The	dichloromethane	extracts	were	 combined,	 dried	
over	 MgSO4,	 and	 the	 solvent	 removed	 by	 rotary	 evaporation	 yielding	 the	 product	 as	 a	
white	 solid.	 To	 produce	 zwitterion	 5,	 3-bromopropyl	 tris(2,4,6-
trimethoxyphenyl)phosphonium	bromide	(0.250	g,	3.82	x	10-4	mol)	and	Na2S2O3	 (0.212	g,	
8.56	 x	 10-4	 mol)	 were	 heated	 under	 reflux	 	 in	 aqueous	 ethanol	 under	 a	 nitrogen	
atmosphere.	 The	 thioacetate	 salt	8	 was	 produced	 by	 refluxing	 3-bromopropyl	 tris(2,4,6-
trimethoxyphenyl)phosphonium	bromide	(0.250	g,	3.82		x	10-4	mol)		and	KSC(O)CH3	(0.098	
g,	8.56	x	10-4	mol)	 in	aqueous	ethanol.	Both	compounds	were	 isolated	from	the	reaction	
mixtures	 by	 extraction	 with	 dichloromethane	 (3	 x	 20	 mL).	 Purification	 of	 the	 products,	
which	 form	 as	 white	 microcrystalline	 powders,	 was	 achieved	 by	 triturating	 with	 diethyl	
ether	 and	 recrystallising	 from	 dichloromethane/diethyl	 ether.	 The	 progress	 of	 all	 of	 the	
reactions	 was	 monitored	 by	 TLC	 using	 a	 mobile	 phase	 of	 80%	 dichloromethane	 :	 20%	
methanol.		
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Tris(2,4,6-trimethoxyphenyl)-	phosphoniopropylthiosulfate	(5)	
White	solid,	M.P.	-	218°	Elemental	Analysis:	found:	C,	52.76%;	H,	5.86%;	S,	9.29%	requires:	
C,	52.47%;	H,	5.67%;	S	9.30%.	1H	NMR: δ 2.3	(2H,	m),	3.1	(2H,	t),	3.8	(2H,m),	7.3–7.6	(15H,	
m)	ppm.	 31P	NMR	(CDCl3)	=	5.24	ppm	
31P	NMR	(CDCl3)	=	2.3(2H,	m).	 IR	υmax/cm
-1	=	2912	
(CH),	1483,	1438,	1209	(SO),	1082,	1010	(SO),	744,	688,	623,	523,	466.	ESI-MS:	686.4	[M]+,	
708.86	[M+Na+]	
	
Tris(2,6-dimethoxyphenyl)-	phosphoniopropylthiosulfate	(6)	
White	 solid,	 M.P.	 =	 237°	 Elemental	 Analysis:	 found:	 C,	 52.42%;	 H,	 5.51%;	 S	 10.19%,	
requires:	 C,	 52.34%;	H,	 5.53%;	 S	 10.33%.	 1H	NMR	 (CDCl3): δ 2.2	 (2H,	m),	 3.1	 (2H,	 t),	 3.5	
(2H,m),	7.2–7.5	(15H,	m)	ppm.	31P	NMR	(CDCl3)	=	7.54	ppm.	IR	υmax/cm
-1	=	2912	(CH),	1483,	
1438,	 1209	 (SO),	 1082,	 1010	 (SO),	 744,	 688,	 623,	 523,	 466.	 ESI-MS:	 577.4	 [M]+,	 619.33	
[M+Na+]	
	
Tri(4-methoxyphenyl)-	phosphoniopropylthiosulfate	(7)	
White	 solid,	 M.P.	 =	 195°	 Elemental	 Analysis:	 found:	 C,	 58.11%;	 H,	 5.64% ;	 S	 10.29%,	
requires:	C,	57.01%;	H,	5.33%;	S	10.62%.	1H	NMR: δ 2.3	(2H,	m),	3.2	(2H,	t),	3.6	(2H,m),	7.6–
7.9	 (15H,	m)	 ppm.	 31P	NMR	 (CDCl3)	 =	 21.28	 ppm.	 IR	υmax/cm
-1	=	 2912	 (CH),	 1483,	 1438,	
1209	(SO),	1082,	1010	(SO),	744,	688,	623,	523,	466.	ESI-MS:	507.2	[M]+,	529.2	[M+Na+]	
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ω-thioacetylpropyltris(2,4,6-trimethoxyphenyl)phosphonium	bromide	(8)	
White	solid,	M.P.	=	243°,	Elemental	Analysis:	found:	C,	53.83%;	H,	5.62%;	S	5.03%,	requires:	
C,	53.62%;	H,	5.54%;	S	5.03%.	1H	NMR	(CDCl3): δ 2.4	(2H,	m),	3.1	(2H,	t),	3.3	(2H,m),	7.1–7.4	
(15H,	m)	ppm.	31P	NMR	(CDCl3)	=	5.27	ppm	
31P	NMR	(CDCl3)	=	2.4(2H,	m).	 IR	υmax/cm
-1	=	
2912	(CH),	1483,	1438,	1209	(SO),	1082,	1010	(SO),	744,	688,	623,	523,	466.	ESI-MS:	649.33	
[M]+,	650.38	[M+H+]	
	
ω-thioacetylpropyltri(2,6-dimethoxyphenyl)phosphonium	bromide	(9)	
White	solid,	M.P.	=	226°	Elemental	Analysis:	found:	C,	54.31%;	H,	5.90%;	S	4.98%,	requires:	
C,	54.46%;	H,	5.63%;	S	5.00%.	1H	NMR: δ 2.2	(2H,	m),	3.3	(2H,	t),	3.5	(2H,m),	7.5–7.8	(15H,	
m)	 ppm.	 31P	NMR	 (CDCl3)	 =	 7.31	ppm.	 IR	υmax/cm
-1	 =	 2912	 (CH),	 1483,	 1438,	 1209	 (SO),	
1082,	1010	(SO),	744,	688,	623,	523,	466.	ESI-MS:	559.37	[M]+,	560.38	[M+H+]	
	
ω-thioacetylpropyltri(4-methoxyphenyl)phosphonium	bromide	(10)	
White	solid,	M.P.	=	207°,	Elemental	Analysis:	found:	C,	57.60%;	H,	5.53%;	S	5.88%,	requires:	
C,	56.83%;	H,	5.28%;	S	5.82%.	1H	NMR	(CDCl3): δ 2.3	(2H,	m),	3.2	(2H,	t),	3.6	(2H,m),	7.6–7.9	
(15H,	m)	ppm.	31P	NMR	(CDCl3)	=	21.33	ppm.	IR	υmax/cm
-1	=	2912	(CH),	1483,	1438,	1209	
(SO),	1082,	1010	(SO),	744,	688,	623,	523,	466.	ESI-MS:	469.34	[M]+,	471.35	[M+H+].	
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3.9.1	 Single	 Crystal	 X-ray	 Analysis	 of	 tris(2,4,6-trimethoxyphenyl)	
phosphoniopropylthiosulfate	
	
Single	 crystals	 of	5	were	 grown	 by	 slow	 diffusion	 of	 diethyl	 ether	 into	 dichloromethane	
solution	of	the	compound,	resulting	in	the	formation	of	colorless	crystals.	The	crystals	were	
sent	for	full	structure	analysis	at	the	EPSRC	X-ray	Crystallography	Service	at	the	University	
of	Southampton.	The	molecular	structure	of	5	 is	shown	in	Figure	3.20	and	selected	bond	
lengths	 and	 angles	 in	 Table	 3.7.	 The	 detailed	 crystallographic	 report	 on	 compound	 5	 is	
presented	in	Appendix	1.	
The	 Bricklebank	 group	 has	 previously	 reported	 the	 structure	 of	 the	
triphenylphosphoniopropylthiosulfate	zwitterion	(11)	 (Ju-Nam	et	al.,	2006),	together	with	
those	 of	 the	 tri(4-fluorophenyl)phosphoniopropylthiosulfate,	 (Y-S	 Chen	 et	 al.,	 2017)	 and	
tributylphosphoniothiosulfate	 (12)	 zwitterions	 	 (Ju-Nam	 et	 al.,	 2006).	 The	 only	 other	
crystallographically-characterized	 thiosulfate	 zwitterions	are	 the	ammonium	derivative	S-
[4-(trimethylammonio)phenyl]thiosulfate (13),	 (J-X	 Chen	 et	 al.,	 2004)	 and	 the	
triphenylarsoniopropylthiosulfate	zwitterion	described	in	chapter	3A.	
	
	
 
	
 
11 12 13 
The	asymmetric	unit	of	5	 contains	 two	 independent	molecules.	 The	molecule	 containing	
atoms	P1,	S1	and	S2	is	referred	to	as	5A,	and	that	containing	atoms	P41,	S41	and	S42	is	5B.		
The	 structure	 of	 5	 is	 highly	 disordered.	 This	 is	 not	 unusual	 for	 derivatives	 of	 tris(2,4,6-
P SSO3
SSO3Me3N
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trimethoxyphenyl)phosphine.		
Both	5A	and	5B	display	the	expected	tetrahedral	geometry	around	the	phosphorus	atoms	
with	a	mean	C-P-C	bond	angle	of	109.2o	in	5A	and	108.9o.	The	corresponding	values	for	the	
triphenyl	 and	 tributyl	 analogues	11	 and	12	are	109.47(11)o	 and	109.47(17)o	 respectively.	
The	bond	lengths	and	angles	in	the	aryl	rings	are	unremarkable	and	are	similar	to	those	in	
the	parent	phosphine,	[2,4,	6-(MeO)3C6H2]3P.	
The	S-O	bonds	in	the	thiosulfate	group	of	5	are	all	similar,	with	a	mean	lengths	of	1.429(5)Å		
and	 1.412(10)Å	 in	 5A	 and	 5B	 respectively,	 [c.f.	 1.4478(19)	 Å	 in	 11	 and	 1.440(3)	 Å	 in	
12],indicative	 of	 multiple	 bond	 character.	 The	 S-S	 bond	 lengths	 [2.059(3)Å	 in	 5A	 and	
2.102(6)Å	in	5B],	are	slightly	shorter	than	that	of		11	[2.1117(9)	Å],	and	similar	to	that	in	12	
[2.1030(14)	Å],	but	all	are	longer	than	the	established	length	of	a	single	S-S	bond	[2.05Å]	
(Huheey,	 1972).	 The	 ammonium	 thiosulfate	 zwitterion	 13	 has	 an	 S-S	 bond	 length	 of	
2.1137(7)	Å,	similar	to	those	of	5,	11	and	12,	but	all	are	appreciably	shorter	than	S-S	bond	
in	the	monoanion	of	thiosulfuric	acid,	HSSO3
-	[2.155]	(Miaskiewicz	and	Steudel,	1992).		
	
	1
1
6
	
	
	
						
Figure	3.20	Molecular	structure	of	5	
	117	
	
	
Table	3.7	Selected	bond	lengths	[Å]	and	angles	[°]	in	compound	5.	
5A	 	 	 	
C1−P1	 1.844(6)	 O31−S1	 1.441(5)	
C11−P1	 1.798(4)	 O32−S1	 1.430(5)	
C21−P1	 1.798(5)	 O33−S1	 1.416(4)	
C31−P1	 1.801(15)	 S1−S2	 2.059(3)	
P1−C131	 1.811(5)	 S101−S102	 2.059(9)	
P1−C101	 1.812(6)	 	 	
	 	 	 	
C11−P1−C21	 110.4(2)	 O33−S1−O32	 118.3(3)	
C11−P1−C131	 96.9(10)	 O33−S1−O31	 115.1(4)	
C21−P1−C131	 107.0(16)	 O32−S1−O31	 107.4(4)	
C11−P1−C31	 110.6(2)	 O33−S1−S2	 100.5(2)	
C11−P1−C101	 103.7(3)	 O32−S1−S2	 107.8(3)	
C21−P1−C31	 105.8(6)	 O31−S1−S2	 107.0(3)	
C21−P1−C101	 112.0(6)	 C33−S2−S1	 100.81(19)	
C131−P1−C101	 123(2)	 	 	
C11−P1−C1	 110.1(6)	 	 	
C21−P1−C1	 114.8(6)	 	 	
C31−P1−C1	 107.0(4)	 	 	
	 	 	 	
5B	 	 	 	
C41−P41	 1.807(4)	 O71−S41	 1.424(9)	
C51−P41	 1.785(5)	 O72−S41	 1.397(11)	
C61−P41	 1.802(4)	 O73−S41	 1.425(9)	
C71−P41	 1.830(10)	 S41−S42	 2.116(6)	
P41−C171	 1.814(11)	 O171−S141	 1.429(9)	
S141−S142	 2.087(6)	 O172−S141	 1.377(12)	
	 	 O173−S141	 1.421(9)	
	 	 	 	
C51−P41−C61	 107.0(2)	 O72−S41−S42	 106.2(7)	
C51−P41−C41	 113.5(2)	 O71−S41−S42	 102.2(5)	
C61−P41−C41	 112.7(2)	 O73−S41−S42	 107.3(6)	
C51−P41−C171	 107.7(8)	 C73−S42−S41	 101.2(5)	
C61−P41−C171	 113.0(14)	 O172−S141−O173	 118.5(9)	
C41−P41−C171	 102.9(12)	 O172−S141−O171	 114.6(9)	
C51−P41−C71	 110.6(14)	 O173−S141−O171	 111.2(9)	
C61−P41−C71	 107.8(8)	 O172−S141−S142	 100.7(7)	
C41−P41−C71	 105.1(12)	 O173−S141−S142	 104.0(6)	
O72−S41−O71	 112.4(8)	 O171−S141−S142	 105.9(5)	
O72−S41−O73	 112.7(8)	 C173−S142−S141	 99.5(5)	
O71−S41−O73	 114.9(9)	 	 	
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3.10	Conclusion	
	
The	 aim	 of	 the	 work	 reported	 in	 this	 chapter	 (3B)	 was	 to	 synthesize	 methoxy-phenyl	
phosphoniopropylthiosulfate	 zwitterions	 (5	 -	 7)	 and	 ω-thioacetylpropyl(methoxyphenyl)	
phosphonium	 bromide	 salts	 (8	 -	 10)	 and	 determines	 their	 cytotoxicity	 in	 PC3	 cells.	 All	
compounds	 are	 easily	 prepared	 and	 have	 been	 characterized	 thoroughly.	 Unlike	 other	
triarylphosphoniopropylthiosulfate	 zwitterions,	 the	methoxy-phenyl	 compounds	 reported	
here	are	soluble	in	water	and	aqueous	media.		
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Chapter	4	
	
4A)	Investigation	of	the	cytotoxicity	and	
cellular	uptake	of	Arsonium	ligands	and	
Gold	nanoparticles	in	cells.	 	
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4.0		 Introduction	
	
The	cytotoxicity	of	arsenic	compounds	is	crucially	dependent	on	the	nature	and	oxidation	
state	 of	 the	 species.	 Inorganic	 compounds,	 such	 as	 arsenite	 and	 arsenate,	 show	 acute	
toxicity;	 for	example,	the	 IC50	of	sodium	arsenate	was	reported	as	6	µM.	In	contrast,	 the	
organic	 derivative	 arsenobetaine,	 Me3As
+CH2CO2
-,	 an	 important	 metabolite	 of	 arsenic	
which	is	widely	distributed	in	marine	ecosystems	and	found	in	comparatively	high	levels	in	
seafood,	is	reported	to	have	no	toxic	effects	and	was	found	to	significantly	enhance	the	cell	
viability	of	bone	marrow	cells	in	vitro	in	a	concentration-dependent	manner	(Sakurai	et	al.,	
2001).	 	
Nanotechnology	is	revolutionising	the	way	in	which	materials	are	engineered	today,	mainly	
due	 to	 their	 surface	 to	 volume	 ratio	 and	 other	 favourable	 characteristics.	 Gold	
nanoparticles	 are	 known	 to	 passively	 target	 tumour	 cells	 because	 of	 the	 nature	 of	 the	
blood	vessels	and	their	inherent	small	size.	It	has	been	reported	that	AuNPs	on	their	own	
do	 not	 target	 all	 cell	 types	 and	 hence	 it	 becomes	 essential	 to	 functionalize	 them	 with	
ligands	which	can	interact	with	the	surface	and/or	receptors	on	the	cell.	(Patra	et	al.,	2007,	
Kirui	et	al.,	2010).		
The	most	commonly	deployed	 ligands	 for	protecting	AuNPs	are	organic	 thiolates	derived	
from	 thiols	 or	 disulfides.	Other	 common	 ligands	 include	 citrate	 and	 tertiary	 phosphines.	
Pan	and	co-workers	(Pan	et	al.,	2009)	have	investigated	the	size-dependent	cytotoxicity	of	
AuNPs	 functionalized	with	water-soluble	 sulfonated	 triphenylphosphines	 (Fig.	 4.1).	 Their	
results	show	that	ultra-small	AuNPs	(1.5	nm)	cause	rapid	cell	death	whereas	larger,	15	nm	
AuNPs,	are	significantly	less	cytotoxic.			
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Figure	4.1	Schematic	representation	of	AuNPs	functionalized	with	sulfonated	
triphenylphosphine	ligands.	
	
The	use	of	 ionic	species	to	functionalize	the	surface	of	AuNPs	is	an	attractive	proposition	
for	improving	the	aqueous	solubility	of	AuNPs	and	facilitating	cellular	uptake.	Research	by	
Goodman	and	co-workers	 (Goodman	et	al.,	 2004)	has	demonstrated	 that	AuNPs	bearing	
cationic	 ligands	 are	 significantly	 less	 cytotoxic	 than	 anionic	 ligands.	 The	 most	 widely	
studied	 ligands	 for	 the	 production	 of	 cationic	 charged	 AuNPs	 are	 thiolates	 bearing	
ammonium	 groups.	 As	 outlined	 in	 Chapter	 1,	 there	 is	 increasing	 interest	 in	 the	 use	 of	
phosphonium	 cations	 to	 functionalize	 nanomaterials	 and	 the	 Bricklebank	 group	 has	
developed	 the	 synthesis	 of	 phosphonium-functionalized	 AuNPs	 and	 investigated	 their	
cellular	uptake	and	cytotoxicity.	However,	there	have	been	no	published	reports	 into	the	
use	of	organoarsonium	cations	to	functionalize	AuNPs.		
	
	
The	 synthesis	 and	 characterisation	 of	 AuNPs	 functionalized	 with	
triphenylarsoniumalkylthiolate	ligands	is	described	in	Chapter	3.	In	this	chapter	the	results	
of	studies	of	the	cytotoxicity	of	the	triphenylarsoniopropylthiolate-AuNPs,	and	the	parent	
triphenylarsoniopropylthiosulfate	 zwitterion,	 ω-thioacetylpropyl(triphenyl)arsonium	
bromide	salts	and	methoxyphenyl	compounds	are	reported.	
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4.1	 	Material	and	methods	
	
4.1.1	 	Chemicals	
Triphenylarsoniopropyllthiosulfate	 zwitterion	 (1),	 ω-thioacetylpropyl(triphenyl)arsonium	
bromide	 salts	 (2)	 salts	 and	 triphenylarsoniopropylthiolate-functionalized	 AuNPs	 were	
prepared	 as	 described	 in	 Chapter	 3.	 CellTiter-Glo	 luminescent	 cell	 viability	 assay	 kit	was	
purchased	 from	 Promega	 Corporation,	 Southampton,	 Hamshire	 UK,	 and	 3-(4,5-
dimethylthiazol-2-yl)-2,5-	 diphenyltetrazolium	bromide	 (MTT)	was	purchased	 from	Sigma	
Aldrich	UK,	and	were	used	as	received.	
4.1.2	Methods	
4.1.2.1	Cytotoxicity	and	MTT	assay	
Cytotoxicity	was	 assessed	using	CellTiter-Glo	 luminescent	 cell	 viability	 assay	 kit.	 PC3	and	
Human	 Fibroblast	 cells	 were	 seeded	 in	 an	 opaque-walled	 96	 well	 plate	 at	 a	 density	 of	
10,000	cells/well	and	allowed	 to	adhere	overnight.	Cells	were	subsequently	 treated	with	
the	 corresponding	 arsonium	 compound	 (0-1000µM)	 for	 24,	 48,	 72	 hours.	 After	 each	
incubation	period	cell	viability	was	measured	according	to	the	manufacturer’s	instructions.	
In	 brief,	 plates	 were	 equilibrated	 at	 room	 temperature	 for	 30	 minutes,	 100µL	 of	 assay	
reagent	was	 added	 to	 each	well,	 placed	 on	 an	 orbital	 shaker	 for	 2mins,	 left	 to	 stand	 at	
room	temperature	 for	10	minutes	and	 read	on	a	Wallac	Victor2	1420	multilabel	 counter	
(PerkinElmer,	Cambridge,	Cambridgeshire,	UK).	
Cytotoxicity	studies	were	also	done	to	assess	IC50	using	the	3-(4,5-dimethylthiazol-2-yl)-2,5-	
diphenyltetrazolium	bromide	(MTT)	assay.	Both	cell	lines	(PC3	and	Human	Fibroblast)	were	
seeded	in	a	96	well	plate	with	the	corresponding	ligand	(0-1000µM)	for	24,	48,	72	hours.	
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The	MTT	mixture	was	added	to	each	well	to	give	a	final	concentration	of	0.3mg/mL	MTT.	
Cells	were	incubated	with	MTT	for	3-4	hours	at	37oC.	The	supernatant	was	then	removed	
and	DMSO	was	added	to	read	the	absorbance	at	570nm.		
All	 plates	 contain	 control	well	 and	 all	measurements	were	 performed	 in	 quadruplicates;	
three	 independent	 experiments	 were	 conducted	 (n=12).	 Data	 are	 expressed	 as	 a	
percentage	of	live	cells	normalized	to	control	and	the	average,	standard	deviation	and	IC50	
values	 were	 plotted	 and	 calculated	 using	 GraphPad	 Prism	 (GraphPad	 software,	 La	 Jolla,	
California,	USA).	
4.1.2.2		 Quantification	of	the	Uptake	of	Arsonium-functionalized	gold	
nanoparticles	in	cells	by	ICP-OES	
PC3	cells	were	treated	 in	a	6	well	plate	at	a	density	of	500,000	cells/well	and	allowed	to	
adhere	 overnight.	 Cells	 were	 treated	 with	 different	 concentration	 of	
triphenylarsoniopropylthiolate-AuNPs	A-Au-Z2#	or	citrate-stabilised	5nm	AuNPs	purchased	
from	Sigma-Aldrich.		The	concentrations	of	the	nanoparticle	solutions	were	12.5,	25.0,	50.0	
mg/mL.	The	cells	were	incubated	with	each	of	these	solutions	overnight.	The	following	day	
the	 cells	 were	 trypsinised,	 washed	 with	 PBS,	 fixed	 in	 100%	 EtOH	 and	 sent	 to	 MEDAC	
(Chobham,	Surrey,	UK)	for	ICP-OES	analysis.	The	Au	analysis	was	carried	out	by	digestion	of	
the	sample	in	8ml	of	aqua	regia	and	the	solution	made	up	to	100ml.	This	solution	was	then	
analyzed	by	ICP-OES.	The	instrument	used	for	this	was	a	Varian	Vista	MPX	ICP-OES.	
#	Refer	to	Chapter	3,	Table	3.3	for	an	explanation	of	compound	labelling.	
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4.2	 Results	and	Discussion	
	
4.2.1	 Cytotoxicity	studies	of	Triphenylarsonium	ligands.	
	
In	 order	 to	 evaluate	 the	 efficacy	 of	 the	 triphenylarsoniumpropylthiolate-functionalized	
AuNPs	 as	 cellular	 transport	 systems	were	 first	 screened	against	 the	PC3	prostate	 cancer	
cell	 lines	 in	 order	 to	 determine	 the	 IC50	 of	 the	 parent	 triphenylarsoniopropylthiosulfate	
zwitterion	(1),	and	ω-thioacetylpropyl(triphenyl)arsonium	bromide	salts	(2).	The	results	are	
summarised	in	Table	4.1		
Table	4.1:		Summary	of	IC50	values	for	triphenylarsoniopropylthiosulfate	zwitterion	(1),	and	
	 			ω-thioacetylpropyl(triphenyl)arsonium	bromide	(2)	against	PC3	Cell	line	(µM)	
	
	 	 CellTiter-Glo	 MTT	
Compound	 24hr	 48hr	 72hr	 24hr	 48hr	 72hr	
1	 600.4	 548.7	 722.2	 89.9	 51.9	 71.8	
2	 969.4	 568.8	 384.5	 74.6	 43.6	 74.9	
The	MTT	assay	measures	mitochondrial	activity	to	determine	the	in	vitro	cytotoxic	effects	
of	chemical	entities.	The	results	(Fig.	4.2)	showed	1	and	2	to	have	IC50	values	of	75	mM	and	
72	mM,	respectively,	after	72	hours.	There	 is	 limited	published	data	on	the	IC50	values	of	
arsonium	 compounds	 and	 the	 publication	 is	 based	 on	 the	 results	 reported	 in	 this	 thesis	
(Lalwani	 et	 al.,	 2015).	 	 As	 noted	 in	 the	 introduction	 to	 this	 chapter,	 arsenobetaine	 is	
believed	to	be	essentially	nontoxic,	whereas	inorganic	arsenic	compounds	are	very	toxic.		
These	data	 reported	here	compare	 favourably	with	 that	 for	 the	analogous	phosphonium	
compounds	 ω-thioacetylpropyl(triphenyl)phosphonium	 bromide	 and	
ω-thioacetylpropyl(tri-4-fluorophenyl)phosphonium	bromide	which	 showed	 IC50	 values	of	
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67.1µM	 and	 252.6µM	 respectively	 (Chen	 et	 al.,	 2017).	 Millard	 and	 co-workers	 have	
screened	a	large	number	of	triphenylphosphonium	salts	using	MTT	against	PC3	cells.	These	
displayed	 IC50	 values	 in	 the	 range	 0.4–5	µM	 (Millard	 et	 al.,	 2010).	 The	 results	 described	
here	are	also	in	accordance	with	cellular	toxicity	data	for	lipophosphoramidate	derivatives,	
where	 phosphonium	 compounds	 show	 greater	 cytotoxicity	 than	 the	 corresponding	
arsonium	compounds	(Millard	et	al.,	2010).	The	cytotoxicity	results	determined	using	the	
CellTiter-Glo	assay	(Fig	4.2),	showed	that	the	IC50	values	were	found	to	be	722	μM	and	384	
μM	 after	 72	 hours	 for	 1	 and	 2	 respectively.	 The	 difference	 between	 toxicity	 might	 be	
attributed	to	the	zwitterionic	(1)	and	cationic	(2)	nature	of	the	respected	compounds.	
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Figure	 4.2:	CellTiter-Glo	 (CTG)	and	MTT	assay	on	 triphenylarsoniopropylthiosulfate	 zwitterion	 (1)	
and	ω-thioacetylpropyl(triphenyl)arsonium	bromide	(2).	Prostate	cancer	(PC3)	cells	were	incubated	
with	 increasing	 concentration	 of	 compound	 1	 and	 2.	 The	 IC50	 was	 then	 determined	 for	 each	
compound	from	a	plot	of	log	[drug	concentration]	versus	percentage	of	cell	normalised	to	control.	
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4.2.2	Cytotoxicity	of	Triphenylarsoniopropylthiolate-functionalized	gold	
nanoparticles	
	
Although	 there	 is	 a	 significant	 body	 of	 evidence,	 generated	 over	 a	 long	 period	 of	 time,	
pertaining	 to	 the	 toxic	 effects	 of	 arsenic	 compounds,	 there	 is	 no	published	work	on	 the	
cytotoxicity	of	gold	nanoparticles	functionalized	with	organoarsonium	compounds.	Organic	
arsenic	 compounds	 have	 long	 been	 investigated	 as	 therapeutic	 drugs	 but	 their	 greatest	
drawback	is	their	toxicity	(Swindell	EP	et	al,	2013).	Most	arsenic	compounds	display	dose-
limiting	 acute	 toxicity	 as	 well	 as	 chronic	 toxicities.	 Organic	 arsenic	 compounds	 are	
considered	to	be	less	toxic	than	inorganic	arsenic.	In	all	cases,	exposure	to	trivalent	arsenic	
As(III)	 is	 more	 toxic	 than	 exposure	 to	 pentavalent	 As(V).	 It	 is	 believed	 that	 the	 greater	
toxicity	 of	 As(III)	 compared	 to	 As(V)	 is	 due	 to	 the	 increased	 affinity	 of	 As(III)	 for	 sulfur	
ligands;	arsenic	exerts	its	effect	in	cells	by	interacting	with	the	sulfhydryl	groups	of	cysteine	
residues	of	proteins	and	peptides	(Swindell	EP	et	al,	2013).	
	
The	 cytotoxicity	 of	 triphenylarsoniopropylthiolate-functionalized	 gold	 nanoparticles	
A-Au-Z2	was	assessed	against	the	PC3	prostate	cancer	cell	line	and	Human	Fibroblast	(Hfb)	
'normal'	cells,	in	order	to	establish	if	there	is	a	difference	between	normal	and	cancerous	
cells.	The	IC50	values	were	determined	using	both	MTT	and	CellTitre-Glo	assays.	The	results	
are	summarised	 in	Table	4.2,	Fig	4.3	and	4.4.	 It	can	be	seen	that	the	 IC50	values	are	very	
similar	 for	 both	 the	 PC3	 and	 the	 Hfb	 cells.	 Furthermore,	 the	A-Au-Z2	 nanoparticles	 are	
significantly	 more	 toxic	 than	 the	 parent	 zwitterion	 1	 or	ω-thioacetyl(triphenyl)arsonium	
bromide	salt	2	(Table	4.1).	
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Table	4.2:		IC50	values	of	A-Au-Z2	nanoparticles	in	PC3	and	Human	Fibroblast	cell	lines	(µM)	
	 	 							Cell	Titer-Glo	(µM)	 						MTT	(µM)	
Cell	line	 24hr	 48hr	 72hr	 24hr	 48hr	 72hr	
PC3		 64.94	 49.77	 31.53	 31.06	 24.76	 14.73	
HFB		 82.37	 63.56	 39.82	 50.27	 38.28	 24.47	
	
							 	
Fig	4.3:	Cytotoxicity	assay	of	A-Au-Z2	nanoparticles	against	PC3	prostate	cancer	cells.	The	
cells	 were	 incubated	 with	 increasing	 concentration	 of	 nanoparticles.	 The	 IC50	 values	
determined	from	a	plot	of	log	[drug	concentration]	versus	percentage	of	cell	normalised	to	
control	using	(a)	CellTitre-Glo,	and	(b)	MTT	assay.	
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Figure	4.4:	Cytotoxicity	assay	of	A-Au-Z2	nanoparticles	against	Human	Fibroblast	cells.	The	
cells	 were	 incubated	 with	 increasing	 concentration	 of	 nanoparticles.	 The	 IC50	 values	
determined	from	a	plot	of	log	[drug	concentration]	versus	percentage	of	cell	normalised	to	
control	using	(a)	CellTitre-Glo,	and	(b)	MTT	assay.	
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4.3	 Quantification	of	the	Uptake	by	PC3	cells	on	Arsonium-functionalized	
gold	nanoparticles	in	cells	by	ICP-	 OES	spectrometry.	
Previous	 research	 on	 the	 cellular	 uptake	 and	 viability	 of	 PC3	 cells	 exposed	 to	 AuNPs	
functionalized	 with	 triphenylhosphoniumpropylthiolate	 ligands	 (P-Au-Z2)	 showed	 that	
triphenyphosphoniopropylthiolate-AuNPs	 with	 a	 concentration	 of	 up	 to	 5.0	 mg/mL	 are	
relatively	non-toxic	to	PC3	cells,	with	cell	viability	above	90%	(Chen	PhD	thesis,	2014).	At	P-
Au-Z2	concentrations	above	5.0	mg/mL,	after	24	hours	exposure	the	majority	of	cells	were	
necrotic.	 Results	 for	 the	 analogous	 arsonium	 AuNPs	A-Au-Z2	 (Fig	 4.5)	 showed	 that	 at	 a	
concentration	of	12.5	mg/ml	11.16%	of	cells	were	viable	after	24	hours	and	that	viability	
decreases	markedly	above	this	concentration.	
	
In	similar	studies,	Pan	and	co-workers	(Pan	et	al.,	2007)	determined	the	cytotoxicity	of	tris-
sulfonated	triphenylphosphine	and	triphenylphosphine	monosulfate	AuNPs	in	logarithmic-
phase	HeLa	cells.		The	toxicity	was	reported	to	be	size	dependent	and	AuNPs	greater	than	
5nm	were	 less	 toxic	 (30	 and	 46µM),	 whereas	 AuNPs	 having	 size	 in	 the	 range	 of	 2-3nm	
showed	much	greater	toxicity	(140-250µm).	It	is	not	very	clear	at	this	stage,	but	the	higher	
cytotoxicity	of	the	triphenylarsonium-functionalized	AuNPs	reported	in	this	thesis	could	be	
due	to	the	toxicity	of	the	small	AuNPs	rather	than	the	triphenylarsonium	ligands.	
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Figure	4.5	ICP-OES	data	showing	the	percentage	uptake	of	Triphenylarsonium-
functionalized	AuNP	(A-AuNPs):	Sigma	AuNPs	(S-AuNPs).	
	
A	solution	of	A-Au-Z2	with	a	concentration	of	10mg/ml	was	analyzed	by	ICP-OES	and	found	
to	contain	2	mg/ml	of	gold.	Based	on	this	result,	a	series	of	solutions	containing	12.5,	25	
and	50mg/ml	of	A-Au-Z2	 nanoparticles	were	produced.	 These	 solutions	 contained	2.5,	 5	
and	10	mg/ml	of	gold	respectively.	PC3	cells	were	incubated	with	each	of	these	solutions	
for	24	hours.	After	incubation	the	cells	were	washed	with	PBS,	fixed	in	100%	EtOH	and	sent	
to	MEDAC	for	analysis.	The	amount	of	gold	present	in	the	cells	was	determined	by	ICP-OES	
spectrometry.	 The	 results	 are	 summarised	 in	 Table	 4.3	 (experiments	 1-3).	 In	 a	 second	
series	 of	 experiments,	 PC3	 cells	 were	 incubated	 with	 similar	 concentrations	 of	 gold	
nanoparticles	purchased	from	Sigma	Aldrich.	The	Sigma	AuNPs	have	a	mean	particle	size	of	
5nm	and	are	spherical	in	shape	and	stabilised	with	citrate	ligands.	The	Sigma	AuNPs	were	
diluted	 to	 create	 solutions	 containing	 2.5,	 5,	 and	 10	mg/ml	 of	 gold.	 The	 PC3	 cells	were	
incubated	with	each	of	these	Sigma	solutions	for	24	hours.	After	incubation	the	cells	were	
washed	 with	 PBS,	 fixed	 in	 100%	 EtOH.	 The	 amount	 of	 gold	 present	 in	 the	 cells	 was	
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determined	 by	 ICP-OES	 spectrometry.	 The	 results	 are	 summarised	 in	 Table	 4.3	
(experiments	4-6).	
Table	4.3.	Percentage	uptake	of	Triphenylarsonium-functionalized-AuNP	(A-AuNPs):	Sigma-
AuNPs	(S-AuNPs).	
Experiment	
Source	
of	gold	
Initial	
concentration	
of	gold	(mg/ml)	
Concentration	of	gold	in	
PC3	cells	after	72	hours	
incubation	(mg/ml)	
Percentage	
uptake	of	gold	
(%)	
1	 A-Au-Z2	 2.5	 0.279	 11.16	
2	 A-Au-Z2	 5.0	 1.204	 24.08	
3	 A-Au-Z2	 10.0	 6.646	 66.46	
4	 Sigma-
AuNPs	
2.5	 7.841	 78.41	
5	 Sigma-
AuNPs	
5.0	 7.688	 76.88	
6	 Sigma-
AuNPs	
10.0	 8.021	 80.21	
	
The	 quantification	 of	 AuNPs	 was	 done	 by	 ICP-OES	 (Allabashi	 et	 al.,	 2009).	 The	 result	
showed	 that	 5nm	 AuNPs	 (stabilised	 suspension	 in	 citrate	 buffer)	 had	 a	 much	 higher	
percentage	 of	 uptake	 than	 the	 triphenylarsonioalkylthiolate-capped	 AuNPs.	 The	 highest	
percentage	 uptake	 for	 arsonium	 AuNPs	 was	 found	 to	 be	 66.46%	 while	 uptake	 for	 5nm	
AuNPs	from	Sigma	Aldrich	was	found	to	be	over	76%	across	all	concentrations.	This	data	is	
comparable	 to	 results	 obtained	 by	 Arnida	 and	 co-workers	 (Arnida	 et	 al.,	 2010)	 who	
reported	that	uptake	of	spherical	AuNPs	with	a	mean	diameter	of	30nm		is	steady	across	
all	concentrations	tested	(0-40nm)	and	this	uptake	may	be	due	to	the	limited	cationic	sites	
available	on	cell	surfaces	(Wilhelm	et	al.,	2003).	
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The	 percentage	 uptake	 of	 the	 triphenylarsonium	 AuNPs	 was	 also	 low	 compared	 to	 the	
analogous	triphenylphosphonium	AuNPs	(Chen	PhD	thesis,	2014),	as	reported	in	Table	4.4.	
The	 reason	 for	 this	 is	 unclear;	 especially	 since	 studies	 comparing	 the	 cell	 biology	 of	
triphenylarsonium-functionalized	 macrocyclic	 copper	 complexes	 with	 their	
triphenylphosphonium-analogues	did	not	note	a	significant	difference	in	behaviour.	
Table	4.4	Comparison	of	Percentage	uptake	of	Triphenylarsoniopropylthiolate-AuNPs	(A-
Au-Z2)	and	Triphenylphosphoniopropylthiolate-AuNPs	(P-Au-Z2)	
	
Sample Initial	Concentration	of	
gold	mg/ml 
Percentage	uptake	of		
A-AuZ2 
Percentage	uptake	of		
P-AuZ2	
 
1	 2.5	 11	 88	
2	 5	 24	 76	
3	 10	 66	 102	
	
	
4.4	 Conclusion	
Arsenic	compounds	have	been	widely	investigated	for	their	medicinal	properties	although	
interest	declined	as	greater	understanding	of	their	toxicity	became	apparent	(Chen	et	al.,	
2011	and	Swindell	et	al.,	2013).	More	recently	there	has	been	a	resurgence	of	 interest	 in	
the	medicinal	properties	of	arsenic	compounds,	 including	 the	use	of	arsenic	 trioxide	and	
organic	arsenic	derivatives	as	treatments	for	leukaemia	and	other	cancers	(Mudhoo	et	al.,	
2011,	Chen	et	al.,	2011	and	Swindell	et	al.,	2013).	
The	 data	 presented	 here	 show	 that	 triphenylarsonium-functionalized	 AuNPs	 are	
significantly	more	 toxic	 then	 the	 parent	 triphenylarsoniopropylthiosulfate	 zwitterion	 and	
ω-thioacetylpropyl	 (triphenyl)	 arsonium	 bromide	 salts.	 In	 contrast,	 results	 for	 the	
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analogous	triphenylphosphonium-AuNPs	showed	they	were	less	toxic	as	compared	to	the	
parent	ligands.	As	described	in	chapter	3,	the	triphenylarsonium-functionalized	AuNPs	are	
slightly	 smaller	 than	 analogous	 triphenylphosphonium-AuNPs	 and	 it	 is	 possible	 that	 the	
greater	toxicity	of	the	arsenic-containing	materials	is	due	to	the	size	of	the	AuNPs.	Further	
research	is	necessary	to	establish	whether	the	cytotoxicity	of	the	triphenylarsonium-AuNPs	
is	due	to	the	triphenylarsonium	ligands,	the	AuNPs	or	a	combination	of	both	species.		
The	use	of	ICP-MS	for	quantifying	the	uptake	of	AuNPs	in	cells	has	also	been	reported.	In	
this	 chapter,	 the	 related	 technique	 ICP-OES	 has	 been	 used	 to	 determine	 the	 amount	 of	
AuNPs	 in	 cells.	 The	 results	 indicate	 that	 the	 triphenylarsonium-AuNPs	 are	 taken-up	 at	
much	 lower	 levels	 than	 the	 triphenylphosphonium-AuNPs	 or	 citrate-stabilised	 AuNPs	
purchased	from	Sigma.	It	is	difficult	to	compare	data	obtained	with	published	studies,	due	
to	variations	in	reporting	the	data,	as	reviewed	by	Lévy	and	colleagues	(Lévy	et	al.,	2010).	
For	 example	 the	 units	 of	 size	 vary	 between	 groups	 thereby	 making	 comparison	 a	
complicated	 task;	 Zhu	et	al.	 (2012)	 reported	 the	uptake	of	AuNPs	by	 ICP-MS	 in	 terms	of	
pmol,	 while	 Arnida	 et	 al.	 (2010)	 reported	 the	 uptake	 of	 AuNPs	 by	 number	 per	 cell	 and	
Chithrani	et	al.	(2006)	reported	the	uptake	by	number	of	AuNPs	per	cell	(103).	Further	work	
is	 also	 needed	 to	 establish	 if	 the	 triphenylarsonium-AuNPs	 are	 actually	 taken	 up	 by	 the	
cells.	
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4B)	Investigation	of	the	cytotoxicity	and	
cellular	uptake	of	Methoxyphenyl	
substituents	
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4.5	Introduction	
Previous	 work	 has	 shown	 that	 alkylthiosulfate	 zwitterion	 and	 alkylthioacetate	 salt	
derivatives	of	 triphenylphosphine,	and	other	 trialkyl-	and	triaryl-phosphines,	can	be	used	
as	precursors	for	the	formation	of	triphenylphosphonium-functionalized	gold	nanoparticles	
(Ju-nam	et	al.,	2006;	Ju-nam	et	al.,	2012;	Yang	et	al.,	2015;	Ju-nam	et	al.,	2007;	Ju-nam	et	
al.,	2015).	Although	the	triphenylphosphonium-functionalized	nanoparticles	are	soluble	in	
water	 and	 biological	media,	 and	 are	 taken-up	 by	 cells	 (Ju-nam	 et	 al.,	 2012),	 the	 parent	
triphenylphosphoniumalkylthiosulfate	 zwitterions	 are	 insoluble	 in	 aqueous	 media	 (Chen	
PhD	 thesis,	 2014)	 This	 observation	 has	 prompted	 us	 to	 investigate	 alternative	
triarylphosphonium	 groups	 in	 an	 attempt	 to	 improve	 the	 aqueous	 solubility	 of	 the	
zwitterions.	The	characterisation	and	synthesis	has	been	reported	in	Chapter	3B.	
4.6	Material	and	methods	
4.6.1	Chemicals	
All	 chemicals	 were	 used	 as	 received;	 tris(2,4,6-trimethoxyphenyl)phosphine	 and	 tris(2,4	
dimethoxyphenyl)phosphine	 and	 tris(4-methoxyphosphine)	 were	 purchased	 from	 Sigma	
Aldrich,	UK	and	used	without	any	further	treatment.		1,	3-	Dibromopropane	was	purchased	
from	Acros	Organics,	UK.	Potassium	thioacetate	(KSCOCH3),	sodium	thiosulfate	(Na2S2O3),	
Potassium	bromide	(KBr),	gold(III)	chloride	trihydrate,	hydrobromic	acid	(HBr),	magnesium	
sulfate	 (MgSO4),	 deuterated	 dichloromethane,	 chloroform	 and	 ICP	 Au	 standard	 were	
purchased	from	Sigma-Aldrich	(Gillingham,	Dorset,	UK).		
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4.6.2	Methods	
4.6.2.1	Cytotoxicity	assay	
Cytotoxicity	was	assessed	using	a	CellTiter-Glo	luminescent	cell	viability	assay	kit	(Promega	
Corporation,	Southampton,	Hamshire,	UK).		
PC3	cells	were	seeded	in	opaque-walled	96	well	plates	at	a	density	of	10,000	cells/well	and	
allowed	 to	 adhere	 overnight.	 Cells	 were	 subsequently	 treated	 with	 the	 corresponding	
phosphonium	 ligand	 (0-1000µm)	 for	 24,	 48,	 72	 hours.	 After	 each	 incubation	 period,	 cell	
viability	was	measured	according	to	the	manufacturer’s	 instructions.	 In	brief,	plates	were	
equilibrated	at	room	temperature	for	30	mins,	100µL	of	assay	reagent	was	added	to	each	
well,	 placed	 on	 an	 orbital	 shaker	 for	 2mins,	 left	 to	 stand	 at	 room	 temperature	 for	 10	
minutes	and	 read	on	a	Wallac	Victor2	1420	multilabel	 counter	 (PerkinElmer,	Cambridge,	
Cambridgeshire,	UK).	
	
Cytotoxicity	 studies	 were	 also	 done	 to	 assess	 IC50	 using	 3-(4,5-dimethyltiazol-2-yl)-2,5-	
diphenyltetrazolium	bromide	 (MTT)	 assay.	 Cells	were	 seeded	 in	 a	 96	well	 plate	with	 the	
corresponding	ligand	(0-1000µm)	for	24,	48,	72	hours.	An	MTT	mixture	was	added	to	each	
well	to	give	a	final	concentration	of	0.3mg/mL	MTT.	Cells	were	incubated	with	MTT	for	3-4	
hours	at	37	oC.	The	supernatant	liquid	was	then	removed	and	DMSO	was	added	to	read	the	
absorbance	at	570nm.		
	
All	plates	contain	control	wells	and	all	measurements	were	performed	 in	quadruplicates,	
three	 independent	 experiments	 were	 conducted	 (n=12).	 Data	 are	 expressed	 as	 a	
percentage	 of	 live	 cells	 normalized	 to	 control,	 the	 average,	 standard	 deviation	 and	 IC50	
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values	 were	 plotted	 and	 calculated	 using	 GraphPad	 Prism	 (GraphPad	 software,	 La	 Jolla,	
California,	USA).	
4.7	Solubility	studies	of	methoxy-phenyl	phosphonium	compounds	
Compounds	 5	 -	 10	 readily	 dissolve	 in	 a	 range	 of	 solvents	 including	 DCM,	 water	 and	
aqueous	 media.	 This	 makes	 them	 suitable	 for	 cell	 biology	 studies.	 The	 solubility	 of	
zwitterions	 5	 -	 7	 in	 aqueous	 media	 is	 notable.	 	 Previous	 research	 from	 our	 own	 group	
(Jenni	Chen	Thesis,	2014;	Chen	et	al.,	2017)	and	by	others	(Ju-nam	2015),	has	shown	that	
triarylphosphoniopropylthiosulfate	 zwitterions	 prepared	 from	 triphenyl-,	 tri(p-
fluorophenyl)-	and	tri(p-tolyl)-phosphine	are	not	so	soluble	in	aqueous	media.	In	contrast,	
the	 corresponding	 ω-thioacetylpropyl(triaryl)phosphonium	 bromide	 salts	 are	 soluble	 in	
aqueous	 media.	 This	 difference	 in	 solubility	 between	 the	 phosphonium	 zwitterions	 and	
phosphonium	salts	was	attributed	 to	 strong	electrostatic	 interactions	 that	exist	between	
the	zwitterions	 in	the	solid	state.	These	 interactions	are	not	present	 in	the	phosphonium	
salts.	 	 	 The	 solubility	 of	 zwitterions	 5	 -	 7	 can	 be	 attributed	 to	 the	 electronic	 and	 steric	
effects	of	the	methoxy-substituents.			
4.8	Cytotoxicity	Screening	of	methoxy-phenyl	phosphonium	compounds	5	-	
10.	
Phosphonium	 compounds	 are	 known	 to	 selectively	 accumulate	 in	 the	 mitochondria	 of	
cancer	cells	and	their	anti-cancer	activity	has	been	of	interest	and	have	been	investigated	
by	several	groups	(Millard	et	al.,	2010,	Rideout	et	al.,	1989,	Sehy	et	al.,	1993,	Manetta	et	
al.,	1996,	Bergeron	et	al.,	2009).	Cell	viability	studies	on	compounds	5	-	10	were	performed	
against	the	PC3	prostate	cancer	cell	line	using	MTT	and	CellTitre-Glo	assays.	The	results	are	
presented	below	(Table	4.5	and	Figures	4.6	and	4.7).		
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Table	4.5		IC50	values	of	methoxy-phenyl	phosphoniopropylthiosulfate	zwitterions	(5	-	7)	
and	ω-thioacetylpropyl(methoxyphenyl)phosphonium	bromide	salts	(8	-	10).	Units	for	data	
values	are	µM.	
	 	 CellTiter-Glo	 MTT	
Compound	 24hr	 48hr	 72hr	 24hr	 48hr	 72hr	
5	 325.50	 288.73	 218.33	 69.55	 55.65	 45.65	
6	 469.33	 344.74	 289.68	 105.83	 78.62	 66.09	
7	 308.54	 261.27	 198.15	 82.21	 64.59	 47.80	
8	 527.16	 420.69	 328.77	 111.80	 86.69	 74.00	
9	 413.22	 341.33	 249.94	 96.84	 72.66	 58.70	
10	 582.27	 390.06	 319.36	 123.90	 83.13	 68.22	
14*	 137.95	 127.07	 67.14	 	 	 	
15*	 654.73	 367.75	 252.63	 	 	 	
16¥	 	 	 	 	 	 0.40	
17¥	 	 	 	 	 	 8.00	
NOTES	
*Data	reported	by	Y-S	Chen,	PhD	Thesis,	Sheffield	Hallam	University,	2014	
¥	Data	reported	by	M.	Millard,	D.	Pathania,	Y.	Shabaik,	L.	Taheri,	J.	Deng	and	N.	Neamati,	
PLoS	One,	2010,	5,	e13131.	
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Figure	 4.6	 PC3	 cells	 treated	 with	 5	 -	 10	 for	 24,	 48,	 72	 hours.	 Cell	 proliferation	 was	
determined	 by	 the	 MTT	 assay.	 Data	 are	 expressed	 as	 a	 percentage	 of	 living	 cells	
normalized	to	control.	
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Figure	 4.7	 PC3	 cells	 treated	 with	 5-10	 for	 24,	 48,	 72	 hours.	 Cell	 proliferation	 was	
determined	by	the	CellTiter-Glo	luminescent	cell	viability	assay	kit.	Data	are	expressed	as	a	
percentage	of	living	cells	normalized	to	control.	
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MTT	measures	mitochondrial	activity	to	determine	the	in	vitro	cytotoxic	effects	of	chemical	
entities.	 The	 results	 showed	 that	 zwitterions	 5	 -	 7	are	more	 toxic	 to	 cells	 after	72	hours	
than	the	corresponding	thioacetate	salts	8	-	10.	These	values	compare	very	favorably	with	
those	 of	 the	 triphenylphosphonium-	 and	 tri(p-fluorophenyl)phosphonium-	 thioacetate	
salts	 14	 and	 15.	 Millard	 and	 coworkers	 have	 reported	 IC50	 values	 for	 33	 different	
phosphonium	 compounds	 (all	 contain	 the	 triphenylphosphonium	 moiety	 with	 different	
side	chains)	in	five	different	cell	lines,	including	PC3	cells,	using	the	MTT	assay	(Millard	et	
al.,	2010).	The	compounds	investigated	had	IC50	values	between	0.4	–	4.1µM	at	72	hours	in	
PC3	cell	 lines.	The	most	toxic	compound	reported	by	Millard	et	al.,	2010	was	TP	731	(16)	
having	IC50	value	of	0.40	µM	while	the	least	toxic	was	TP	764	(17)	with	IC50	value	of	8	µM.	
The	 IC50	 values	 which	Millard	 reported	 showed	 that	 triphenyl-substituted	 phosphonium	
salts	are	significantly	more	toxic	towards	PC3	cells	than	5	-	10.	
	
The	 viability	 of	 PC3	 cells	 in	 the	 presence	 of	 compound	5	 -10	 has	 also	 been	 determined	
using	the	CellTitre-Glo	assay	to	confirm	the	MTT	cytotoxicity	data.	This	uses	luminescence	
to	determine	the	number	of	viable	cells	based	on	a	quantification	of	ATP	levels.	Although,	
the	 IC50	 for	CTG	 is	much	higher	 then	MTT;	which	 is	comparable	 to	work	done	by	Millard	
and	co-worker	(Millard	et	al.,	2010),	The	data	showed	a	similar	trend	to	that	determined	
using	MTT,	with	zwitterions	5	-	7	showing	slightly	greater	toxicity	than	thioacetate	salts	8	-	
10.	
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4.9	 Conclusion	
	
Cell	 viability	 results	 show	 that	 all	 compounds	 are	 cytotoxic	 towards	 cells	 at	 very	 high	
concentrations	and	at	prolonged	period	 incubation	 times.	The	main	purpose	was	also	 to	
synthesize	 compounds	 which	 were	 less	 toxic	 compared	 to	 the	 other	 phosphonium	
compounds	 studied	previously	 (Millard	 et	 al.,	 2010,	Rideout	 et	 al.,	 1989,	Manetta	 et	 al.,	
1996)	 and	 this	 has	been	achieved.	 The	 IC50	 values	of	5	 -	10	 at	 72	hours	 are	 significantly	
higher	 than	 other	 phosphonium	 derivatives	 which	 indicate	 that	 methoxy-phenyl	
phosphonium	 compounds	 could	 be	 ideal	 compounds	 for	 the	 surface-functionalization	 of	
AuNPs	for	biological	applications.	
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5.1	 Conclusion	and	Future	Work		
	
This	thesis	presents	a	body	of	original	research	relating	to	the	synthesis	and	chemical	and	
biological	 characterization	 of	 triphenylarsonium-alkylthiosulfate	 zwitterions	 and	
alkylthioacetate	 salts,	 and	 the	 associated	 triphenylarsoniumalkylthiolate-protected	 gold	
nanoparticles,	 and	 a	 series	 of	 triarylphosphonium-alkylthiosulfate	 zwitterions	 and	
alkylthioacetate	salts	based	on	triarylphosphines	bearing	methoxyphenyl	substituents.		
	
Chapter	 3A	 reports	 the	 synthesis	 of	 the	 triphenylarsoniopropylthiosulfate	 zwitterion	 and	
ω-thioacetylpropyl(triphenyl)arsonium	 salt.	 Both	 compounds	 have	been	 characterized	by	
single-crystal	X-ray	crystallography,	elemental	analysis,	NMR	and	IR	spectroscopy	and	mass	
spectrometry.	 Investigations	 into	the	cytotoxicity	of	the	triphenylarsoniopropylthiosulfate	
zwitterions	 and	ω-thioacetylpropyl(triphenyl)arsonium	 towards	 PC3	 prostate	 cancer	 cells	
are	described	 in	 chapter	4	 and	 show	 that	both	 compounds	are	 toxic	 to	 the	 cells	 at	high	
concentrations	 and	 at	 prolonged	 incubation	 times	 (Lalwani	 et	 al.,	 2015).	 However,	 the	
triphenylarsonium	 compounds	 reported	 here	 are	 less	 cytotoxic	 than	 the	 analogous	
phosphonium	 compounds.	 Similarly,	Millard	 et	 al	 (2010)	 investigated	 the	 cytotoxicity	 of	
numerous	triphenylphosphonium	compounds	in	several	cancer	cell	lines	including	the	PC3	
cells	utilized	 in	 this	 study.	 Their	most	 toxic	 compound	has	an	 IC50	value	of	0.4	μM	at	72	
hours	 in	 PC3	 which	 is	 significantly	 more	 toxic	 than	 the	 triphenylarsonium	 compounds	
described	here.	 Further	work	 should	be	 carried	out	 to	determine	 the	 cytotoxicity	 of	 the	
triphenylarsoniopropylthiosulfate	 zwitterion	 and	 ω-thioacetylpropyl	 (triphenyl)	 arsonium	
salt	towards	other	cell	 lines,	 including	cancer	cells	and	normal	cell	 lines.	Research	should	
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also	 be	 done	 to	 determine	 how	 much	 of	 the	 compounds	 are	 taken-up	 by	 cells	 and	 to	
establish	if	the	compounds	are	localized	within	the	mitochondria	of	the	cells.	
	
The	 triphenylarsoniopropylthiosulfate	 zwitterion	 and	
ω-thioacetylpropyl(triphenyl)arsonium	 salt	 can	 be	 used	 to	 prepare	 AuNPs	 functionalized	
with	triphenylarsoniumpropylthiolate	ligands	using	a	modification	of	the	well-known	Brust-
Schiffrin	 synthesis	 (Brust	 et	 al.,	 1995).	 The	 resulting	 triphenylarsoniumpropylthiolate-
capped	 AuNPs	 are	 cationic	 and	 water-soluble,	 making	 them	 potential	 candidates	 for	
biological	applications.	A	number	of	analytical	techniques	have	been	used	to	characterize	
the	 triphenylarsoniumpropylthiolate-capped	 AuNPs,	 including	 XPS,	 TEM,	 mass	
spectrometry,	 UV-visible,	 IR	 and	 Raman	 spectroscopy.	 TEM	 results	 showed	 all	
triphenylarsoniumpropylthiolate-capped	 AuNPs	 synthesized	 have	 a	 uniform	 spherical	
shape	 with	 mean	 core	 sizes	 of	 c.a.	 3	 nm.	 	 The	 presence	 of	 triphenylarsonium-
propylthiolate	 groups	 on	 the	 surface	 of	 the	 AuNPs	 was	 confirmed	 by	 TEM	 and	 mass	
spectrometry	which	show	that	the	S-S	bond	of	the	thiosulfate	group	of	the	zwitterion	and	
the	S-C	bond	of	the	thioacetate	group	of	the	triphenylarsonium	salt	are	cleaved	under	the	
reductive	conditions	employed	in	the	Brust-Schiffrin	method.		
Chapter	 3B	 reports	 the	 synthesis	 of	 a	 family	 of	 methoxy-phenyl	 substituted	
phosphoniopropylthiosulfate	 zwitterions	 and	 ω-thioacetylpropyl(triaryl)phosphonium	
salts.	 	 All	 compounds	 have	 been	 characterized	 by	 elemental	 analysis,	 NMR	 and	 IR	
spectroscopy	 and	mass	 spectrometry.	A	 single	 crystal	 X-ray	 diffraction	 study	of	 tri(2,4,6-
trimethoxyphenyl)phosphoniopropyl-thiosulfate	 zwitterions	 showed	 the	 compound	 to	be	
very	 disordered.	 This	 is	 not	 unusual	 for	 derivatives	 of	 tri(2,4,6-
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trimethoxyphenyl)phosphine.	 The	 next	 step	 is	 to	 investigate	 the	 use	 of	 the	 methoxy-
phenyl	 substituted	 phosphoniopropylthiosulfate	 zwitterions	 and	 ω-thioacetylpropyl	
(methoxy-phenyl)phosphonium	 salts	 as	 capping	 ligands	 for	 the	 functionalized	 gold	
nanoparticles	 and	 to	 determine	 the	 biological	 properties	 of	 the	 resulting	
methoxyphenylphosphoniumalkylthiolate-capped	AuNPs.	
	
Chapter	 4A	 reports	 the	 preliminary	 investigation	 into	 the	 cytotoxicity	 of	 the	
triphenylarsoniumpropylthiolate-capped	AuNPs	 towards	 PC3	 prostate	 cancer	 and	 human	
fibroblast	normal	cell	lines.	The	results	show	that	the	AuNPs	have	a	similar	toxicity	toward	
both	 cell	 lines.	 This	 result	 contrasts	 with	 previous	 studies	 on	
triphenylphosphoniumpropylthiolate-capped	 AuNPs	 which	 were	 not	 toxic	 towards	 cells	
(Chen	 PhD	 thesis,	 2014).	 Previous	 studies	 by	 Pan	 and	 coworkers	 (Pan	 et	 al.,	 2007)	 have	
demonstrated	 that	 the	 cytotoxicity	 of	 AuNPs	 is	 size-dependent.	 Larger	 AuNPs,	 with	
diameters	 >15nm,	 are	 relatively	 non-toxic	 to	 cells	whereas	 small	 AuNPs,	with	 diameters	
<5nm,	 are	 toxic	 towards	 cells.	 It	 is	 not	 clear	 whether	 the	 toxicity	 of	 the	
triphenylarsoniumpropylthiolate-capped	 AuNPs	 is	 due	 to	 the	 small	 size	 of	 the	 AuNPs	 or	
some	intra-cellular	metabolite	of	the	triphenylarsoniumpropylthiolate	moiety,	or	possibly	a	
combination	 of	 both.	 Further	 research	 could	 be	 undertaken	 to	 prepare	 larger	 AuNPs	
functionalized	 with	 triphenylarsoniumpropylthiolate	 ligands	 and	 determine	 their	
cytotoxicity	towards	different	cell	lines.	
	
The	 amount	 of	 gold	 taken-up	by	 the	 cells	was	 determined	by	 ICP-OES	 spectroscopy	 and	
showed	that	a	much	lower	amount	of	the	triphenylarsoniumpropylthiolate-capped	AuNPs	
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were	taken-up	by	the	cells	compared	to	triphenylphosphoniumalkylthiolate-capped	AuNPs	
(Chen	 PhD	 thesis,	 2014)	 and	 citrate-stabilized	 AuNPs	 purchased	 from	 Sigma-Aldrich.	
Further	 research	 is	 necessary	 to	 confirm	 this	 result	 and	 to	 investigate	 the	 why	 the	
triphenylarsoniumpropylthiolate-capped	AuNPs	do	not	appear	to	be	taken-up	as	readily	as	
the	analogous	triphenylphosphoniumalkylthiolate-capped	AuNPs.	
	
Chapter	 4B	 reports	 preliminary	 investigation	 into	 the	 cytotoxicity	 of	 methoxy-phenyl	
substituted	 phosphoniopropylthiosulfate	 zwitterions	 and	 ω-
thioacetylpropyl(triaryl)phosphonium	 salts	 	 towards	 PC3	 prostate	 cancer	 lines.	 Previous	
work	 has	 shown	 that	 analogous	 triphenylphosphoniopropylthiosulfate	 zwitterions	 are	
essentially	 insoluble	 in	 water	 and	 biological	media,	 which	 has	 prevented	 its	 cytotoxicity	
from	 being	 determined	 (Chen	 et	 al.,	 2017)	 In	 contrast,	 the	
tri(methoxyphenyl)phosphoniopropylthiosulfate	zwitterions	are	soluble	in	water.		The	IC50	
values	of	all	of	 the	methoxy-phenyl	 substituted	phosphonio-propylthiosulfate	 zwitterions	
and	ω-thioacetylpropyl(methoxy-phenyl)	phosphonium	salts	towards	PC3	prostate	cancer	
have	 been	 determined.	 All	 of	 the	 compounds	 are	 less	 cytotoxic	 than	 the	 analogous	 ω-
thioacetylpropyl(triphenyl)phosphonium	salt	and	other	triphenylphosphonium	derivatives.		
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6.4	Appendices	
Appendix	1.		
	
Crystal	data	and	structure	refinement	details	for	triphenylarsoniopropylthiosulfate	
zwitterion.	Compound	2,	described	in	chapter	3A.	
	
Table	A1.1.	Crystal	data	and	structure	refinement	details.	
		
Identification	code		 2011ncs0152aa					
Empirical	formula		 C21H21AsO3S2	
Formula	weight		 460.42	
Temperature		 100(2)	K	
Wavelength		 0.71073	Å	
Crystal	system		 Monoclinic	
Space	group		 P21/n		
Unit	cell	dimensions	 a	=	11.687(5)	Å	 α	=	90°	
	 b	=	14.366(6)	Å	 β	=	106.254(5)°	
	 c	=	12.127(5)	Å	 γ		=	90°	
Volume	 1954.7(14)	Å3	
Z	 4	
Density	(calculated)	 1.565	Mg	/	m3	
Absorption	coefficient	 1.972	mm−1	
F(000)	 944	
Crystal	 Needle;	Colourless	
Crystal	size	 0.30	×	0.15	×	0.02	mm3	
θ	range	for	data	collection	 3.19	−	27.48°	
Index	ranges	 −15	≤	h	≤	15,	−18	≤	k	≤	11,	−15	≤	l	≤	11	
Reflections	collected	 10357	
Independent	reflections	 4425	[Rint	=	0.0510]	
Completeness	to	θ	=	27.48°	 98.7	%		
Absorption	correction	 Semi−empirical	from	equivalents	
Max.	and	min.	transmission	 0.9616	and	0.5892	
Refinement	method	 Full-matrix	least-squares	on	F2	
Data	/	restraints	/	parameters	 4425	/	0	/	244	
Goodness-of-fit	on	F2	 1.143	
Final	R	indices	[F2	>	2σ(F2)]	 R1	=	0.0730,	wR2	=	0.1111	
R	indices	(all	data)	 R1	=	0.0858,	wR2	=	0.1173	
Largest	diff.	peak	and	hole	 0.644	and	−1.100	e	Å−3	
		
Diffractometer: Rigaku Saturn724+ area detector (φ scans and ω scans to fill asymmetric 
unit sphere). Cell determination: CrystalClear-SM Expert 2.0 r7 (Rigaku, 2011). Data 
collection: CrystalClear-SM Expert 2.0 r7 (Rigaku, 2011). Data reduction and cell 
refinement: CrystalClear-SM Expert 2.0 r7 (Rigaku, 2011). Absorption correction: 
CrystalClear-SM Expert 2.0 r7 (Rigaku, 2011). Structure solution: SUPERFLIP 
(Palatinus, L. & Chapuis, G. (2007). J. Appl. Cryst. 40, 786-790.) Structure refinement: 
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SHELXL97 (G Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122.). Graphics: OLEX2 
(Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. (2009). 
J. Appl. Cryst. 42, 339-341.) 
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Table	A1.2	.	Atomic	coordinates	[×	104],	equivalent	isotropic	displacement	parameters	[Å2	
×	103]	and	site	occupancy	factors.	Ueq	is	defined	as	one	third	of	the	trace	of	the	
orthogonalized	Uij	tensor.	
	
Atom		 x	 y	 z	 Ueq	 S.o.f.	
	
C1	 10852(4)	 2610(3)	 223(4)	 18(1)	 1	
C2	 11673(4)	 3452(3)	 379(5)	 19(1)	 1	
C3	 12695(4)	 3257(3)	 −142(4)	 20(1)	 1	
C4	 8898(4)	 1613(3)	 1032(4)	 15(1)	 1	
C5	 8489(4)	 1465(3)	 1987(4)	 20(1)	 1	
C6	 8134(5)	 573(4)	 2186(5)	 24(1)	 1	
C7	 8179(4)	 −141(3)	 1444(5)	 21(1)	 1	
C8	 8559(4)	 15(3)	 478(5)	 22(1)	 1	
C9	 8926(4)	 901(3)	 258(4)	 18(1)	 1	
C10	 8238(4)	 3486(3)	 −372(4)	 15(1)	 1	
C11	 8406(5)	 3749(3)	 −1413(4)	 19(1)	 1	
C12	 7532(5)	 4280(3)	 −2164(5)	 22(1)	 1	
C13	 6513(4)	 4541(3)	 −1860(4)	 20(1)	 1	
C14	 6351(4)	 4262(3)	 −829(5)	 21(1)	 1	
C15	 7210(4)	 3722(3)	 −67(4)	 18(1)	 1	
C16	 9876(4)	 3530(3)	 2102(4)	 19(1)	 1	
C17	 9548(4)	 4453(3)	 2085(5)	 20(1)	 1	
C18	 9934(5)	 4987(4)	 3071(5)	 26(1)	 1	
C19	 10651(4)	 4584(4)	 4064(5)	 24(1)	 1	
C20	 10948(5)	 3649(4)	 4089(5)	 25(1)	 1	
C21	 10579(4)	 3116(4)	 3106(4)	 23(1)	 1	
O1	 14228(3)	 3273(2)	 2672(3)	 22(1)	 1	
O2	 15307(3)	 3774(2)	 1338(3)	 24(1)	 1	
O3	 15745(3)	 2278(3)	 2301(3)	 32(1)	 1	
S1	 13657(1)	 2293(1)	 505(1)	 23(1)	 1	
S2	 14873(1)	 2999(1)	 1861(1)	 19(1)	 1	
As1	 9451(1)	 2811(1)	 728(1)	 15(1)	 1	
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Table	A1.3	Bond	lengths	[Å]	and	angles	[°].	
		
C1−C2	 1.523(6)	
C1−As1	 1.923(5)	
C1−H1A	 0.9900	
C1−H1B	 0.9900	
C2−C3	 1.527(7)	
C2−H2A	 0.9900	
C2−H2B	 0.9900	
C3−S1	 1.817(5)	
C3−H3A	 0.9900	
C3−H3B	 0.9900	
C4−C5	 1.388(7)	
C4−C9	 1.395(7)	
C4−As1	 1.910(5)	
C5−C6	 1.388(7)	
C5−H5	 0.9500	
C6−C7	 1.376(7)	
C6−H6	 0.9500	
C7−C8	 1.382(7)	
C7−H7	 0.9500	
C8−C9	 1.393(7)	
C8−H8	 0.9500	
C9−H9	 0.9500	
C10−C11	 1.383(7)	
C10−C15	 1.395(7)	
C10−As1	 1.916(4)	
C11−C12	 1.391(7)	
C11−H11	 0.9500	
C12−C13	 1.393(7)	
C12−H12	 0.9500	
C13−C14	 1.375(7)	
C13−H13	 0.9500	
C14−C15	 1.394(7)	
C14−H14	 0.9500	
C15−H15	 0.9500	
C16−C17	 1.379(7)	
C16−C21	 1.396(7)	
C16−As1	 1.904(5)	
C17−C18	 1.385(7)	
C17−H17	 0.9500	
C18−C19	 1.387(7)	
C18−H18	 0.9500	
C19−C20	 1.386(8)	
C19−H19	 0.9500	
C20−C21	 1.380(7)	
C20−H20	 0.9500	
C21−H21	 0.9500	
O1−S2	 1.452(4)	
O2−S2	 1.443(4)	
O3−S2	 1.446(4)	
S1−S2	 2.1081(18)	
	
C2−C1−As1	 113.8(3)	
C2−C1−H1A	 108.8	
As1−C1−H1A	 108.8	
C2−C1−H1B	 108.8	
As1−C1−H1B	 108.8	
H1A−C1−H1B	 107.7	
C1−C2−C3	 109.9(4)	
C1−C2−H2A	 109.7	
C3−C2−H2A	 109.7	
C1−C2−H2B	 109.7	
C3−C2−H2B	 109.7	
H2A−C2−H2B	 108.2	
C2−C3−S1	 115.0(4)	
C2−C3−H3A	 108.5	
S1−C3−H3A	 108.5	
C2−C3−H3B	 108.5	
S1−C3−H3B	 108.5	
H3A−C3−H3B	 107.5	
C5−C4−C9	 121.9(5)	
C5−C4−As1	 120.9(4)	
C9−C4−As1	 117.3(4)	
C6−C5−C4	 118.4(5)	
C6−C5−H5	 120.8	
C4−C5−H5	 120.8	
C7−C6−C5	 120.4(5)	
C7−C6−H6	 119.8	
C5−C6−H6	 119.8	
C6−C7−C8	 121.0(5)	
C6−C7−H7	 119.5	
C8−C7−H7	 119.5	
C7−C8−C9	 120.0(5)	
C7−C8−H8	 120.0	
C9−C8−H8	 120.0	
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C8−C9−C4	 118.3(5)	
C8−C9−H9	 120.8	
C4−C9−H9	 120.8	
C11−C10−C15	 122.0(4)	
C11−C10−As1	 120.5(4)	
C15−C10−As1	 117.5(4)	
C10−C11−C12	 118.8(5)	
C10−C11−H11	 120.6	
C12−C11−H11	 120.6	
C11−C12−C13	 120.0(5)	
C11−C12−H12	 120.0	
C13−C12−H12	 120.0	
C14−C13−C12	 120.5(5)	
C14−C13−H13	 119.8	
C12−C13−H13	 119.8	
C13−C14−C15	 120.6(5)	
C13−C14−H14	 119.7	
C15−C14−H14	 119.7	
C14−C15−C10	 118.2(5)	
C14−C15−H15	 120.9	
C10−C15−H15	 120.9	
C17−C16−C21	 121.0(5)	
C17−C16−As1	 120.3(4)	
C21−C16−As1	 118.6(4)	
C16−C17−C18	 119.9(5)	
C16−C17−H17	 120.1	
C18−C17−H17	 120.1	
C17−C18−C19	 119.3(5)	
C17−C18−H18	 120.4	
C19−C18−H18	 120.4	
C20−C19−C18	 120.7(5)	
C20−C19−H19	 119.6	
C18−C19−H19	 119.6	
C21−C20−C19	 120.2(5)	
C21−C20−H20	 119.9	
C19−C20−H20	 119.9	
C20−C21−C16	 118.9(5)	
C20−C21−H21	 120.6	
C16−C21−H21	 120.6	
C3−S1−S2	 99.84(17)	
O2−S2−O3	 114.6(2)	
O2−S2−O1	 113.7(2)	
O3−S2−O1	 113.0(2)	
O2−S2−S1	 105.78(16)	
O3−S2−S1	 101.28(17)	
O1−S2−S1	 107.13(16)	
C16−As1−C4	 109.8(2)	
C16−As1−C10	 107.2(2)	
C4−As1−C10	 111.5(2)	
C16−As1−C1	 108.8(2)	
C4−As1−C1	 106.9(2)	
C10−As1−C1	 112.6(2)	
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Table	A1.4.	Anisotropic	displacement	parameters	[Å2×	103].	The	anisotropic	displacement	
factor	exponent	takes	the	form:	−2π	2[h2a*2U11	+	...	+	2	h	k	a*	b*	U12	].	
	
Atom	 U11	 U22	 U33	 U23	 U13	 U12	
	
C1	 18(3)		 16(2)	 17(2)		 −2(2)	 1(2)		 2(2)	
C2	 13(2)		 18(2)	 25(3)		 0(2)	 5(2)		 0(2)	
C3	 16(3)		 24(3)	 17(3)		 3(2)	 −2(2)		 −7(2)	
C4	 10(2)		 16(2)	 18(2)		 −1(2)	 1(2)		 2(2)	
C5	 21(3)		 21(2)	 17(3)		 −4(2)	 6(2)		 −6(2)	
C6	 26(3)		 25(3)	 19(3)		 3(2)	 5(2)		 −8(2)	
C7	 19(3)		 14(2)	 27(3)		 4(2)	 3(2)		 −2(2)	
C8	 20(3)		 17(2)	 26(3)		 −5(2)	 1(2)		 2(2)	
C9	 14(2)		 22(2)	 17(3)		 −2(2)	 0(2)		 4(2)	
C10	 11(2)		 15(2)	 18(2)		 2(2)	 1(2)		 3(2)	
C11	 19(3)		 19(2)	 21(3)		 0(2)	 8(2)		 4(2)	
C12	 22(3)		 22(3)	 21(3)		 1(2)	 6(2)		 0(2)	
C13	 17(3)		 19(2)	 19(3)		 0(2)	 −3(2)		 4(2)	
C14	 13(3)		 20(2)	 26(3)		 −6(2)	 2(2)		 0(2)	
C15	 15(2)		 16(2)	 18(3)		 −3(2)	 0(2)		 −1(2)	
C16	 16(3)		 23(2)	 16(2)		 −1(2)	 2(2)		 −1(2)	
C17	 16(3)		 19(2)	 23(3)		 −1(2)	 3(2)		 3(2)	
C18	 21(3)		 25(3)	 31(3)		 −11(2)	 8(2)		 0(2)	
C19	 13(3)		 39(3)	 21(3)		 −14(2)	 6(2)		 −6(2)	
C20	 18(3)		 41(3)	 16(3)		 4(2)	 4(2)		 1(2)	
C21	 16(3)		 25(3)	 24(3)		 −1(2)	 1(2)		 3(2)	
O1	 26(2)		 27(2)	 16(2)		 −1(2)	 10(2)		 2(2)	
O2	 21(2)		 29(2)	 22(2)		 1(2)	 6(2)		 −9(2)	
O3	 22(2)		 29(2)	 36(2)		 1(2)	 −5(2)		 13(2)	
S1	 18(1)		 24(1)	 26(1)		 −8(1)	 2(1)		 0(1)	
S2	 17(1)		 19(1)	 19(1)		 0(1)	 1(1)		 1(1)	
As1	 14(1)		 14(1)	 16(1)		 −1(1)	 2(1)		 1(1)	
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Table	A1.5.	Hydrogen	coordinates	[×	104]	and	isotropic	displacement	parameters	[Å2	×	
103].	
	
Atom		 x	 y	 z	 Ueq	 S.o.f.
	
	
H1A	 11303	 2079	 655	 21	 1	
H1B	 10602	 2438	 −600	 21	 1	
H2A	 11996	 3593	 1208	 23	 1	
H2B	 11217	 4001	 0	 23	 1	
H3A	 13188	 3825	 −74	 24	 1	
H3B	 12356	 3126	 −971	 24	 1	
H5	 8452	 1962	 2493	 23	 1	
H6	 7857	 456	 2839	 29	 1	
H7	 7946	 −749	 1597	 25	 1	
H8	 8570	 −482	 −35	 26	 1	
H9	 9189	 1017	 −403	 22	 1	
H11	 9106	 3570	 −1611	 23	 1	
H12	 7630	 4464	 −2885	 26	 1	
H13	 5926	 4915	 −2368	 24	 1	
H14	 5648	 4438	 −636	 25	 1	
H15	 7098	 3521	 642	 21	 1	
H17	 9058	 4721	 1399	 24	 1	
H18	 9711	 5623	 3066	 31	 1	
H19	 10941	 4952	 4734	 29	 1	
H20	 11406	 3373	 4785	 30	 1	
H21	 10800	 2480	 3112	 27	 1	
	
	169	
	
Table	A1.6.	Torsion	angles	[°].	
		
As1−C1−C2−C3	 −174.9(3)	
C1−C2−C3−S1	 −61.7(5)	
C9−C4−C5−C6	 1.9(7)	
As1−C4−C5−C6	 −177.9(4)	
C4−C5−C6−C7	 −0.6(8)	
C5−C6−C7−C8	 −1.0(8)	
C6−C7−C8−C9	 1.3(8)	
C7−C8−C9−C4	 0.0(7)	
C5−C4−C9−C8	 −1.7(7)	
As1−C4−C9−C8	 178.2(4)	
C15−C10−C11−C12	 1.3(7)	
As1−C10−C11−C12	 −176.7(4)	
C10−C11−C12−C13	 0.3(7)	
C11−C12−C13−C14	 −1.4(8)	
C12−C13−C14−C15	 0.8(7)	
C13−C14−C15−C10	 0.8(7)	
C11−C10−C15−C14	 −1.8(7)	
As1−C10−C15−C14	 176.2(3)	
C21−C16−C17−C18	 1.1(8)	
As1−C16−C17−C18	 −175.4(4)	
C16−C17−C18−C19	 0.1(8)	
C17−C18−C19−C20	 −2.2(8)	
C18−C19−C20−C21	 3.1(8)	
C19−C20−C21−C16	 −1.9(8)	
C17−C16−C21−C20	 −0.2(8)	
As1−C16−C21−C20	 176.3(4)	
C2−C3−S1−S2	 −86.9(3)	
C3−S1−S2−O2	 −52.7(2)	
C3−S1−S2−O3	 −172.6(3)	
C3−S1−S2−O1	 68.8(2)	
C17−C16−As1−C4	 −136.6(4)	
C21−C16−As1−C4	 46.8(5)	
C17−C16−As1−C10	 −15.3(5)	
C21−C16−As1−C10	 168.1(4)	
C17−C16−As1−C1	 106.7(4)	
C21−C16−As1−C1	 −69.9(5)	
C5−C4−As1−C16	 20.8(5)	
C9−C4−As1−C16	 −159.1(3)	
C5−C4−As1−C10	 −97.9(4)	
C9−C4−As1−C10	 82.2(4)	
C5−C4−As1−C1	 138.7(4)	
C9−C4−As1−C1	 −41.2(4)	
	170	
	
C11−C10−As1−C16	 121.6(4)	
C15−C10−As1−C16	 −56.5(4)	
C11−C10−As1−C4	 −118.1(4)	
C15−C10−As1−C4	 63.8(4)	
C11−C10−As1−C1	 2.0(5)	
C15−C10−As1−C1	 −176.1(3)	
C2−C1−As1−C16	 −39.1(4)	
C2−C1−As1−C4	 −157.7(3)	
C2−C1−As1−C10	 79.6(4)	
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Appendix	2.		
	
Crystal	data	and	structure	refinement	details	for	ω-thioacetylpropyl(triphenyl)aronium	
bromide.	Compound	3,	described	in	chapter	3A.	
	
	
Table	A2.1.	Crystal	data	and	structure	refinement	details.	
		
NCS	Identification	code		 2012ncs0291a					
Empirical	formula		 C23H24AsBrOS	
Formula	weight		 503.31	
Temperature		 120(2)	K	
Wavelength		 0.71075	Å	
Crystal	system		 Monoclinic	
Space	group		 P21/n		
Unit	cell	dimensions	 a	=	11.1700(3)	Å	 α	=	90°	
	 b	=	13.6075(4)	Å	 β	=	91.738(7)°	
	 c	=	14.4757(10)	Å	 γ		=	90°	
Volume	 2199.23(18)	Å3	
Z	 4	
Density	(calculated)	 1.520	Mg	/	m3	
Absorption	coefficient	 3.467	mm−1	
F(000)	 1016	
Crystal	 Block;	Colourless	
Crystal	size	 0.52	×	0.32	×	0.14	mm3	
θ	range	for	data	collection	 2.99	−	27.44°	
Index	ranges	 −14	≤	h	≤	13,	−16	≤	k	≤	17,	−18	≤	l	≤	18	
Reflections	collected	 13491	
Independent	reflections	 4973	[Rint	=	0.0274]	
Completeness	to	θ	=	27.44°	 99.0	%		
Absorption	correction	 Semi−empirical	from	equivalents	
Max.	and	min.	transmission	 0.6424	and	0.2658	
Refinement	method	 Full-matrix	least-squares	on	F2	
Data	/	restraints	/	parameters	 4973	/	0	/	245	
Goodness-of-fit	on	F2	 0.960	
Final	R	indices	[F2	>	2σ(F2)]	 R1	=	0.0267,	wR2	=	0.0530	
R	indices	(all	data)	 R1	=	0.0398,	wR2	=	0.0641	
Largest	diff.	peak	and	hole	 0.546	and	−0.505	e	Å−3	
		
Diffractometer: Rigaku R-Axis Spider including curved Fujifilm image plate and a graphite monochromated sealed tube 
Mo generator.  Cell determination and data collection: CrystalClear-SM Expert 2.0 r11 (Rigaku, 2011). Data reduction, 
cell refinement and absorption correction: CrystalClear-SM Expert 2.0 r13 (Rigaku, 2011). Structure solution: 
SUPERFLIP (Palatinus, L. & Chapuis, G. (2007). J. Appl. Cryst. 40, 786-790). Structure refinement: SHELXL97 
(Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122).  Graphics: OLEX2 (Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., 
Howard, J. A. K. & Puschmann, H. (2009). J. Appl. Cryst. 42, 339-341). 
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Table	A2.2.	Atomic	coordinates	[×	104],	equivalent	isotropic	displacement	parameters	[Å2	
×	103]	and	site	occupancy	factors.	Ueq	is	defined	as	one	third	of	the	trace	of	the	
orthogonalized	Uij	tensor.	
	
Atom		 x	 y	 z	 Ueq	 S.o.f.	
	
C1	 6685(2)	 1183(2)	 1381(2)	 18(1)	 1	
C2	 6645(3)	 501(2)	 549(2)	 24(1)	 1	
C3	 6381(3)	 1059(2)	 −354(2)	 26(1)	 1	
C4	 6847(3)	 3069(2)	 −447(2)	 26(1)	 1	
C5	 7651(3)	 3928(2)	 −628(2)	 39(1)	 1	
C6	 6981(2)	 1506(2)	 3484(2)	 16(1)	 1	
C7	 5994(2)	 2133(2)	 3503(2)	 19(1)	 1	
C8	 5974(2)	 2870(2)	 4165(2)	 21(1)	 1	
C9	 6916(2)	 2978(2)	 4801(2)	 20(1)	 1	
C10	 7891(2)	 2348(2)	 4784(2)	 20(1)	 1	
C11	 7929(2)	 1603(2)	 4130(2)	 19(1)	 1	
C12	 8626(2)	 −2(2)	 2526(2)	 18(1)	 1	
C13	 9481(2)	 422(2)	 1968(2)	 25(1)	 1	
C14	 10641(3)	 61(2)	 2014(2)	 32(1)	 1	
C15	 10944(3)	 −705(2)	 2597(2)	 33(1)	 1	
C16	 10093(3)	 −1132(2)	 3146(2)	 32(1)	 1	
C17	 8924(3)	 −779(2)	 3115(2)	 24(1)	 1	
C18	 5955(2)	 −514(2)	 2795(2)	 16(1)	 1	
C19	 5949(2)	 −1352(2)	 2246(2)	 21(1)	 1	
C20	 5105(3)	 −2080(2)	 2395(2)	 24(1)	 1	
C21	 4298(2)	 −1983(2)	 3100(2)	 26(1)	 1	
C22	 4332(2)	 −1158(2)	 3664(2)	 26(1)	 1	
C23	 5155(2)	 −416(2)	 3512(2)	 22(1)	 1	
As1	 7043(1)	 531(1)	 2538(1)	 15(1)	 1	
O1	 5828(2)	 3146(2)	 −207(2)	 37(1)	 1	
S1	 7546(1)	 1917(1)	 −639(1)	 30(1)	 1	
Br1	 3579(1)	 1232(1)	 1856(1)	 22(1)	 1	
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Table	A2.3.	Bond	lengths	[Å]	and	angles	[°].	
		
C1−C2	 1.521(3)	
C1−As1	 1.927(2)	
C1−H1A	 0.9900	
C1−H1B	 0.9900	
C2−C3	 1.533(4)	
C2−H2A	 0.9900	
C2−H2B	 0.9900	
C3−S1	 1.806(3)	
C3−H3A	 0.9900	
C3−H3B	 0.9900	
C4−O1	 1.204(3)	
C4−C5	 1.501(4)	
C4−S1	 1.777(3)	
C5−H5A	 0.9800	
C5−H5B	 0.9800	
C5−H5C	 0.9800	
C6−C11	 1.396(3)	
C6−C7	 1.396(4)	
C6−As1	 1.909(2)	
C7−C8	 1.387(4)	
C7−H7	 0.9500	
C8−C9	 1.385(4)	
C8−H8	 0.9500	
C9−C10	 1.387(4)	
C9−H9	 0.9500	
C10−C11	 1.388(4)	
C10−H10	 0.9500	
C11−H11	 0.9500	
C12−C17	 1.392(4)	
C12−C13	 1.394(4)	
C12−As1	 1.912(2)	
C13−C14	 1.385(4)	
C13−H13	 0.9500	
C14−C15	 1.378(4)	
C14−H14	 0.9500	
C15−C16	 1.385(5)	
C15−H15	 0.9500	
C16−C17	 1.390(4)	
C16−H16	 0.9500	
C17−H17	 0.9500	
C18−C19	 1.390(4)	
C18−C23	 1.396(4)	
C18−As1	 1.914(3)	
C19−C20	 1.389(4)	
C19−H19	 0.9500	
C20−C21	 1.388(4)	
C20−H20	 0.9500	
C21−C22	 1.388(4)	
C21−H21	 0.9500	
C22−C23	 1.388(4)	
C22−H22	 0.9500	
C23−H23	 0.9500	
	
C2−C1−As1	 114.06(18)	
C2−C1−H1A	 108.7	
As1−C1−H1A	 108.7	
C2−C1−H1B	 108.7	
As1−C1−H1B	 108.7	
H1A−C1−H1B	 107.6	
C1−C2−C3	 111.9(2)	
C1−C2−H2A	 109.2	
C3−C2−H2A	 109.2	
C1−C2−H2B	 109.2	
C3−C2−H2B	 109.2	
H2A−C2−H2B	 107.9	
C2−C3−S1	 113.17(19)	
C2−C3−H3A	 108.9	
S1−C3−H3A	 108.9	
C2−C3−H3B	 108.9	
S1−C3−H3B	 108.9	
H3A−C3−H3B	 107.8	
O1−C4−C5	 124.0(3)	
O1−C4−S1	 123.0(2)	
C5−C4−S1	 113.0(2)	
C4−C5−H5A	 109.5	
C4−C5−H5B	 109.5	
H5A−C5−H5B	 109.5	
C4−C5−H5C	 109.5	
H5A−C5−H5C	 109.5	
H5B−C5−H5C	 109.5	
C11−C6−C7	 120.8(2)	
C11−C6−As1	 120.18(19)	
	
	174	
	
C7−C6−As1	 118.98(18)	
C8−C7−C6	 119.0(2)	
C8−C7−H7	 120.5	
C6−C7−H7	 120.5	
C9−C8−C7	 120.5(2)	
C9−C8−H8	 119.7	
C7−C8−H8	 119.7	
C8−C9−C10	 120.2(2)	
C8−C9−H9	 119.9	
C10−C9−H9	 119.9	
C11−C10−C9	 120.3(2)	
C11−C10−H10	 119.9	
C9−C10−H10	 119.9	
C10−C11−C6	 119.2(2)	
C10−C11−H11	 120.4	
C6−C11−H11	 120.4	
C17−C12−C13	 120.9(2)	
C17−C12−As1	 119.1(2)	
C13−C12−As1	 119.9(2)	
C14−C13−C12	 118.8(3)	
C14−C13−H13	 120.6	
C12−C13−H13	 120.6	
C15−C14−C13	 120.6(3)	
C15−C14−H14	 119.7	
C13−C14−H14	 119.7	
C14−C15−C16	 120.6(3)	
C14−C15−H15	 119.7	
C16−C15−H15	 119.7	
C17−C16−C15	 119.8(3)	
C17−C16−H16	 120.1	
C15−C16−H16	 120.1	
C16−C17−C12	 119.3(3)	
C16−C17−H17	 120.4	
C12−C17−H17	 120.4	
C19−C18−C23	 120.8(2)	
C19−C18−As1	 119.36(19)	
C23−C18−As1	 119.84(19)	
C20−C19−C18	 119.2(2)	
C20−C19−H19	 120.4	
C18−C19−H19	 120.4	
C19−C20−C21	 120.4(3)	
C19−C20−H20	 119.8	
C21−C20−H20	 119.8	
C22−C21−C20	 120.1(3)	
C22−C21−H21	 119.9	
C20−C21−H21	 119.9	
C23−C22−C21	 120.1(3)	
C23−C22−H22	 119.9	
C21−C22−H22	 119.9	
C22−C23−C18	 119.4(2)	
C22−C23−H23	 120.3	
C18−C23−H23	 120.3	
C6−As1−C12	 108.90(10)	
C6−As1−C18	 109.88(10)	
C12−As1−C18	 108.21(11)	
C6−As1−C1	 107.02(11)	
C12−As1−C1	 109.52(11)	
C18−As1−C1	 113.24(10)	
C4−S1−C3	 102.23(14)	
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Table	A2.4.	Anisotropic	displacement	parameters	[Å2×	103].	The	anisotropic	displacement	
factor	exponent	takes	the	form:	−2π	2[h2a*2U11	+	...	+	2	h	k	a*	b*	U12	].	
	
Atom	 U11	 U22	 U33	 U23	 U13	 U12	
	
C1	 19(1)		 18(1)	 18(1)		 1(1)	 −1(1)		 2(1)	
C2	 30(1)		 19(1)	 21(1)		 −1(1)	 −4(1)		 −2(1)	
C3	 32(2)		 25(1)	 20(1)		 0(1)	 −4(1)		 −4(1)	
C4	 32(2)		 31(2)	 16(1)		 −3(1)	 1(1)		 −7(1)	
C5	 52(2)		 37(2)	 29(2)		 −1(1)	 6(1)		 −16(2)	
C6	 17(1)		 16(1)	 15(1)		 1(1)	 2(1)		 −5(1)	
C7	 16(1)		 21(1)	 21(1)		 1(1)	 −2(1)		 −1(1)	
C8	 19(1)		 19(1)	 25(1)		 −2(1)	 3(1)		 3(1)	
C9	 27(1)		 18(1)	 16(1)		 0(1)	 4(1)		 −4(1)	
C10	 21(1)		 23(1)	 16(1)		 2(1)	 −2(1)		 −4(1)	
C11	 18(1)		 20(1)	 19(1)		 4(1)	 −1(1)		 0(1)	
C12	 14(1)		 19(1)	 21(1)		 −4(1)	 −3(1)		 2(1)	
C13	 21(1)		 23(1)	 31(1)		 −3(1)	 1(1)		 −1(1)	
C14	 19(1)		 38(2)	 40(2)		 −9(1)	 6(1)		 −3(1)	
C15	 18(1)		 43(2)	 37(2)		 −13(1)	 −6(1)		 10(1)	
C16	 33(2)		 35(2)	 28(1)		 −2(1)	 −10(1)		 14(1)	
C17	 25(1)		 24(1)	 24(1)		 1(1)	 −1(1)		 4(1)	
C18	 16(1)		 15(1)	 18(1)		 2(1)	 −1(1)		 2(1)	
C19	 25(1)		 20(1)	 19(1)		 1(1)	 1(1)		 −2(1)	
C20	 32(2)		 18(1)	 22(1)		 0(1)	 −1(1)		 −4(1)	
C21	 22(1)		 21(1)	 33(2)		 8(1)	 −1(1)		 −6(1)	
C22	 24(1)		 23(1)	 32(1)		 5(1)	 11(1)		 1(1)	
C23	 23(1)		 18(1)	 25(1)		 0(1)	 2(1)		 1(1)	
As1	 14(1)		 14(1)	 16(1)		 0(1)	 1(1)		 0(1)	
O1	 32(1)		 33(1)	 48(1)		 −9(1)	 11(1)		 −2(1)	
S1	 27(1)		 34(1)	 29(1)		 5(1)	 10(1)		 1(1)	
Br1	 19(1)		 25(1)	 23(1)		 3(1)	 −4(1)		 −2(1)	
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Table	A2.	5.	Hydrogen	coordinates	[×	104]	and	isotropic	displacement	parameters	[Å2	×	
103].	
	
Atom		 x	 y	 z	 Ueq	 S.o.f.
	
	
H1A	 5900	 1516	 1420	 22	 1	
H1B	 7297	 1696	 1284	 22	 1	
H2A	 6019	 −4	 633	 28	 1	
H2B	 7425	 159	 508	 28	 1	
H3A	 5617	 1421	 −301	 31	 1	
H3B	 6277	 579	 −864	 31	 1	
H5A	 7236	 4540	 −480	 59	 1	
H5B	 7859	 3932	 −1281	 59	 1	
H5C	 8384	 3872	 −241	 59	 1	
H7	 5345	 2057	 3069	 23	 1	
H8	 5308	 3303	 4183	 25	 1	
H9	 6895	 3486	 5250	 24	 1	
H10	 8535	 2426	 5221	 24	 1	
H11	 8591	 1166	 4121	 22	 1	
H13	 9272	 948	 1564	 30	 1	
H14	 11233	 345	 1639	 38	 1	
H15	 11744	 −943	 2623	 40	 1	
H16	 10307	 −1665	 3542	 38	 1	
H17	 8336	 −1065	 3492	 29	 1	
H19	 6516	 −1426	 1774	 26	 1	
H20	 5079	 −2647	 2013	 28	 1	
H21	 3721	 −2483	 3197	 31	 1	
H22	 3792	 −1101	 4155	 31	 1	
H23	 5174	 154	 3891	 26	 1	
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Table	A2.6.	Torsion	angles	[°].	
		
As1−C1−C2−C3	 −178.94(19)	
C1−C2−C3−S1	 64.7(3)	
C11−C6−C7−C8	 1.1(4)	
As1−C6−C7−C8	 −177.16(19)	
C6−C7−C8−C9	 −0.3(4)	
C7−C8−C9−C10	 −0.2(4)	
C8−C9−C10−C11	 −0.1(4)	
C9−C10−C11−C6	 0.8(4)	
C7−C6−C11−C10	 −1.3(4)	
As1−C6−C11−C10	 176.91(19)	
C17−C12−C13−C14	 −0.4(4)	
As1−C12−C13−C14	 176.0(2)	
C12−C13−C14−C15	 0.3(4)	
C13−C14−C15−C16	 0.3(5)	
C14−C15−C16−C17	 −0.6(5)	
C15−C16−C17−C12	 0.4(4)	
C13−C12−C17−C16	 0.1(4)	
As1−C12−C17−C16	 −176.4(2)	
C23−C18−C19−C20	 2.4(4)	
As1−C18−C19−C20	 −175.73(19)	
C18−C19−C20−C21	 −1.7(4)	
C19−C20−C21−C22	 −0.2(4)	
C20−C21−C22−C23	 1.5(4)	
C21−C22−C23−C18	 −0.8(4)	
C19−C18−C23−C22	 −1.2(4)	
As1−C18−C23−C22	 177.0(2)	
C11−C6−As1−C12	 −11.0(2)	
C7−C6−As1−C12	 167.21(19)	
C11−C6−As1−C18	 107.3(2)	
C7−C6−As1−C18	 −74.4(2)	
C11−C6−As1−C1	 −129.3(2)	
C7−C6−As1−C1	 48.9(2)	
C17−C12−As1−C6	 86.1(2)	
C13−C12−As1−C6	 −90.5(2)	
C17−C12−As1−C18	 −33.3(2)	
C13−C12−As1−C18	 150.1(2)	
C17−C12−As1−C1	 −157.2(2)	
C13−C12−As1−C1	 26.3(2)	
C19−C18−As1−C6	 −173.19(19)	
C23−C18−As1−C6	 8.6(2)	
C19−C18−As1−C12	 −54.4(2)	
C23−C18−As1−C12	 127.4(2)	
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C19−C18−As1−C1	 67.2(2)	
C23−C18−As1−C1	 −111.0(2)	
C2−C1−As1−C6	 −177.66(18)	
C2−C1−As1−C12	 64.4(2)	
C2−C1−As1−C18	 −56.4(2)	
O1−C4−S1−C3	 −1.6(3)	
C5−C4−S1−C3	 179.3(2)	
C2−C3−S1−C4	 −109.1(2)	
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Appendix	3.		
	
Crystal	data	and	structure	refinement	details	for	tri(2,4,6-trimethoxyphenyl)	
phosphoniopropylthiosulfate	zwitterion.	Compound	5,	described	in	chapter	3B.	
	
Table	A3.1.		Crystal	data	and	structure	refinement.	
		
Identification	code		 2013ncs0299	/	NL2					
Empirical	formula		 C32H44O12.50PS2	
Formula	weight		 723.76	
Temperature		 120(2)	K	
Wavelength		 0.71075	Å	
Crystal	system		 Triclinic	
Space	group		 P−1		
Unit	cell	dimensions	 a	=	12.2838(5)	Å	 α	=	72.355(5)°	
	 b	=	15.5187(8)	Å	 β	=	85.430(6)°	
	 c	=	19.4586(13)	Å	 γ		=	84.513(6)°	
Volume	 3513.6(3)	Å3	
Z	 4	
Density	(calculated)	 1.368	Mg	/	m3	
Absorption	coefficient	 0.259	mm−1	
F(000)	 1532	
Crystal	 Prism;	Colourless	
Crystal	size	 0.800	×	0.200	×	0.100	mm3	
θ	range	for	data	collection	 2.988	−	27.449°	
Index	ranges	 −15	≤	h	≤	13,	−20	≤	k	≤	20,	−25	≤	l	≤	25	
Reflections	collected	 52696	
Independent	reflections	 15872	[Rint	=	0.0682]	
Completeness	to	θ	=	25.242°	 99.3	%		
Absorption	correction	 Semi−empirical	from	equivalents	
Max.	and	min.	transmission	 1.000	and	0.730	
Refinement	method	 Full-matrix	least-squares	on	F2	
Data	/	restraints	/	parameters	 15872	/	1937	/	1145	
Goodness-of-fit	on	F2	 1.080	
Final	R	indices	[F2	>	2σ(F2)]	 R1	=	0.0956,	wR2	=	0.2678	
R	indices	(all	data)	 R1	=	0.1771,	wR2	=	0.3340	
Extinction	coefficient	 n/a	
Largest	diff.	peak	and	hole	 0.916	and	−0.640	e	Å−3	
	Diffractometer: Rigaku AFC12 goniometer equipped with an enhanced sensitivity (HG) Saturn724+ detector mounted at the window of 
an FR-E+ SuperBright molybdenum rotating anode generator with HF Varimax optics (100µm focus). Cell determination and data 
collection: CrystalClear-SM Expert 2.0 r13 (Rigaku, 2011). Data reduction, cell refinement and absorption correction: CrystalClear-
SM Expert 3.1 b25 (Rigaku, 2012). Structure solution: SHELXS97 (G Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122.) Structure 
refinement: SHELXL-2012 (Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122). Graphics: ORTEP3 for Windows (L. J. Farrugia, J. 
Appl. Crystallogr. 1997, 30, 565 
97, 30, 565 
 
Special details:		
	
There	is	disorder	in	the	molecules,	for	which	various	geometrical	(SAME		and	SADI)	anisotropic	displacement	(DELU	and	SIMU)	restraints	were	used.	
	180	
	
	Table	A3.2.	Atomic	coordinates	[×	104],	equivalent	isotropic	displacement	parameters	[Å2	
×	103]	and	site	occupancy	factors.	Ueq	is	defined	as	one	third	of	the	trace	of	the	
orthogonalized	Uij	tensor.	
	
Atom		 x	 y	 z	 Ueq	 S.o.f.	
	
	
C1	 7762(12)	 4732(12)	 8013(5)	 55(2)	 0.490(10)	
C2	 7420(10)	 5251(9)	 8471(6)	 65(3)	 0.490(10)	
C3	 7928(10)	 5098(8)	 9115(5)	 78(3)	 0.490(10)	
C4	 8778(10)	 4426(8)	 9301(5)	 91(3)	 0.490(10)	
C5	 9121(10)	 3907(8)	 8842(5)	 80(3)	 0.490(10)	
C6	 8612(12)	 4060(10)	 8198(5)	 62(3)	 0.490(10)	
C7	 6030(20)	 6330(20)	 8709(17)	 105(8)	 0.490(10)	
C8	 8780(20)	 4764(17)	 10442(11)	 176(8)	 0.490(10)	
C9	 9720(30)	 2814(18)	 7975(14)	 94(7)	 0.490(10)	
C11	 7265(3)	 6284(3)	 6703(2)	 51(1)	 1	
C12	 6448(4)	 7019(3)	 6598(2)	 54(1)	 1	
C13	 6684(4)	 7889(3)	 6229(2)	 60(1)	 1	
C14	 7729(4)	 8072(3)	 5969(2)	 62(1)	 1	
C15	 8579(4)	 7400(3)	 6066(3)	 71(1)	 1	
C16	 8331(4)	 6512(3)	 6437(3)	 64(1)	 1	
C17	 4552(5)	 7516(4)	 6769(4)	 93(2)	 1	
C18	 8963(5)	 9247(4)	 5503(3)	 82(2)	 1	
C19	 10269(7)	 5973(9)	 6492(10)	 65(4)	 0.47(2)	
C21	 5655(4)	 4901(3)	 7219(3)	 60(1)	 1	
C22	 5068(4)	 4455(3)	 7864(3)	 77(1)	 1	
C23	 3930(5)	 4390(4)	 7865(4)	 97(2)	 1	
C24	 3407(5)	 4773(4)	 7225(5)	 101(2)	 1	
C25	 3952(4)	 5169(4)	 6587(4)	 85(2)	 1	
C26	 5075(4)	 5230(3)	 6588(3)	 66(1)	 1	
C27	 5097(8)	 3737(6)	 9140(4)	 149(4)	 1	
C28	 1756(14)	 4361(16)	 8017(16)	 123(7)	 0.52(3)	
C29	 5140(6)	 6141(5)	 5357(4)	 103(2)	 1	
C31	 7704(6)	 4410(3)	 6604(3)	 53(2)	 0.862(4)	
C32	 7278(5)	 3468(4)	 6813(3)	 64(2)	 0.862(4)	
C33	 7824(6)	 2867(4)	 6370(3)	 72(2)	 0.862(4)	
P1	 7081(1)	 5106(1)	 7149(1)	 50(1)	 1	
O1	 6574(17)	 5868(15)	 8232(11)	 67(3)	 0.490(10)	
O2	 9254(11)	 4279(8)	 9941(5)	 113(3)	 0.490(10)	
O3	 8950(20)	 3581(16)	 7735(10)	 71(4)	 0.490(10)	
O11	 5425(3)	 6801(2)	 6884(2)	 69(1)	 1	
O12	 7873(3)	 8970(2)	 5627(2)	 74(1)	 1	
O13	 9099(3)	 5795(2)	 6579(2)	 81(1)	 1	
O21	 5663(4)	 4080(3)	 8456(2)	 92(1)	 1	
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O22	 2281(9)	 4718(19)	 7309(14)	 118(5)	 0.52(3)	
O23	 5682(3)	 5601(3)	 5976(2)	 74(1)	 1	
O31	 9194(4)	 2190(6)	 5075(3)	 107(2)	 0.862(4)	
O32	 7564(5)	 1514(4)	 5451(3)	 108(2)	 0.862(4)	
O33	 7693(4)	 2687(3)	 4287(2)	 84(1)	 0.862(4)	
S1	 8026(2)	 2321(1)	 5004(1)	 62(1)	 0.862(4)	
S2	 7466(2)	 3363(1)	 5421(1)	 125(1)	 0.862(4)	
C101	 7642(12)	 4857(11)	 8028(4)	 58(3)	 0.510(10)	
C102	 7098(10)	 5334(9)	 8469(5)	 65(3)	 0.510(10)	
C103	 7355(9)	 5124(7)	 9187(5)	 79(3)	 0.510(10)	
C104	 8156(10)	 4437(8)	 9464(4)	 85(3)	 0.510(10)	
C105	 8701(9)	 3960(8)	 9022(5)	 77(3)	 0.510(10)	
C106	 8444(11)	 4170(10)	 8304(5)	 59(2)	 0.510(10)	
C107	 5609(17)	 6377(19)	 8629(15)	 77(5)	 0.510(10)	
C108	 7696(18)	 4492(14)	 10667(7)	 152(8)	 0.510(10)	
C109	 9520(20)	 2849(15)	 8204(12)	 84(5)	 0.510(10)	
O101	 6321(18)	 5979(16)	 8176(11)	 74(3)	 0.510(10)	
O102	 8365(11)	 4105(7)	 10164(4)	 110(3)	 0.510(10)	
O103	 8960(20)	 3711(14)	 7871(9)	 65(3)	 0.510(10)	
C119	 10071(11)	 5881(9)	 6035(10)	 87(6)	 0.53(2)	
C128	 1607(14)	 4282(15)	 7577(19)	 112(7)	 0.48(3)	
O122	 2341(11)	 4780(20)	 6999(14)	 113(5)	 0.48(3)	
C131	 7710(40)	 4680(20)	 6440(20)	 61(4)	 0.138(4)	
C132	 7320(30)	 3754(18)	 6500(20)	 72(5)	 0.138(4)	
C133	 7960(30)	 3317(16)	 5962(18)	 87(4)	 0.138(4)	
O131	 9040(19)	 2230(30)	 4940(20)	 141(11)	 0.138(4)	
O132	 7940(30)	 1041(14)	 5211(16)	 128(8)	 0.138(4)	
O133	 7140(30)	 2540(20)	 4636(12)	 119(8)	 0.138(4)	
S101	 7926(16)	 1999(12)	 5108(9)	 101(5)	 0.138(4)	
S102	 7389(12)	 2216(8)	 6076(7)	 108(4)	 0.138(4)	
C41	 7544(3)	 8863(3)	 2879(2)	 51(1)	 1	
C42	 8528(4)	 8744(3)	 3217(2)	 58(1)	 1	
C43	 8866(4)	 7920(3)	 3718(2)	 63(1)	 1	
C44	 8228(5)	 7193(3)	 3848(3)	 70(1)	 1	
C45	 7271(5)	 7251(3)	 3508(3)	 69(1)	 1	
C46	 6934(4)	 8087(3)	 3022(2)	 58(1)	 1	
C47	 10169(4)	 9375(4)	 3365(4)	 89(2)	 1	
C48	 8205(9)	 5663(7)	 4541(6)	 85(3)	 0.575(11)	
C49	 5202(5)	 7576(4)	 2899(4)	 96(2)	 1	
C51	 7742(4)	 10850(3)	 2151(2)	 53(1)	 1	
C52	 8280(4)	 11398(3)	 1520(2)	 60(1)	 1	
C53	 8823(4)	 12130(3)	 1532(3)	 67(1)	 1	
C54	 8838(4)	 12338(3)	 2162(3)	 63(1)	 1	
C55	 8308(4)	 11848(3)	 2800(3)	 60(1)	 1	
C56	 7774(4)	 11109(3)	 2782(2)	 54(1)	 1	
C57	 8645(6)	 11741(5)	 237(3)	 107(2)	 1	
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C58	 10072(8)	 13539(6)	 1638(5)	 90(3)	 0.680(11)	
C59	 7423(5)	 10575(4)	 4073(2)	 74(1)	 1	
C61	 5586(3)	 10192(3)	 2472(2)	 52(1)	 1	
C62	 5007(4)	 9812(3)	 3143(2)	 53(1)	 1	
C63	 3884(4)	 10054(3)	 3237(3)	 61(1)	 1	
C64	 3367(4)	 10690(4)	 2670(3)	 66(1)	 1	
C65	 3911(4)	 11112(3)	 2022(3)	 64(1)	 1	
C66	 5021(4)	 10847(3)	 1940(2)	 56(1)	 1	
C67	 5081(5)	 8909(4)	 4384(3)	 84(2)	 1	
C68	 1756(5)	 11663(5)	 2316(4)	 108(2)	 1	
C69	 5162(6)	 11662(6)	 678(3)	 120(3)	 1	
C71	 7030(20)	 9630(30)	 1384(13)	 62(3)	 0.503(5)	
C72	 8070(17)	 9062(17)	 1242(9)	 69(3)	 0.503(5)	
C73	 8335(11)	 9178(10)	 447(8)	 91(3)	 0.503(5)	
P41	 6991(1)	 9889(1)	 2242(1)	 52(1)	 1	
O41	 9136(3)	 9474(2)	 3044(2)	 67(1)	 1	
O42	 8787(8)	 6457(5)	 4330(5)	 76(3)	 0.575(11)	
O43	 6018(3)	 8217(2)	 2651(2)	 67(1)	 1	
O51	 8253(3)	 11136(2)	 914(2)	 80(1)	 1	
O52	 9385(3)	 13054(2)	 2193(3)	 90(1)	 1	
O53	 7203(3)	 10583(2)	 3360(2)	 59(1)	 1	
O61	 5586(3)	 9228(2)	 3676(2)	 61(1)	 1	
O62	 2281(3)	 10877(3)	 2814(2)	 87(1)	 1	
O63	 5643(3)	 11238(2)	 1329(2)	 72(1)	 1	
O71	 7104(8)	 7105(7)	 −227(6)	 101(3)	 0.503(5)	
O72	 8907(8)	 7456(8)	 −183(7)	 119(4)	 0.503(5)	
O73	 7865(9)	 6944(7)	 908(4)	 127(4)	 0.503(5)	
S41	 7858(8)	 7406(5)	 154(4)	 86(2)	 0.503(5)	
S42	 7237(3)	 8759(3)	 37(2)	 108(2)	 0.503(5)	
C171	 7020(20)	 9580(30)	 1414(13)	 59(3)	 0.497(5)	
C172	 8130(18)	 9102(17)	 1263(10)	 73(3)	 0.497(5)	
C173	 8129(11)	 8855(11)	 567(9)	 88(3)	 0.497(5)	
O171	 7901(9)	 7815(7)	 −703(4)	 118(3)	 0.497(5)	
O172	 7229(9)	 6535(8)	 174(6)	 124(4)	 0.497(5)	
O173	 8966(7)	 7060(7)	 286(6)	 104(3)	 0.497(5)	
S141	 7893(8)	 7242(5)	 26(4)	 75(2)	 0.497(5)	
S142	 7072(3)	 8014(3)	 646(2)	 105(2)	 0.497(5)	
O142	 8257(9)	 6299(7)	 4305(7)	 71(3)	 0.425(11)	
C148	 9221(10)	 6135(9)	 4721(7)	 67(4)	 0.425(11)	
C158	 9292(16)	 13415(12)	 2736(8)	 91(6)	 0.320(11)	
C301	 2032(8)	 9557(9)	 1597(6)	 179(4)	 1	
C302	 882(6)	 9795(6)	 1451(4)	 115(2)	 1	
C303	 3177(9)	 8425(8)	 1274(6)	 180(4)	 1	
C304	 4009(11)	 9066(9)	 1043(8)	 232(6)	 1	
O301	 2270(7)	 9021(6)	 1146(5)	 198(3)	 1	
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	Table	A3.3.	Bond	lengths	[Å]	and	angles	[°].	
		
	
C1−C2	 1.3900	
C1−C6	 1.3900	
C1−P1	 1.844(6)	
C2−O1	 1.353(10)	
C2−C3	 1.3900	
C3−C4	 1.3900	
C3−H3	 0.9500	
C4−O2	 1.366(8)	
C4−C5	 1.3900	
C5−C6	 1.3900	
C5−H5	 0.9500	
C6−O3	 1.352(10)	
C7−O1	 1.425(12)	
C7−H7A	 0.9800	
C7−H7B	 0.9800	
C7−H7C	 0.9800	
C8−O2	 1.457(13)	
C8−H8A	 0.9800	
C8−H8B	 0.9800	
C8−H8C	 0.9800	
C9−O3	 1.431(12)	
C9−H9A	 0.9800	
C9−H9B	 0.9800	
C9−H9C	 0.9800	
C11−C16	 1.405(6)	
C11−C12	 1.423(6)	
C11−P1	 1.798(4)	
C12−O11	 1.365(5)	
C12−C13	 1.370(6)	
C13−C14	 1.364(6)	
C13−H13	 0.9500	
C14−O12	 1.372(5)	
C14−C15	 1.386(6)	
C15−C16	 1.399(6)	
C15−H15	 0.9500	
C16−O13	 1.363(5)	
C17−O11	 1.447(6)	
C17−H17A	 0.9800	
C17−H17B	 0.9800	
C17−H17C	 0.9800	
C18−O12	 1.424(6)	
C18−H18A	 0.9800	
C18−H18B	 0.9800	
C18−H18C	 0.9800	
C19−O13	 1.476(9)	
C19−H19A	 0.9800	
C19−H19B	 0.9800	
C19−H19C	 0.9800	
C21−C26	 1.403(7)	
C21−C22	 1.413(7)	
C21−P1	 1.798(5)	
C22−O21	 1.359(7)	
C22−C23	 1.411(8)	
C23−C24	 1.387(9)	
C23−H23	 0.9500	
C24−C25	 1.361(9)	
C24−O22	 1.388(11)	
C24−O122	 1.410(12)	
C25−C26	 1.392(7)	
C25−H25	 0.9500	
C26−O23	 1.352(6)	
C27−O21	 1.425(7)	
C27−H27A	 0.9800	
C27−H27B	 0.9800	
C27−H27C	 0.9800	
C28−O22	 1.443(13)	
C28−H28A	 0.9800	
C28−H28B	 0.9800	
C28−H28C	 0.9800	
C29−O23	 1.417(6)	
C29−H29A	 0.9800	
C29−H29B	 0.9800	
C29−H29C	 0.9800	
C31−C32	 1.526(7)	
C31−P1	 1.811(5)	
C31−H31A	 0.9900	
C31−H31B	 0.9900	
C32−C33	 1.529(7)	
C32−H32A	 0.9900	
C32−H32B	 0.9900	
C33−S2	 1.843(6)	
C33−H33A	 0.9900	
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C33−H33B	 0.9900	
P1−C131	 1.801(15)	
P1−C101	 1.812(6)	
O13−C119	 1.519(10)	
O31−S1	 1.441(5)	
O32−S1	 1.430(5)	
O33−S1	 1.416(4)	
S1−S2	 2.059(3)	
C101−C102	 1.3900	
C101−C106	 1.3900	
C102−O101	 1.340(9)	
C102−C103	 1.3900	
C103−C104	 1.3900	
C103−H103	 0.9500	
C104−O102	 1.339(8)	
C104−C105	 1.3900	
C105−C106	 1.3900	
C105−H105	 0.9500	
C106−O103	 1.347(11)	
C107−O101	 1.424(12)	
C107−H10A	 0.9800	
C107−H10B	 0.9800	
C107−H10C	 0.9800	
C108−O102	 1.459(12)	
C108−H10D	 0.9800	
C108−H10E	 0.9800	
C108−H10F	 0.9800	
C109−O103	 1.432(12)	
C109−H10G	 0.9800	
C109−H10H	 0.9800	
C109−H10I	 0.9800	
C119−H11A	 0.9800	
C119−H11B	 0.9800	
C119−H11C	 0.9800	
C128−O122	 1.457(13)	
C128−H12A	 0.9800	
C128−H12B	 0.9800	
C128−H12C	 0.9800	
C131−C132	 1.528(12)	
C131−H13A	 0.9900	
C131−H13B	 0.9900	
C132−C133	 1.536(12)	
C132−H13C	 0.9900	
C132−H13D	 0.9900	
C133−S102	 1.851(10)	
C133−H13E	 0.9900	
C133−H13F	 0.9900	
O131−S101	 1.434(10)	
O132−S101	 1.438(10)	
O133−S101	 1.414(10)	
S101−S102	 2.059(9)	
C41−C42	 1.392(6)	
C41−C46	 1.423(6)	
C41−P41	 1.807(4)	
C42−O41	 1.359(5)	
C42−C43	 1.402(6)	
C43−C44	 1.383(7)	
C43−H43	 0.9500	
C44−C45	 1.377(7)	
C44−O42	 1.400(8)	
C44−O142	 1.402(10)	
C45−C46	 1.402(6)	
C45−H45	 0.9500	
C46−O43	 1.350(5)	
C47−O41	 1.433(5)	
C47−H47A	 0.9800	
C47−H47B	 0.9800	
C47−H47C	 0.9800	
C48−O42	 1.419(11)	
C48−H48A	 0.9800	
C48−H48B	 0.9800	
C48−H48C	 0.9800	
C49−O43	 1.432(6)	
C49−H49A	 0.9800	
C49−H49B	 0.9800	
C49−H49C	 0.9800	
C51−C56	 1.407(6)	
C51−C52	 1.419(6)	
C51−P41	 1.785(5)	
C52−O51	 1.363(6)	
C52−C53	 1.378(6)	
C53−C54	 1.361(7)	
C53−H53	 0.9500	
C54−O52	 1.372(6)	
C54−C55	 1.391(6)	
C55−C56	 1.385(6)	
C55−H55	 0.9500	
C56−O53	 1.360(5)	
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C57−O51	 1.443(6)	
C57−H57A	 0.9800	
C57−H57B	 0.9800	
C57−H57C	 0.9800	
C58−O52	 1.388(8)	
C58−H58A	 0.9800	
C58−H58B	 0.9800	
C58−H58C	 0.9800	
C59−O53	 1.432(5)	
C59−H59A	 0.9800	
C59−H59B	 0.9800	
C59−H59C	 0.9800	
C61−C66	 1.389(6)	
C61−C62	 1.422(6)	
C61−P41	 1.802(4)	
C62−O61	 1.352(5)	
C62−C63	 1.407(6)	
C63−C64	 1.387(7)	
C63−H63	 0.9500	
C64−O62	 1.363(5)	
C64−C65	 1.384(7)	
C65−C66	 1.397(6)	
C65−H65	 0.9500	
C66−O63	 1.368(5)	
C67−O61	 1.426(6)	
C67−H67A	 0.9800	
C67−H67B	 0.9800	
C67−H67C	 0.9800	
C68−O62	 1.441(7)	
C68−H68A	 0.9800	
C68−H68B	 0.9800	
C68−H68C	 0.9800	
C69−O63	 1.390(6)	
C69−H69A	 0.9800	
C69−H69B	 0.9800	
C69−H69C	 0.9800	
C71−C72	 1.539(8)	
C71−P41	 1.830(10)	
C71−H71A	 0.9900	
C71−H71B	 0.9900	
C72−C73	 1.514(10)	
C72−H72A	 0.9900	
C72−H72B	 0.9900	
C73−S42	 1.879(10)	
C73−H73A	 0.9900	
C73−H73B	 0.9900	
P41−C171	 1.814(11)	
O52−C158	 1.332(13)	
O71−S41	 1.424(9)	
O72−S41	 1.397(11)	
O73−S41	 1.425(9)	
S41−S42	 2.116(6)	
C171−C172	 1.542(9)	
C171−H17D	 0.9900	
C171−H17E	 0.9900	
C172−C173	 1.515(10)	
C172−H17F	 0.9900	
C172−H17G	 0.9900	
C173−S142	 1.893(10)	
C173−H17H	 0.9900	
C173−H17I	 0.9900	
O171−S141	 1.429(9)	
O172−S141	 1.377(12)	
O173−S141	 1.421(9)	
S141−S142	 2.087(6)	
O142−C148	 1.447(11)	
C148−H14A	 0.9800	
C148−H14B	 0.9800	
C148−H14C	 0.9800	
C158−H15A	 0.9800	
C158−H15B	 0.9800	
C158−H15C	 0.9800	
C301−O301	 1.379(8)	
C301−C302	 1.454(8)	
C301−H30A	 0.9900	
C301−H30B	 0.9900	
C302−H30C	 0.9800	
C302−H30D	 0.9800	
C302−H30E	 0.9800	
C303−O301	 1.367(8)	
C303−C304	 1.445(9)	
C303−H30F	 0.9900	
C303−H30G	 0.9900	
C304−H30H	 0.9800	
C304−H30I	 0.9800	
C304−H30J	 0.9800	
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C2−C1−C6	 120.0	
C2−C1−P1	 113.6(6)	
C6−C1−P1	 126.2(6)	
O1−C2−C3	 126.1(9)	
O1−C2−C1	 113.9(9)	
C3−C2−C1	 120.0	
C2−C3−C4	 120.0	
C2−C3−H3	 120.0	
C4−C3−H3	 120.0	
O2−C4−C3	 118.9(8)	
O2−C4−C5	 121.1(8)	
C3−C4−C5	 120.0	
C6−C5−C4	 120.0	
C6−C5−H5	 120.0	
C4−C5−H5	 120.0	
O3−C6−C5	 120.9(9)	
O3−C6−C1	 119.0(9)	
C5−C6−C1	 120.0	
O1−C7−H7A	 109.5	
O1−C7−H7B	 109.5	
H7A−C7−H7B	 109.5	
O1−C7−H7C	 109.5	
H7A−C7−H7C	 109.5	
H7B−C7−H7C	 109.5	
O2−C8−H8A	 109.5	
O2−C8−H8B	 109.5	
H8A−C8−H8B	 109.5	
O2−C8−H8C	 109.5	
H8A−C8−H8C	 109.5	
H8B−C8−H8C	 109.5	
O3−C9−H9A	 109.5	
O3−C9−H9B	 109.5	
H9A−C9−H9B	 109.5	
O3−C9−H9C	 109.5	
H9A−C9−H9C	 109.5	
H9B−C9−H9C	 109.5	
C16−C11−C12	 116.0(4)	
C16−C11−P1	 117.0(3)	
C12−C11−P1	 127.0(3)	
O11−C12−C13	 122.6(4)	
O11−C12−C11	 115.8(4)	
C13−C12−C11	 121.6(4)	
C14−C13−C12	 120.1(4)	
C14−C13−H13	 119.9	
C12−C13−H13	 119.9	
C13−C14−O12	 115.0(4)	
C13−C14−C15	 122.0(4)	
O12−C14−C15	 123.0(5)	
C14−C15−C16	 117.6(4)	
C14−C15−H15	 121.2	
C16−C15−H15	 121.2	
O13−C16−C15	 123.0(4)	
O13−C16−C11	 114.2(4)	
C15−C16−C11	 122.7(4)	
O11−C17−H17A	 109.5	
O11−C17−H17B	 109.5	
H17A−C17−H17B	 109.5	
O11−C17−H17C	 109.5	
H17A−C17−H17C	 109.5	
H17B−C17−H17C	 109.5	
O12−C18−H18A	 109.5	
O12−C18−H18B	 109.5	
H18A−C18−H18B	 109.5	
O12−C18−H18C	 109.5	
H18A−C18−H18C	 109.5	
H18B−C18−H18C	 109.5	
O13−C19−H19A	 109.5	
O13−C19−H19B	 109.5	
H19A−C19−H19B	 109.5	
O13−C19−H19C	 109.5	
H19A−C19−H19C	 109.5	
H19B−C19−H19C	 109.5	
C26−C21−C22	 117.6(5)	
C26−C21−P1	 117.3(4)	
C22−C21−P1	 125.1(4)	
O21−C22−C23	 123.4(5)	
O21−C22−C21	 116.5(5)	
C23−C22−C21	 120.1(6)	
C24−C23−C22	 118.7(6)	
C24−C23−H23	 120.6	
C22−C23−H23	 120.6	
C25−C24−C23	 122.8(6)	
C25−C24−O22	 124.2(12)	
C23−C24−O22	 113.0(12)	
C25−C24−O122	 101.4(12)	
C23−C24−O122	 135.3(12)	
C24−C25−C26	 118.2(6)	
C24−C25−H25	 120.9	
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C26−C25−H25	 120.9	
O23−C26−C25	 122.0(5)	
O23−C26−C21	 115.6(4)	
C25−C26−C21	 122.4(5)	
O21−C27−H27A	 109.5	
O21−C27−H27B	 109.5	
H27A−C27−H27B	 109.5	
O21−C27−H27C	 109.5	
H27A−C27−H27C	 109.5	
H27B−C27−H27C	 109.5	
O22−C28−H28A	 109.5	
O22−C28−H28B	 109.5	
H28A−C28−H28B	 109.5	
O22−C28−H28C	 109.5	
H28A−C28−H28C	 109.5	
H28B−C28−H28C	 109.5	
O23−C29−H29A	 109.5	
O23−C29−H29B	 109.5	
H29A−C29−H29B	 109.5	
O23−C29−H29C	 109.5	
H29A−C29−H29C	 109.5	
H29B−C29−H29C	 109.5	
C32−C31−P1	 113.5(4)	
C32−C31−H31A	 108.9	
P1−C31−H31A	 108.9	
C32−C31−H31B	 108.9	
P1−C31−H31B	 108.9	
H31A−C31−H31B	 107.7	
C31−C32−C33	 113.8(5)	
C31−C32−H32A	 108.8	
C33−C32−H32A	 108.8	
C31−C32−H32B	 108.8	
C33−C32−H32B	 108.8	
H32A−C32−H32B	 107.7	
C32−C33−S2	 109.0(4)	
C32−C33−H33A	 109.9	
S2−C33−H33A	 109.9	
C32−C33−H33B	 109.9	
S2−C33−H33B	 109.9	
H33A−C33−H33B	 108.3	
C11−P1−C21	 110.4(2)	
C11−P1−C131	 96.9(10)	
C21−P1−C131	 107.0(16)	
C11−P1−C31	 110.6(2)	
C21−P1−C31	 103.7(3)	
C11−P1−C101	 105.8(6)	
C21−P1−C101	 112.0(6)	
C131−P1−C101	 123(2)	
C11−P1−C1	 110.1(6)	
C21−P1−C1	 114.8(6)	
C31−P1−C1	 107.0(4)	
C2−O1−C7	 118.9(13)	
C4−O2−C8	 118.9(12)	
C6−O3−C9	 118.2(14)	
C12−O11−C17	 118.2(4)	
C14−O12−C18	 118.1(4)	
C16−O13−C19	 119.0(6)	
C16−O13−C119	 115.4(6)	
C22−O21−C27	 118.6(6)	
C24−O22−C28	 120.6(13)	
C26−O23−C29	 118.8(5)	
O33−S1−O32	 118.3(3)	
O33−S1−O31	 115.1(4)	
O32−S1−O31	 107.4(4)	
O33−S1−S2	 100.5(2)	
O32−S1−S2	 107.8(3)	
O31−S1−S2	 107.0(3)	
C33−S2−S1	 100.81(19)	
C102−C101−C106	 120.0	
C102−C101−P1	 114.2(6)	
C106−C101−P1	 125.2(7)	
O101−C102−C103	 122.6(10)	
O101−C102−C101	 117.4(10)	
C103−C102−C101	 120.0	
C102−C103−C104	 120.0	
C102−C103−H103	 120.0	
C104−C103−H103	 120.0	
O102−C104−C105	 114.9(7)	
O102−C104−C103	 124.5(7)	
C105−C104−C103	 120.0	
C104−C105−C106	 120.0	
C104−C105−H105	 120.0	
C106−C105−H105	 120.0	
O103−C106−C105	 120.6(9)	
O103−C106−C101	 119.4(9)	
C105−C106−C101	 120.0	
O101−C107−H10A	 109.5	
O101−C107−H10B	 109.5	
	188	
	
H10A−C107−H10B	 109.5	
O101−C107−H10C	 109.5	
H10A−C107−H10C	 109.5	
H10B−C107−H10C	 109.5	
O102−C108−H10D	 109.5	
O102−C108−H10E	 109.5	
H10D−C108−H10E	 109.5	
O102−C108−H10F	 109.5	
H10D−C108−H10F	 109.5	
H10E−C108−H10F	 109.5	
O103−C109−H10G	 109.5	
O103−C109−H10H	 109.5	
H10G−C109−H10H	 109.5	
O103−C109−H10I	 109.5	
H10G−C109−H10I	 109.5	
H10H−C109−H10I	 109.5	
C102−O101−C107	 119.6(14)	
C104−O102−C108	 117.3(9)	
C106−O103−C109	 118.0(13)	
O13−C119−H11A	 109.5	
O13−C119−H11B	 109.5	
H11A−C119−H11B	 109.5	
O13−C119−H11C	 109.5	
H11A−C119−H11C	 109.5	
H11B−C119−H11C	 109.5	
O122−C128−H12A	 109.5	
O122−C128−H12B	 109.5	
H12A−C128−H12B	 109.5	
O122−C128−H12C	 109.5	
H12A−C128−H12C	 109.5	
H12B−C128−H12C	 109.5	
C24−O122−C128	 112.7(13)	
C132−C131−P1	 110.8(15)	
C132−C131−H13A	 109.5	
P1−C131−H13A	 109.5	
C132−C131−H13B	 109.5	
P1−C131−H13B	 109.5	
H13A−C131−H13B	 108.1	
C131−C132−C133	 111.7(13)	
C131−C132−H13C	 109.3	
C133−C132−H13C	 109.3	
C131−C132−H13D	 109.3	
C133−C132−H13D	 109.3	
H13C−C132−H13D	 107.9	
C132−C133−S102	 107.7(12)	
C132−C133−H13E	 110.2	
S102−C133−H13E	 110.2	
C132−C133−H13F	 110.2	
S102−C133−H13F	 110.2	
H13E−C133−H13F	 108.5	
O133−S101−O131	 116.6(14)	
O133−S101−O132	 114.9(13)	
O131−S101−O132	 106.5(13)	
O133−S101−S102	 102.0(11)	
O131−S101−S102	 109.2(12)	
O132−S101−S102	 107.1(12)	
C133−S102−S101	 100.3(8)	
C42−C41−C46	 116.8(4)	
C42−C41−P41	 126.7(3)	
C46−C41−P41	 116.4(3)	
O41−C42−C41	 116.4(4)	
O41−C42−C43	 121.7(4)	
C41−C42−C43	 121.9(4)	
C44−C43−C42	 118.7(5)	
C44−C43−H43	 120.7	
C42−C43−H43	 120.7	
C45−C44−C43	 122.5(4)	
C45−C44−O42	 131.0(6)	
C43−C44−O42	 106.4(6)	
C45−C44−O142	 101.3(6)	
C43−C44−O142	 136.1(6)	
C44−C45−C46	 117.9(5)	
C44−C45−H45	 121.0	
C46−C45−H45	 121.0	
O43−C46−C45	 123.0(4)	
O43−C46−C41	 115.0(4)	
C45−C46−C41	 122.0(4)	
O41−C47−H47A	 109.5	
O41−C47−H47B	 109.5	
H47A−C47−H47B	 109.5	
O41−C47−H47C	 109.5	
H47A−C47−H47C	 109.5	
H47B−C47−H47C	 109.5	
O42−C48−H48A	 109.5	
O42−C48−H48B	 109.5	
H48A−C48−H48B	 109.5	
O42−C48−H48C	 109.5	
H48A−C48−H48C	 109.5	
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H48B−C48−H48C	 109.5	
O43−C49−H49A	 109.5	
O43−C49−H49B	 109.5	
H49A−C49−H49B	 109.5	
O43−C49−H49C	 109.5	
H49A−C49−H49C	 109.5	
H49B−C49−H49C	 109.5	
C56−C51−C52	 116.3(4)	
C56−C51−P41	 115.5(3)	
C52−C51−P41	 128.1(4)	
O51−C52−C53	 122.7(4)	
O51−C52−C51	 115.8(4)	
C53−C52−C51	 121.5(4)	
C54−C53−C52	 119.4(4)	
C54−C53−H53	 120.3	
C52−C53−H53	 120.3	
C53−C54−O52	 120.6(4)	
C53−C54−C55	 122.6(4)	
O52−C54−C55	 116.7(5)	
C56−C55−C54	 117.4(4)	
C56−C55−H55	 121.3	
C54−C55−H55	 121.3	
O53−C56−C55	 123.7(4)	
O53−C56−C51	 113.5(4)	
C55−C56−C51	 122.7(4)	
O51−C57−H57A	 109.5	
O51−C57−H57B	 109.5	
H57A−C57−H57B	 109.5	
O51−C57−H57C	 109.5	
H57A−C57−H57C	 109.5	
H57B−C57−H57C	 109.5	
O52−C58−H58A	 109.5	
O52−C58−H58B	 109.5	
H58A−C58−H58B	 109.5	
O52−C58−H58C	 109.5	
H58A−C58−H58C	 109.5	
H58B−C58−H58C	 109.5	
O53−C59−H59A	 109.5	
O53−C59−H59B	 109.5	
H59A−C59−H59B	 109.5	
O53−C59−H59C	 109.5	
H59A−C59−H59C	 109.5	
H59B−C59−H59C	 109.5	
C66−C61−C62	 117.5(4)	
C66−C61−P41	 116.6(3)	
C62−C61−P41	 125.9(3)	
O61−C62−C63	 122.5(4)	
O61−C62−C61	 117.1(4)	
C63−C62−C61	 120.4(4)	
C64−C63−C62	 118.6(4)	
C64−C63−H63	 120.7	
C62−C63−H63	 120.7	
O62−C64−C65	 123.0(5)	
O62−C64−C63	 114.1(5)	
C65−C64−C63	 123.0(4)	
C64−C65−C66	 117.2(4)	
C64−C65−H65	 121.4	
C66−C65−H65	 121.4	
O63−C66−C61	 114.8(4)	
O63−C66−C65	 121.9(4)	
C61−C66−C65	 123.2(4)	
O61−C67−H67A	 109.5	
O61−C67−H67B	 109.5	
H67A−C67−H67B	 109.5	
O61−C67−H67C	 109.5	
H67A−C67−H67C	 109.5	
H67B−C67−H67C	 109.5	
O62−C68−H68A	 109.5	
O62−C68−H68B	 109.5	
H68A−C68−H68B	 109.5	
O62−C68−H68C	 109.5	
H68A−C68−H68C	 109.5	
H68B−C68−H68C	 109.5	
O63−C69−H69A	 109.5	
O63−C69−H69B	 109.5	
H69A−C69−H69B	 109.5	
O63−C69−H69C	 109.5	
H69A−C69−H69C	 109.5	
H69B−C69−H69C	 109.5	
C72−C71−P41	 113.6(13)	
C72−C71−H71A	 108.8	
P41−C71−H71A	 108.8	
C72−C71−H71B	 108.8	
P41−C71−H71B	 108.8	
H71A−C71−H71B	 107.7	
C73−C72−C71	 113.0(11)	
C73−C72−H72A	 109.0	
C71−C72−H72A	 109.0	
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C73−C72−H72B	 109.0	
C71−C72−H72B	 109.0	
H72A−C72−H72B	 107.8	
C72−C73−S42	 111.5(8)	
C72−C73−H73A	 109.3	
S42−C73−H73A	 109.3	
C72−C73−H73B	 109.3	
S42−C73−H73B	 109.3	
H73A−C73−H73B	 108.0	
C51−P41−C61	 107.0(2)	
C51−P41−C41	 113.5(2)	
C61−P41−C41	 112.7(2)	
C51−P41−C171	 113.0(14)	
C61−P41−C171	 107.7(8)	
C41−P41−C171	 102.9(12)	
C51−P41−C71	 110.6(14)	
C61−P41−C71	 107.8(8)	
C41−P41−C71	 105.1(12)	
C42−O41−C47	 118.3(4)	
C44−O42−C48	 113.0(8)	
C46−O43−C49	 118.6(4)	
C52−O51−C57	 117.8(4)	
C158−O52−C54	 125.3(9)	
C54−O52−C58	 124.3(6)	
C56−O53−C59	 119.5(4)	
C62−O61−C67	 119.5(4)	
C64−O62−C68	 116.5(5)	
C66−O63−C69	 120.9(5)	
O72−S41−O71	 112.4(8)	
O72−S41−O73	 112.7(8)	
O71−S41−O73	 114.9(9)	
O72−S41−S42	 106.2(7)	
O71−S41−S42	 102.2(5)	
O73−S41−S42	 107.3(6)	
C73−S42−S41	 101.2(5)	
C172−C171−P41	 111.8(13)	
C172−C171−H17D	 109.3	
P41−C171−H17D	 109.3	
C172−C171−H17E	 109.3	
P41−C171−H17E	 109.3	
H17D−C171−H17E	 107.9	
C173−C172−C171	 110.6(9)	
C173−C172−H17F	 109.5	
C171−C172−H17F	 109.5	
C173−C172−H17G	 109.5	
C171−C172−H17G	 109.5	
H17F−C172−H17G	 108.1	
C172−C173−S142	 110.4(9)	
C172−C173−H17H	 109.6	
S142−C173−H17H	 109.6	
C172−C173−H17I	 109.6	
S142−C173−H17I	 109.6	
H17H−C173−H17I	 108.1	
O172−S141−O173	 118.5(9)	
O172−S141−O171	 114.6(9)	
O173−S141−O171	 111.2(9)	
O172−S141−S142	 100.7(7)	
O173−S141−S142	 104.0(6)	
O171−S141−S142	 105.9(5)	
C173−S142−S141	 99.5(5)	
C44−O142−C148	 108.1(9)	
O142−C148−H14A	 109.5	
O142−C148−H14B	 109.5	
H14A−C148−H14B	 109.5	
O142−C148−H14C	 109.5	
H14A−C148−H14C	 109.5	
H14B−C148−H14C	 109.5	
O52−C158−H15A	 109.5	
O52−C158−H15B	 109.5	
H15A−C158−H15B	 109.5	
O52−C158−H15C	 109.5	
H15A−C158−H15C	 109.5	
H15B−C158−H15C	 109.5	
O301−C301−C302	 98.1(7)	
O301−C301−H30A	 112.2	
C302−C301−H30A	 112.2	
O301−C301−H30B	 112.2	
C302−C301−H30B	 112.2	
H30A−C301−H30B	 109.8	
C301−C302−H30C	 109.5	
C301−C302−H30D	 109.5	
H30C−C302−H30D	 109.5	
C301−C302−H30E	 109.5	
H30C−C302−H30E	 109.5	
H30D−C302−H30E	 109.5	
O301−C303−C304	 98.8(9)	
O301−C303−H30F	 112.0	
C304−C303−H30F	 112.0	
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O301−C303−H30G	 112.0	
C304−C303−H30G	 112.0	
H30F−C303−H30G	 109.7	
C303−C304−H30H	 109.5	
C303−C304−H30I	 109.5	
H30H−C304−H30I	 109.5	
C303−C304−H30J	 109.5	
H30H−C304−H30J	 109.5	
H30I−C304−H30J	 109.5	
C303−O301−C301	 117.6(10)	
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Table	A3.4.	Anisotropic	displacement	parameters	[Å2×	103].	The	anisotropic	displacement	
factor	exponent	takes	the	form:	−2π	2[h2a*2U11	+	...	+	2	h	k	a*	b*	U12	].	
	
Atom	 U11	 U22	 U33	 U23	 U13	 U12	
	
	
C1	 65(6)		 48(5)	 51(4)		 −11(4)	 −3(4)		 −11(4)	
C2	 80(7)		 58(5)	 53(4)		 −13(4)	 −4(4)		 3(5)	
C3	 92(7)		 78(6)	 63(5)		 −19(4)	 −15(5)		 −1(6)	
C4	 101(7)		 99(6)	 67(5)		 −12(5)	 −24(5)		 5(7)	
C5	 89(8)		 72(6)	 69(6)		 −4(5)	 −16(5)		 3(6)	
C6	 66(6)		 50(6)	 62(5)		 −3(4)	 −7(5)		 2(5)	
C7	 141(18)		 89(10)	 79(10)		 −31(8)	 14(14)		 27(13)	
C8	 210(18)		 208(17)	 124(12)		 −75(11)	 −44(13)		 20(15)	
C9	 71(10)		 83(9)	 116(17)		 −20(10)	 −11(11)		 32(7)	
C11	 42(2)		 52(2)	 56(2)		 −8(2)	 −4(2)		 −5(2)	
C12	 52(2)		 50(2)	 60(3)		 −14(2)	 −3(2)		 −3(2)	
C13	 59(3)		 53(2)	 64(3)		 −11(2)	 −14(2)		 −2(2)	
C14	 74(3)		 47(2)	 56(3)		 0(2)	 −6(2)		 −7(2)	
C15	 54(3)		 59(3)	 83(3)		 4(2)	 9(2)		 −11(2)	
C16	 49(3)		 54(2)	 75(3)		 −1(2)	 3(2)		 −3(2)	
C17	 58(3)		 70(4)	 150(6)		 −36(4)	 −5(3)		 14(3)	
C18	 85(4)		 63(3)	 88(4)		 −3(3)	 1(3)		 −21(3)	
C19	 41(5)		 87(8)	 69(9)		 −20(6)	 −8(5)		 −18(5)	
C21	 50(2)		 51(2)	 80(3)		 −21(2)	 9(2)		 −7(2)	
C22	 66(3)		 54(3)	 106(4)		 −21(3)	 25(3)		 −14(2)	
C23	 65(3)		 67(3)	 150(5)		 −27(3)	 44(3)		 −21(3)	
C24	 45(3)		 66(4)	 194(6)		 −46(4)	 12(3)		 −7(3)	
C25	 48(3)		 65(3)	 151(5)		 −41(3)	 −15(3)		 −3(2)	
C26	 46(2)		 54(3)	 104(3)		 −33(2)	 −12(2)		 4(2)	
C27	 156(8)		 137(7)	 110(5)		 12(5)	 71(5)		 −23(6)	
C28	 56(8)		 151(13)	 149(14)		 −23(13)	 −4(8)		 −18(8)	
C29	 102(5)		 110(5)	 100(4)		 −35(4)	 −51(4)		 22(4)	
C31	 55(3)		 49(3)	 53(3)		 −12(3)	 −4(3)		 0(3)	
C32	 62(3)		 50(3)	 80(4)		 −23(3)	 −7(3)		 5(3)	
C33	 82(4)		 61(3)	 76(3)		 −24(3)	 −19(3)		 13(3)	
P1	 43(1)		 50(1)	 54(1)		 −9(1)	 −1(1)		 −7(1)	
O1	 82(9)		 61(7)	 63(6)		 −26(5)	 −6(5)		 4(5)	
O2	 133(8)		 134(7)	 71(5)		 −21(5)	 −47(5)		 −9(6)	
O3	 68(6)		 63(7)	 72(7)		 −12(4)	 −10(6)		 16(5)	
O11	 43(2)		 62(2)	 100(3)		 −24(2)	 −1(2)		 −1(2)	
O12	 85(3)		 53(2)	 74(2)		 0(2)	 −2(2)		 −11(2)	
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O13	 38(2)		 58(2)	 124(3)		 8(2)	 9(2)		 −5(2)	
O21	 95(3)		 76(2)	 83(2)		 1(2)	 37(2)		 −21(2)	
O22	 47(4)		 99(7)	 202(11)		 −43(11)	 32(5)		 −18(5)	
O23	 64(2)		 84(2)	 77(2)		 −27(2)	 −18(2)		 7(2)	
O31	 59(3)		 158(6)	 84(3)		 −9(4)	 −3(2)		 3(3)	
O32	 152(5)		 84(3)	 93(3)		 −27(3)	 29(3)		 −65(4)	
O33	 89(3)		 94(3)	 78(3)		 −32(2)	 −18(3)		 −12(3)	
S1	 58(1)		 63(1)	 63(1)		 −16(1)	 −2(1)		 −12(1)	
S2	 187(2)		 88(1)	 116(2)		 −56(1)	 −90(2)		 64(2)	
C101	 62(5)		 45(5)	 55(4)		 5(4)	 −5(4)		 −9(4)	
C102	 80(7)		 56(5)	 58(4)		 −13(4)	 −11(5)		 −2(5)	
C103	 95(8)		 73(5)	 65(5)		 −20(4)	 −16(5)		 18(6)	
C104	 102(7)		 87(6)	 60(4)		 −17(4)	 −22(5)		 27(6)	
C105	 87(7)		 68(5)	 62(5)		 −4(4)	 −6(5)		 13(5)	
C106	 61(6)		 52(5)	 58(4)		 −9(4)	 −5(4)		 −4(4)	
C107	 82(11)		 74(8)	 70(8)		 −23(6)	 1(8)		 14(8)	
C108	 187(17)		 181(15)	 65(7)		 −28(9)	 −5(9)		 64(13)	
C109	 99(14)		 61(7)	 78(11)		 −6(7)	 −7(9)		 12(7)	
O101	 85(8)		 66(6)	 59(5)		 −9(4)	 −8(5)		 19(5)	
O102	 140(8)		 117(6)	 64(4)		 −22(4)	 −28(5)		 37(6)	
O103	 71(6)		 55(6)	 67(6)		 −12(4)	 −20(5)		 1(4)	
C119	 60(7)		 76(7)	 104(11)		 −2(7)	 11(7)		 −2(5)	
C128	 49(7)		 133(12)	 156(17)		 −39(12)	 0(9)		 −29(7)	
O122	 50(5)		 97(7)	 192(11)		 −42(10)	 20(6)		 −25(5)	
C131	 54(9)		 57(8)	 65(8)		 −13(8)	 6(8)		 9(9)	
C132	 71(9)		 58(8)	 80(9)		 −12(7)	 −10(9)		 9(8)	
C133	 101(9)		 68(8)	 96(9)		 −28(7)	 −35(9)		 19(8)	
O131	 82(12)		 136(19)	 150(20)		 38(19)	 19(13)		 −6(14)	
O132	 160(20)		 98(11)	 131(18)		 −42(11)	 −29(17)		 −8(13)	
O133	 91(14)		 130(15)	 118(11)		 −22(15)	 23(12)		 11(14)	
S101	 93(9)		 91(10)	 126(9)		 −38(8)	 3(7)		 −36(8)	
S102	 113(8)		 79(6)	 133(7)		 −36(6)	 0(6)		 −5(6)	
C41	 46(2)		 51(2)	 51(2)		 −7(2)	 −3(2)		 −3(2)	
C42	 54(3)		 55(2)	 57(3)		 −8(2)	 −1(2)		 0(2)	
C43	 65(3)		 63(3)	 54(3)		 −11(2)	 −7(2)		 13(2)	
C44	 89(4)		 52(2)	 57(3)		 −3(2)	 −2(2)		 19(2)	
C45	 81(3)		 46(2)	 69(3)		 −4(2)	 2(2)		 0(2)	
C46	 60(3)		 50(2)	 61(3)		 −10(2)	 −2(2)		 −6(2)	
C47	 62(3)		 93(4)	 113(5)		 −26(4)	 −28(3)		 −5(3)	
C48	 77(7)		 59(6)	 98(7)		 6(5)	 −7(6)		 −2(5)	
C49	 86(4)		 62(3)	 137(5)		 −14(3)	 −12(4)		 −37(3)	
C51	 46(2)		 54(2)	 55(2)		 −9(2)	 −3(2)		 −2(2)	
C52	 60(3)		 54(3)	 61(3)		 −8(2)	 11(2)		 −11(2)	
C53	 69(3)		 57(3)	 68(3)		 −7(2)	 13(2)		 −17(2)	
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C54	 53(3)		 47(2)	 84(3)		 −11(2)	 −1(2)		 −8(2)	
C55	 49(3)		 56(3)	 74(3)		 −20(2)	 −6(2)		 2(2)	
C56	 44(2)		 52(2)	 61(2)		 −9(2)	 −3(2)		 −3(2)	
C57	 137(6)		 120(5)	 67(3)		 −27(3)	 34(4)		 −63(5)	
C58	 92(7)		 69(5)	 101(7)		 −6(4)	 −3(5)		 −30(5)	
C59	 75(4)		 88(4)	 57(3)		 −16(3)	 −14(3)		 −6(3)	
C61	 47(2)		 48(2)	 57(2)		 −9(2)	 −5(2)		 −2(2)	
C62	 47(2)		 52(2)	 57(2)		 −13(2)	 0(2)		 −6(2)	
C63	 55(3)		 60(3)	 68(3)		 −18(2)	 3(2)		 −12(2)	
C64	 43(2)		 72(3)	 91(3)		 −35(3)	 −7(2)		 −1(2)	
C65	 61(3)		 60(3)	 74(3)		 −20(2)	 −23(2)		 3(2)	
C66	 55(3)		 53(2)	 57(2)		 −10(2)	 −7(2)		 −6(2)	
C67	 74(4)		 94(4)	 65(3)		 3(3)	 12(3)		 −8(3)	
C68	 52(3)		 107(5)	 163(7)		 −37(4)	 −25(4)		 11(3)	
C69	 124(6)		 137(6)	 67(4)		 4(4)	 −19(4)		 40(5)	
C71	 66(7)		 67(7)	 51(5)		 −16(5)	 −3(5)		 −7(6)	
C72	 70(6)		 83(6)	 65(5)		 −37(5)	 −12(5)		 −5(5)	
C73	 88(7)		 116(7)	 77(6)		 −43(6)	 −2(5)		 4(6)	
P41	 48(1)		 50(1)	 50(1)		 −4(1)	 −2(1)		 −5(1)	
O41	 46(2)		 69(2)	 76(2)		 −6(2)	 −13(2)		 −2(2)	
O42	 78(6)		 61(4)	 70(4)		 5(3)	 −10(5)		 14(4)	
O43	 61(2)		 56(2)	 82(2)		 −12(2)	 −2(2)		 −14(2)	
O51	 102(3)		 75(2)	 59(2)		 −14(2)	 21(2)		 −34(2)	
O52	 67(2)		 61(2)	 140(4)		 −26(2)	 6(2)		 −20(2)	
O53	 59(2)		 65(2)	 49(2)		 −12(1)	 −4(1)		 −7(2)	
O61	 54(2)		 65(2)	 52(2)		 1(1)	 2(1)		 −5(2)	
O62	 46(2)		 99(3)	 120(3)		 −39(2)	 −14(2)		 6(2)	
O63	 74(2)		 69(2)	 57(2)		 6(2)	 −10(2)		 1(2)	
O71	 66(5)		 125(7)	 112(7)		 −33(6)	 −39(5)		 11(5)	
O72	 85(6)		 124(8)	 153(9)		 −52(7)	 43(7)		 −41(6)	
O73	 128(8)		 147(7)	 84(5)		 10(5)	 −18(5)		 −41(6)	
S41	 64(3)		 87(3)	 94(4)		 −4(2)	 −16(3)		 −9(2)	
S42	 110(3)		 146(3)	 84(2)		 −58(2)	 −45(2)		 31(2)	
C171	 62(6)		 64(7)	 49(5)		 −12(5)	 −1(5)		 −9(6)	
C172	 68(6)		 83(7)	 68(6)		 −25(5)	 −1(5)		 2(5)	
C173	 76(6)		 115(7)	 85(6)		 −47(6)	 6(5)		 −10(5)	
O171	 129(8)		 152(8)	 54(4)		 −15(4)	 −5(4)		 33(6)	
O172	 109(7)		 164(8)	 136(8)		 −96(7)	 51(7)		 −76(7)	
O173	 63(5)		 110(7)	 119(7)		 1(6)	 −24(5)		 −10(4)	
S141	 65(3)		 97(3)	 62(2)		 −21(2)	 6(2)		 −17(2)	
S142	 92(3)		 146(4)	 90(3)		 −58(3)	 23(2)		 −27(2)	
O142	 56(6)		 67(5)	 76(6)		 3(4)	 −10(5)		 −7(5)	
C148	 66(8)		 64(7)	 61(7)		 1(5)	 −18(6)		 1(6)	
C158	 101(14)		 63(10)	 108(12)		 −11(8)	 −48(11)		 −14(9)	
	195	
	
C301	 186(8)		 228(11)	 134(7)		 −79(7)	 −38(7)		 29(8)	
C302	 91(4)		 173(7)	 82(4)		 −26(4)	 13(4)		 −61(5)	
C303	 181(10)		 204(11)	 158(8)		 −55(8)	 −42(8)		 6(6)	
C304	 279(11)		 172(11)	 261(15)		 −53(10)	 −125(12)		 −47(9)	
O301	 241(7)		 170(7)	 184(6)		 −71(5)	 12(6)		 19(5)	
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Table	A3.5.	Hydrogen	coordinates	[×	104]	and	isotropic	displacement	parameters	[Å2	×	
103].	
	
Atom		 x	 y	 z	 Ueq	 S.o.f.
	
H3	 7695	 5453	 9428	 94	 0.490(10)	
H5	 9702	 3448	 8969	 96	 0.490(10)	
H7A	 5460	 6769	 8455	 158	 0.490(10)	
H7B	 6558	 6641	 8877	 158	 0.490(10)	
H7C	 5689	 5885	 9125	 158	 0.490(10)	
H8A	 9212	 4593	 10872	 263	 0.490(10)	
H8B	 8025	 4607	 10583	 263	 0.490(10)	
H8C	 8790	 5419	 10207	 263	 0.490(10)	
H9A	 9915	 2544	 7582	 141	 0.490(10)	
H9B	 9398	 2365	 8390	 141	 0.490(10)	
H9C	 10386	 3008	 8116	 141	 0.490(10)	
H13	 6120	 8366	 6154	 72	 1	
H15	 9305	 7537	 5888	 86	 1	
H17A	 3868	 7265	 7004	 140	 1	
H17B	 4462	 7785	 6250	 140	 1	
H17C	 4735	 7984	 6975	 140	 1	
H18A	 8946	 9900	 5257	 124	 1	
H18B	 9388	 8918	 5201	 124	 1	
H18C	 9303	 9113	 5967	 124	 1	
H19A	 10719	 5396	 6606	 98	 0.47(2)	
H19B	 10423	 6313	 6819	 98	 0.47(2)	
H19C	 10443	 6329	 5992	 98	 0.47(2)	
H23	 3530	 4090	 8296	 116	 1	
H25	 3576	 5399	 6152	 102	 1	
H27A	 5628	 3486	 9513	 224	 1	
H27B	 4641	 3260	 9123	 224	 1	
H27C	 4631	 4230	 9255	 224	 1	
H28A	 964	 4376	 7974	 185	 0.52(3)	
H28B	 1901	 4732	 8322	 185	 0.52(3)	
H28C	 2047	 3735	 8234	 185	 0.52(3)	
H29A	 5681	 6358	 4958	 154	 1	
H29B	 4728	 6661	 5466	 154	 1	
H29C	 4634	 5778	 5219	 154	 1	
H31A	 7564	 4723	 6091	 63	 0.862(4)	
H31B	 8506	 4345	 6651	 63	 0.862(4)	
H32A	 6479	 3533	 6752	 77	 0.862(4)	
H32B	 7397	 3163	 7330	 77	 0.862(4)	
H33A	 7569	 2248	 6563	 87	 0.862(4)	
H33B	 8628	 2824	 6402	 87	 0.862(4)	
H103	 6983	 5450	 9488	 94	 0.510(10)	
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H105	 9249	 3490	 9211	 92	 0.510(10)	
H10A	 5059	 6801	 8338	 115	 0.510(10)	
H10B	 6035	 6704	 8860	 115	 0.510(10)	
H10C	 5243	 5900	 9001	 115	 0.510(10)	
H10D	 7936	 4202	 11158	 228	 0.510(10)	
H10E	 6926	 4389	 10648	 228	 0.510(10)	
H10F	 7778	 5145	 10534	 228	 0.510(10)	
H10G	 9858	 2591	 7829	 126	 0.510(10)	
H10H	 8997	 2439	 8509	 126	 0.510(10)	
H10I	 10091	 2927	 8501	 126	 0.510(10)	
H11A	 10569	 5332	 6176	 130	 0.53(2)	
H11B	 10460	 6409	 6024	 130	 0.53(2)	
H11C	 9812	 5958	 5555	 130	 0.53(2)	
H12A	 885	 4300	 7390	 169	 0.48(3)	
H12B	 1538	 4560	 7970	 169	 0.48(3)	
H12C	 1905	 3651	 7759	 169	 0.48(3)	
H13A	 7536	 5111	 5964	 73	 0.138(4)	
H13B	 8520	 4621	 6469	 73	 0.138(4)	
H13C	 6527	 3828	 6401	 86	 0.138(4)	
H13D	 7400	 3348	 6995	 86	 0.138(4)	
H13E	 8743	 3223	 6061	 105	 0.138(4)	
H13F	 7876	 3716	 5461	 105	 0.138(4)	
H43	 9520	 7861	 3963	 76	 1	
H45	 6852	 6740	 3601	 83	 1	
H47A	 10516	 9950	 3192	 134	 1	
H47B	 10644	 8901	 3230	 134	 1	
H47C	 10053	 9205	 3891	 134	 1	
H48A	 8621	 5178	 4890	 127	 0.575(11)	
H48B	 8104	 5472	 4116	 127	 0.575(11)	
H48C	 7488	 5790	 4764	 127	 0.575(11)	
H49A	 4590	 7757	 2579	 144	 1	
H49B	 4938	 7558	 3391	 144	 1	
H49C	 5521	 6973	 2896	 144	 1	
H53	 9183	 12486	 1105	 81	 1	
H55	 8312	 12015	 3232	 72	 1	
H57A	 8570	 11477	 −153	 160	 1	
H57B	 9418	 11831	 265	 160	 1	
H57C	 8214	 12326	 141	 160	 1	
H58A	 10368	 14017	 1784	 135	 0.680(11)	
H58B	 9656	 13812	 1205	 135	 0.680(11)	
H58C	 10675	 13129	 1533	 135	 0.680(11)	
H59A	 6952	 10161	 4427	 111	 1	
H59B	 7274	 11188	 4118	 111	 1	
H59C	 8193	 10372	 4163	 111	 1	
H63	 3489	 9789	 3679	 73	 1	
H65	 3545	 11563	 1649	 77	 1	
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H67A	 5605	 8495	 4705	 126	 1	
H67B	 4440	 8588	 4365	 126	 1	
H67C	 4852	 9425	 4567	 126	 1	
H68A	 981	 11729	 2470	 162	 1	
H68B	 1816	 11590	 1831	 162	 1	
H68C	 2112	 12205	 2308	 162	 1	
H69A	 5730	 11904	 304	 180	 1	
H69B	 4641	 12160	 732	 180	 1	
H69C	 4775	 11223	 538	 180	 1	
H71A	 6381	 9297	 1379	 74	 0.503(5)	
H71B	 6972	 10206	 986	 74	 0.503(5)	
H72A	 8695	 9238	 1448	 83	 0.503(5)	
H72B	 7976	 8414	 1495	 83	 0.503(5)	
H73A	 9042	 8839	 388	 110	 0.503(5)	
H73B	 8412	 9828	 190	 110	 0.503(5)	
H17D	 6430	 9169	 1451	 71	 0.497(5)	
H17E	 6869	 10131	 1006	 71	 0.497(5)	
H17F	 8720	 9509	 1226	 88	 0.497(5)	
H17G	 8279	 8546	 1668	 88	 0.497(5)	
H17H	 8863	 8587	 460	 106	 0.497(5)	
H17I	 7962	 9409	 163	 106	 0.497(5)	
H14A	 9293	 5497	 5012	 101	 0.425(11)	
H14B	 9151	 6522	 5040	 101	 0.425(11)	
H14C	 9871	 6277	 4394	 101	 0.425(11)	
H15A	 9752	 13928	 2622	 136	 0.320(11)	
H15B	 9529	 12956	 3178	 136	 0.320(11)	
H15C	 8527	 13627	 2808	 136	 0.320(11)	
H30A	 2465	 10095	 1456	 214	 1	
H30B	 2136	 9213	 2110	 214	 1	
H30C	 565	 10186	 1738	 173	 1	
H30D	 490	 9242	 1579	 173	 1	
H30E	 815	 10117	 936	 173	 1	
H30F	 3218	 8002	 979	 216	 1	
H30G	 3213	 8076	 1791	 216	 1	
H30H	 4735	 8738	 1080	 347	 1	
H30I	 3947	 9466	 1351	 347	 1	
H30J	 3909	 9429	 541	 347	 1	
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	Table	A3.6.	Torsion	angles	[°].	
		
	
C6−C1−C2−O1	 −178.8(16)	
P1−C1−C2−O1	 6.6(15)	
C6−C1−C2−C3	 0.0	
P1−C1−C2−C3	 −174.6(12)	
O1−C2−C3−C4	 178.7(18)	
C1−C2−C3−C4	 0.0	
C2−C3−C4−O2	 −179.0(12)	
C2−C3−C4−C5	 0.0	
O2−C4−C5−C6	 179.0(12)	
C3−C4−C5−C6	 0.0	
C4−C5−C6−O3	 178.0(19)	
C4−C5−C6−C1	 0.0	
C2−C1−C6−O3	 −178.0(19)	
P1−C1−C6−O3	 −4.2(18)	
C2−C1−C6−C5	 0.0	
P1−C1−C6−C5	 173.8(14)	
C16−C11−C12−O11	 −177.3(4)	
P1−C11−C12−O11	 1.6(6)	
C16−C11−C12−C13	 3.0(7)	
P1−C11−C12−C13	 −178.1(3)	
O11−C12−C13−C14	 178.5(4)	
C11−C12−C13−C14	 −1.8(7)	
C12−C13−C14−O12	 −178.3(4)	
C12−C13−C14−C15	 −0.1(8)	
C13−C14−C15−C16	 0.7(8)	
O12−C14−C15−C16	 178.7(5)	
C14−C15−C16−O13	 −178.7(5)	
C14−C15−C16−C11	 0.6(8)	
C12−C11−C16−O13	 176.9(4)	
P1−C11−C16−O13	 −2.1(6)	
C12−C11−C16−C15	 −2.4(7)	
P1−C11−C16−C15	 178.6(4)	
C26−C21−C22−O21	 175.0(4)	
P1−C21−C22−O21	 −6.7(7)	
C26−C21−C22−C23	 −3.0(7)	
P1−C21−C22−C23	 175.4(4)	
O21−C22−C23−C24	 −177.9(5)	
C21−C22−C23−C24	 −0.2(8)	
C22−C23−C24−C25	 3.4(10)	
C22−C23−C24−O22	 −175.8(14)	
C22−C23−C24−O122	 174(2)	
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C23−C24−C25−C26	 −3.2(9)	
O22−C24−C25−C26	 175.9(16)	
O122−C24−C25−C26	 −176.1(14)	
C24−C25−C26−O23	 179.0(5)	
C24−C25−C26−C21	 −0.3(8)	
C22−C21−C26−O23	 −176.1(4)	
P1−C21−C26−O23	 5.4(6)	
C22−C21−C26−C25	 3.3(7)	
P1−C21−C26−C25	 −175.3(4)	
P1−C31−C32−C33	 −178.3(4)	
C31−C32−C33−S2	 −65.3(6)	
C16−C11−P1−C21	 −163.7(4)	
C12−C11−P1−C21	 17.4(5)	
C16−C11−P1−C131	 −53(2)	
C12−C11−P1−C131	 128(2)	
C16−C11−P1−C31	 −49.5(5)	
C12−C11−P1−C31	 131.6(5)	
C16−C11−P1−C101	 75.0(6)	
C12−C11−P1−C101	 −104.0(6)	
C16−C11−P1−C1	 68.5(6)	
C12−C11−P1−C1	 −110.4(6)	
C26−C21−P1−C11	 50.4(4)	
C22−C21−P1−C11	 −128.0(4)	
C26−C21−P1−C131	 −53.9(16)	
C22−C21−P1−C131	 127.7(16)	
C26−C21−P1−C31	 −68.1(4)	
C22−C21−P1−C31	 113.5(4)	
C26−C21−P1−C101	 168.0(6)	
C22−C21−P1−C101	 −10.3(7)	
C26−C21−P1−C1	 175.5(6)	
C22−C21−P1−C1	 −2.8(7)	
C32−C31−P1−C11	 −161.1(4)	
C32−C31−P1−C21	 −42.8(5)	
C32−C31−P1−C131	 −148(8)	
C32−C31−P1−C101	 79.4(8)	
C32−C31−P1−C1	 78.9(8)	
C2−C1−P1−C11	 55.5(8)	
C6−C1−P1−C11	 −118.7(8)	
C2−C1−P1−C21	 −69.8(8)	
C6−C1−P1−C21	 116.0(8)	
C2−C1−P1−C131	 164.3(11)	
C6−C1−P1−C131	 −9.9(15)	
C2−C1−P1−C31	 175.7(6)	
C6−C1−P1−C31	 1.6(10)	
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C2−C1−P1−C101	 −1(9)	
C6−C1−P1−C101	 −175(10)	
C3−C2−O1−C7	 −10(3)	
C1−C2−O1−C7	 169(2)	
C3−C4−O2−C8	 6.4(19)	
C5−C4−O2−C8	 −172.7(15)	
C5−C6−O3−C9	 10(3)	
C1−C6−O3−C9	 −172(2)	
C13−C12−O11−C17	 2.1(7)	
C11−C12−O11−C17	 −177.6(5)	
C13−C14−O12−C18	 164.5(5)	
C15−C14−O12−C18	 −13.6(7)	
C15−C16−O13−C19	 14.3(11)	
C11−C16−O13−C19	 −165.0(9)	
C15−C16−O13−C119	 −29.3(12)	
C11−C16−O13−C119	 151.4(11)	
C23−C22−O21−C27	 −11.0(9)	
C21−C22−O21−C27	 171.2(6)	
C25−C24−O22−C28	 −174.2(17)	
C23−C24−O22−C28	 5(3)	
O122−C24−O22−C28	 166(8)	
C25−C26−O23−C29	 16.0(7)	
C21−C26−O23−C29	 −164.6(5)	
C32−C33−S2−S1	 −169.3(4)	
C11−P1−C101−C102	 63.5(8)	
C21−P1−C101−C102	 −56.9(8)	
C131−P1−C101−C102	 173.1(11)	
C31−P1−C101−C102	 −174.5(5)	
C1−P1−C101−C102	 −171(10)	
C11−P1−C101−C106	 −125.2(7)	
C21−P1−C101−C106	 114.5(7)	
C131−P1−C101−C106	 −15.5(16)	
C31−P1−C101−C106	 −3.1(11)	
C1−P1−C101−C106	 1(9)	
C106−C101−C102−O101	 −179.0(17)	
P1−C101−C102−O101	 −7.1(17)	
C106−C101−C102−C103	 0.0	
P1−C101−C102−C103	 171.9(12)	
O101−C102−C103−C104	 178.9(18)	
C101−C102−C103−C104	 0.0	
C102−C103−C104−O102	 −171.0(13)	
C102−C103−C104−C105	 0.0	
O102−C104−C105−C106	 171.8(12)	
C103−C104−C105−C106	 0.0	
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C104−C105−C106−O103	 −179.8(18)	
C104−C105−C106−C101	 0.0	
C102−C101−C106−O103	 179.8(18)	
P1−C101−C106−O103	 8.9(17)	
C102−C101−C106−C105	 0.0	
P1−C101−C106−C105	 −170.9(13)	
C103−C102−O101−C107	 −10(3)	
C101−C102−O101−C107	 169.0(19)	
C105−C104−O102−C108	 −171.0(14)	
C103−C104−O102−C108	 0.4(19)	
C105−C106−O103−C109	 19(3)	
C101−C106−O103−C109	 −161(2)	
C25−C24−O122−C128	 172.6(18)	
C23−C24−O122−C128	 1(3)	
O22−C24−O122−C128	 −24(4)	
C11−P1−C131−C132	 −157(3)	
C21−P1−C131−C132	 −44(4)	
C31−P1−C131−C132	 35(6)	
C101−P1−C131−C132	 88(4)	
C1−P1−C131−C132	 86(4)	
P1−C131−C132−C133	 −172(3)	
C131−C132−C133−S102	 −179(3)	
C132−C133−S102−S101	 160(3)	
C46−C41−C42−O41	 176.1(4)	
P41−C41−C42−O41	 −0.6(6)	
C46−C41−C42−C43	 −4.8(7)	
P41−C41−C42−C43	 178.5(4)	
O41−C42−C43−C44	 −177.5(4)	
C41−C42−C43−C44	 3.5(7)	
C42−C43−C44−C45	 −0.5(8)	
C42−C43−C44−O42	 176.5(6)	
C42−C43−C44−O142	 −177.6(10)	
C43−C44−C45−C46	 −1.0(8)	
O42−C44−C45−C46	 −177.1(7)	
O142−C44−C45−C46	 177.0(7)	
C44−C45−C46−O43	 179.0(5)	
C44−C45−C46−C41	 −0.5(7)	
C42−C41−C46−O43	 −176.2(4)	
P41−C41−C46−O43	 0.9(5)	
C42−C41−C46−C45	 3.3(7)	
P41−C41−C46−C45	 −179.6(4)	
C56−C51−C52−O51	 179.4(4)	
P41−C51−C52−O51	 −2.7(7)	
C56−C51−C52−C53	 1.4(7)	
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P41−C51−C52−C53	 179.4(4)	
O51−C52−C53−C54	 −178.3(5)	
C51−C52−C53−C54	 −0.5(8)	
C52−C53−C54−O52	 179.0(5)	
C52−C53−C54−C55	 −1.1(8)	
C53−C54−C55−C56	 1.7(7)	
O52−C54−C55−C56	 −178.4(4)	
C54−C55−C56−O53	 −178.5(4)	
C54−C55−C56−C51	 −0.7(7)	
C52−C51−C56−O53	 177.2(4)	
P41−C51−C56−O53	 −1.0(5)	
C52−C51−C56−C55	 −0.8(7)	
P41−C51−C56−C55	 −179.0(4)	
C66−C61−C62−O61	 −174.9(4)	
P41−C61−C62−O61	 6.0(6)	
C66−C61−C62−C63	 4.2(7)	
P41−C61−C62−C63	 −174.9(4)	
O61−C62−C63−C64	 177.1(4)	
C61−C62−C63−C64	 −2.0(7)	
C62−C63−C64−O62	 179.9(4)	
C62−C63−C64−C65	 −1.5(7)	
O62−C64−C65−C66	 −179.0(4)	
C63−C64−C65−C66	 2.6(7)	
C62−C61−C66−O63	 175.0(4)	
P41−C61−C66−O63	 −5.8(6)	
C62−C61−C66−C65	 −3.1(7)	
P41−C61−C66−C65	 176.0(4)	
C64−C65−C66−O63	 −178.2(4)	
C64−C65−C66−C61	 −0.1(7)	
P41−C71−C72−C73	 −155.7(19)	
C71−C72−C73−S42	 −64(2)	
C56−C51−P41−C61	 63.2(4)	
C52−C51−P41−C61	 −114.8(4)	
C56−C51−P41−C41	 −61.8(4)	
C52−C51−P41−C41	 120.2(4)	
C56−C51−P41−C171	 −178.5(10)	
C52−C51−P41−C171	 3.6(10)	
C56−C51−P41−C71	 −179.7(9)	
C52−C51−P41−C71	 2.3(10)	
C66−C61−P41−C51	 68.2(4)	
C62−C61−P41−C51	 −112.7(4)	
C66−C61−P41−C41	 −166.3(3)	
C62−C61−P41−C41	 12.8(5)	
C66−C61−P41−C171	 −53.5(15)	
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C62−C61−P41−C171	 125.6(15)	
C66−C61−P41−C71	 −50.7(15)	
C62−C61−P41−C71	 128.4(15)	
C42−C41−P41−C51	 −8.2(5)	
C46−C41−P41−C51	 175.1(3)	
C42−C41−P41−C61	 −130.0(4)	
C46−C41−P41−C61	 53.2(4)	
C42−C41−P41−C171	 114.2(12)	
C46−C41−P41−C171	 −62.5(12)	
C42−C41−P41−C71	 112.8(12)	
C46−C41−P41−C71	 −63.9(12)	
C72−C71−P41−C51	 83(3)	
C72−C71−P41−C61	 −160(2)	
C72−C71−P41−C41	 −40(3)	
C72−C71−P41−C171	 −71(33)	
C41−C42−O41−C47	 −178.4(5)	
C43−C42−O41−C47	 2.6(7)	
C45−C44−O42−C48	 −6.0(13)	
C43−C44−O42−C48	 177.4(8)	
O142−C44−O42−C48	 5.5(14)	
C45−C46−O43−C49	 17.9(7)	
C41−C46−O43−C49	 −162.5(5)	
C53−C52−O51−C57	 −11.0(8)	
C51−C52−O51−C57	 171.1(5)	
C53−C54−O52−C158	 167.2(11)	
C55−C54−O52−C158	 −12.6(12)	
C53−C54−O52−C58	 −8.9(9)	
C55−C54−O52−C58	 171.2(6)	
C55−C56−O53−C59	 −20.9(6)	
C51−C56−O53−C59	 161.1(4)	
C63−C62−O61−C67	 −6.3(7)	
C61−C62−O61−C67	 172.7(4)	
C65−C64−O62−C68	 −11.7(7)	
C63−C64−O62−C68	 167.0(5)	
C61−C66−O63−C69	 158.5(5)	
C65−C66−O63−C69	 −23.3(8)	
C72−C73−S42−S41	 −92.9(11)	
C51−P41−C171−C172	 75(3)	
C61−P41−C171−C172	 −167(2)	
C41−P41−C171−C172	 −48(3)	
C71−P41−C171−C172	 102(35)	
P41−C171−C172−C173	 −180(2)	
C171−C172−C173−S142	 −63(2)	
C172−C173−S142−S141	 −145.0(11)	
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C45−C44−O142−C148	 −178.5(10)	
C43−C44−O142−C148	 −1.0(17)	
O42−C44−O142−C148	 10.3(12)	
C304−C303−O301−C301	 −71.2(13)	
C302−C301−O301−C303	 −160.0(9)	
		
	
